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iAbstract
Monocytes and macrophages are key mediators of the immune response in the host immune
system and are principally responsible for pathogen clearance, inflammatory induction and
tissue repair. A pathogenic role for these immune cells has also been identified in a number
of diseases including cancer, atherosclerosis, liver fibrosis and rheumatoid arthritis. There
is growing evidence that phenotypic variations within monocytes and macrophages have
individual, and in some cases, opposing roles in many of these diseases. This presents a need
for tools that can selectively target phenotypic subsets of monocytes and macrophages for
both research and therapeutic purposes. CCL2 is a chemokine which has been shown to be
involved in these diseases in terms of recruitment of pathogenic monocyte subsets and also in
the direction of adaptive immune responses. The chemokine is selective for the CCR2 receptor
which is expressed on classical and intermediate monocytes, M1 macrophages, MDSCs and
some subsets of lymphocytes. CCL2 is a potentially attractive target for use as a targeting
vector towards these phenotypes which are implicated in disease and has recently been the
utilised in a number of protein conjugates including fluorophores and peptide toxins.
The work herein describes the design of CCL2 constructs to include an alkyne tag for copper-
mediated alkyne-azide cycloaddition reactions which do not affect the biological function of
the chemokines. Three CCL2 sequences were designed and synthesised: WT-CCL2, P8A-
CCL2 and CCL2 Ala−1 each containing small modifications at the C-terminus to include a
propargyl glycine for CuAAC. These CCL2 variants are known in the literature to have
distinct functional activities and behaviours which were selected to identify the optimal
sequence for monocyte targeting and fluorophore delivery. A range of azide-containing fluo-
rophores and a FRET pair were synthesised in chapter 3 which differed in lipophilicity and
linker stability in intracellular environments. These fluorophores were then conjugated using
copper-catalysed azide-alkyne cycloaddition (CuAAC) to the CCL2 variants, including ex-
tensive optimisation of reaction conditions for compatibility with poorly soluble and disulfide
linked fluorophores in chapter 4. This resulted in the formation of 10 CCL2 conjugates across
ii
the three CCL2 variants. Chapter 5 then extensively characterised the functional activity
of alkyl-linked hydrophilic CCL2-fluorophore conjugates using chemotaxis assays. Induction
of chemotaxis and internalisation of the fluorescent conjugates was determined, highlighting
differences between the variants. CCR2-dependent chemotaxis and internalisation was de-
termined through the use of the CCR2 antagonist INCB 3284, surface depletion of CCR2
using high concentrations of CCL2, and also experiments using CCR2− jurkat cells. The
functional activity of the CCL2 alanine addition (CCL2 Ala−1) and P8A-CCL2 conjugates
synthesised through the optimised methods was also determined using these assays which
revealed an incompatibility of CCL2 with a combination of DMSO and sodium ascorbate.
The P8A-CCL2 conjugates were therefore taken forward into primary cell experiments with
the alkyl-linked hydrophilic WT-CCL2 and CCL2 Ala−1 conjugates. Uptake of five CCL2
conjugates was then measured across peripheral blood mononuclear cells (PBMCs) using
flow cytometry, in these experiments neutrophils and the majority of lymphocytes were not
labelled by the CCL2 conjugates. Further experiments determined that CCL2 uptake was
highly selective for CCR2+ cells, these included classical monocytes, intermediate mono-
cytes, NKT cells, subsets of NK cells and minor subsets of T cells. Some uptake was also
observed in non-classical monocytes although all CCL2 uptake was dependent on the pres-
ence of surface CCR2 and correlated with the magnitude of receptor expression. Evidence
for endosomal escape of lipophilic disulfide linked conjugates was observed most likely due to
leaching into CCR2− cells. Fluorescence microscopy in THP-1 cells and PBMCs identified
that fluorescence from hydrophilic fluorophores was constricted to vesicles and the disulfide-
linked lipophilic fluorophore exhibited a diffuse fluorescence profile suggesting this compound
was escaping the vesicles. This project successfully developed general methods for forming a
diverse array of CCL2 conjugates of varying CCR2 affinities which will aid in the research of
monocytes and could potentially translate into targeted therapeutics towards monocyte and
lymphocyte subsets.
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1.1 Background
Many debilitating and life threatening conditions are caused by inflammatory processes both
in advanced economies and also in Lower and Middle Income Countries (LMICs). The mech-
anism of these processes are complex, involving a variety of cell types and as such, broad
spectrum therapeutics have been largely ineffective.1 Successful therapies such as anti-TNF
(Tumour Necrosis Factor) treatment in rheumatoid arthritis are highly selective for disease
causing cells. Furthermore, understanding the mechanistic process behind inflammatory dis-
ease requires in vivo experiments using research tools which can interrogate cells selectively.
This project aims to develop tools targeted at monocytes, this is a platform technology
which could be designed for research and therapeutics. Monocytes are innate immune cells
which clear pathogens, repair damaged tissues and also produce pro-inflammatory mediators.
The cells are implicated in a number of inflammatory diseases such as cancer, liver fibro-
sis, rheumatoid arthritis and atherosclerosis.2 However, monocytes have many phenotypic
variations which in some cases have dual or even opposing functions in disease progression
meaning targeted therapies are needed.3,4 This project aims to utilise chemical conjugates
of the chemokine, CCL2, to target monocytes. CCL2 is a small protein which is highly
specific for the receptor C-C chemokine receptor type 2 (CCR2), a number of conjugates
have been reported but a simple method to form a wide variety of conjugates is lacking.5–7
The use of CCL2 provides subset specificity for monocytes aligned with the pathogenesis of
many diseases through differential expression of it’s major receptor CCR2. The use of CCL2
conjugates provides selectivity for classical and intermediate monocytes which are high in
CCR2, and it is these monocyte subsets which are pro-inflammatory.8–10 The aims of the
project are therefore:
1. To develop a CCL2 construct which contains an alkyne tag for subsequent CuAAC
conjugations.
2. To synthesise a range of fluorophores with varying physicochemical properties with an
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azide tag for CuAAC conjugation.
3. To form the fluorescent CCL2 conjugates and then assess their biological function with
in vitro experiments in monocytic cells.
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1.2 Monocytes
White blood cells are key mediators of the human immune system and have three major
roles in the body: pathogen destruction, tissue repair and phagocytosis of dead cells.2 Tra-
ditionally, these roles are grouped into the innate immune system and the adaptive immune
system; innate immunity is a naive system which mainly deals with the non-specific destruc-
tion of pathogens, whereas adaptive immunity is a higher-learned process concerned with
antibody production towards encountered antigens and antigen presentation.11 Recently, ev-
idence suggests this classification is over-simplistic and cell-types previously considered part
of innate immunity have an intricate and complex role in adaptive immunity as well, with
many feedback mechanisms relaying into both systems. Monocytes represent around 2-8%
of white blood cells and are classified as part of the innate immune system. Monocytes are
mononuclear white blood cells which circulate in the blood, often for extended periods, be-
fore differentiating into macrophages, dendritic cells and osteoclasts.2 The cells are relatively
large in diameter (ranging from 16-25 um, depending on phenotype) and possess a distinc-
tive elliptical (or kidney-shaped) nucleus.12 Monocytes have a complex range of phenotypes
and it is this feature which has gained these cells significant research attention due to their
unparalleled heterogeneity. These cell types cannot be distinguished by light microscopy or
by light scatter in flow cytometric analysis and so the majority of research into these cells
has been achieved via antibody labelling in flow cytometry. This body of research has been
performed on both human and murine cells and much conflicting nomenclature has arisen in
the field as a result of heterogeneity in surface markers between the species. The structure of
this section on the biology of these cells will therefore cover macrophages first, followed by a
broad discussion of diseases related to macrophages and monocytes, before finally reviewing
monocyte subsets in more detail and then applying this information to diseases linked to
specific monocyte subsets. This structure has been used due to the distinct terminology used
surrounding macrophages and monocytes in broad terms (often interchangeably), relative to
the description of individual monocyte subsets.
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Monocytes circulate in the blood and are the precursor cell for many cell types such as
macrophages, specialised antigen presenting cells (APCs) such as dendritic cells (DCs), and
osteoclasts.2 Monocytes originate in the bone marrow from hematopoietic stem cells (HSCs),
this lineage is also shared with neutrophils. They are stimulated with growth factors to dif-
ferentiate towards monocytes before entering the peripheral blood for eventual recruitment
into tissues where they may differentiate into tissue macrophages or dendritic cells. Even at
early stages in their development monocytes represent a hetergeneous population of cells that
differ in size, surface marker expression and their differentiation potency in response to many
factors.13 Monocytes generally have irregular shape and an oval-shaped nuclues, along with
a high nucleus:cytoplasm ratio. The development of monocytes from stem cell precursors de-
pends on the growth factor macrophage colony-stimulating factor (M-CSF) as demonstrated
by knockout mice studies.14,15 The developmental pathway (see Figure 1.1) from HSCs to
monocytes includes several intermediate progenitors including the common myeloid progen-
itor (CMP), the granulocyte-macrophage progenitor (GMP), and the macrophage-dendritic
cell progenitor (MDP).13,16 Myeloid progenitor cells are known to respond to CSF-1 by both
differentiating and proliferating, monocytes however are not thought to proliferate and differ-
entiated monocytes can sense CSF-1 but do not respond by proliferation, ending in cell-cycle
arrest.17,18
Until recently, immunologists believed that homeostasis of tissue-resident macrophages is
dependent on the recruitment of blood monocytes. Further research has since shown that
macrophages do not rely on this recruitment pathway to maintain their population or expand.
Indeed, monocytes can differentiate into macrophages (particularly during inflammation),
however, it would appear this is not an exclusive, or even necessary, pathway. Adult tissue
macrophages are derived from embryonic precursors where tissues are seeded before birth and
macrophages can actually self-maintain their population.19,20 It would appear that monocytes
represent a separate, plastic and dynamic cellular system which is complementary to tissue
macrophages, rather than being an intermediate cell-type towards the final macrophage.21
Thus, macrophages which have descended from monocytes are termed monocyte-derived
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Figure 1.1: The development of adult and fetal monocytes are broadly identical in the early stages.
Both begin as HSCs before differentiating into GM-CFUs, followed by M-CFUs, monoblasts and
pro-monocytes. Adults and adult bone marrow and fetal lover then diverge, with the latter forming
Ly6C ‘inflammatory’ monocytes (in mice) and entering the peripheral blood. Here the inflammatory
monocyte can either invade tissues or differentiate into ‘anti-inflammatory’ monocytes. Once trans-
migrated into tissues each subset can differentiate into macrophages, dendritic cells or osteoclasts.
At each progressive stage the differntial potential is reduced as can be seen from the highly potent
GM-CFU transitioning into the less potent M-CFU. Reproduced with permission from Gordon et
al.2
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macrophages and macrophages derived from an organ or tissue are termed tissue-resident
macrophages.
Ly6C is a common marker used to identify murine monocytes, Ly6Chi monocytes have a
poorly defined function in the blood circulation, however, the mobilisation of this subset
could be controlled by circadian rhythms through association with the gene Bmal1; this
gene releases Ly6Chi monocytes in diurnal waves in a process termed ‘anticipatory inflamma-
tion’.22 This preparatory behaviour is thought to be an evolutionary response to predicted
environmental challenges in an effort to boost the innate immune system. The mobilisation
of Ly6Chi monocytes into the peripheral blood is CCR2-dependent as demonstrated by para-
biosis experiments in mice.23 In these experiments, bone-marrow grafts of wild-type mice
are adoptively transferred into CCR2-deficient mice and the relative genotypically distinct
monocytes are tracked through the body.23 Only ∼30% of circulating blood monocytes were
the endogenous CCR2− monocytes, the remaining proportion were the wild-type parabiont.
Evidence of the separation of lineages between monocytes and tissue-resident macrophages
was exemplified by the lack of chimeric change in the resident-macrophages.23 The life cycle
of monocytes has been shown to include extravasation into tissues without differentiation into
macrophages or DCs.24 Expansion of monocyte-derived macrophages is heavily contextual
in the steady state, with the majority of tissues not having any contribution from monocyte-
derived macrophages.21 However, some tissues are dependent on this subset, for example,
in the gut; adoptive transfer of monocytes into macrophage ablated mice demonstrated that
intestinal M2 macrophages are descended from Ly6Chi monocytes.25,26 Another study involv-
ing chimeric mice (containing both CCR2− and CCR2+ monocytes) showed that intestinal
macrophages were exclusively descended from the wild-type CCR2+ monocytes.27
1.2.0.1 Biology of Macrophages
The steady state homeostasis of macrophages is not wholly dependent on replenishment by
bone-marrow derived monocytes, except in tissue specific environments. This situation is not
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Figure 1.2: Murine monocyte development from HSCs to Ly6Chi monocytes which are recruited from
bone marrow into the peripheral blood in a CCR2-dependent manner. These monocytes circulate
before transmigrating at inflammation sites to differentiate into monocyte-derived macrophages or
DCs, joining the alternately descended tissue-resident macrophages. The Ly6Chi monocytes can
also differentiate to Ly6Clow monocytes in the blood which proceed to patrol the luminal side of
the endothelium in a protective function. Reproduced with permission from Ginhoux et al.21
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reflected in pathological inflammation, where Ly6Chi monocytes form a large part of tissue
resident macrophages (Figure 1.2).21 These monocytes exhibit potency towards differenti-
ating towards M1 or M2 macrophages for increased inflammation or resolution depending
on environmental stimuli, and it is suspected these monocytes are sequentially recruited for
this purpose.28 This behaviour is reflected in atherosclerosis where lesions are first identified
using Ly6C+ (in mice, and the human equivalent) accumulation at the blood vessel wall.29,30
The monocytes differentiate into macrophages which ingest lipoproteins and contribute to
the advancement of the atherosclerotic plaque via their development into foam cells (lipid
rich macrophages). This relationship has been confirmed through a study in the reduction
of monocyte specific chemokines such as, chemokine (C-X3-C motif) ligand 1 (CX3CL1) or
CX3C chemokine receptor 1 (CX3CR1), leading to a reduction of monocytes and foam cells in
atherosclerotic plaques, linked with a reduction in atherogenesis.31 Monocytes would there-
fore seem to be responsible for circulating in blood for the anticipation of inflammation and
also for transient, short-lived differentiation into macrophages in response to environmental
stimuli.
Macrophage development within tissues is generally dependent on embryonic cues which
linger into adulthood, whereby the macrophages self-proliferate.32,33 Initially, it was thought
T cells direct adaptive immunity and the innate immune system, however, it is now believed
that macrophages are the directors which initiate T cell proliferation and T helper cell (Th)
responses.34 This led to classification of macrophages as M1 and M2 to reflect this link to
T helper cell activation; M1 preferentially express inducible nitric oxide synthase (iNOS)
and major histocompatibility complex (MHC) class II, whereas M2 macrophages express
arginase and do not express MHC class II.35 This expression denotes a difference in arginine
metabolism where M1 macrophages produce NO using arginine and M2 produce ornithine
and polyamines to promote healing and growth.36 M1 macrophages are generally terminally
differentiated cells but M2 have been shown to differentiate to M1 macrophages in response
to differentiating stimuli.35 M1 macrophages display an inflammatory phenotype whereas M2
macrophages display a tissue-repair functional phenotype.37 A critical aspect of research in
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this area is that innate immunity is dynamic, with many cell-cell interactions meaning that
in vitro studies on one or two subsets can lead to cellular responses that do not occur in
vivo.34 As macrophages appear to be at the centre of many immune responses there is a
great need for better understanding of these cells and specific targeting of therapeutics to
M1/M2 subsets.
Figure 1.3: The four activation subsets of macrophages and the surface markers which classify
them. Initially, iNOS and MHC class II expression was an identifier of M1 macrophages but it
has been shown that M2a macrophages also express MHC class II, therefore multiple markers are
needed to fully attribute a subset. Both major subsets incite killing of pathogens though through
distinct Th1 and Th2 immunoregulatory pathways. The receptor expression and functional contexts
of macrophages should therefore be considered in this research. Reproduced with permission from
Martinez et al.38
The grouping of macrophages into two subsets is an over-simplification of two extremes of
macrophage polarisation.39 Figure 1.3 shows the four subsets of macrophage activation and
the markers involved in classification and activation of these subsets. It is well known that
monocytes respond to various environmental stimuli such as Interferon-gamma (IFN-γ) or
IL-4 by differentiating into macrophages with distinct functional phenotypes, such as M1
or M2 respectively.40 Polarisation towards an M1 state is initiated by pro-inflammatory cy-
tokines such as IFN-γ, tumour necrosis factor alpha (TNF-α) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) or by bacterial stimuli such as lipopolysaccharide (LPS).
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M2 polarisation on the other hand is initiated by IL-4, IL-13 and other Th2 associated
cytokines such as IL-33. Furthermore, macrophages can be polarised towards an M2-like
state which partially resemble the M2 phenotype, this is generally caused by stimulation
with immune complexes together with LPS, transforming growth factor beta (TGF-β) or
interleukin-10 (IL-10) to produce functions such as high expression of angiogenic factors but
not all M2-characteristics.36,40 The function of M1 macrophages is to induce and effect Th1
responses such as combating intracellular parasites and anti-tumour activity; this is achieved
through production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and
increased expression of cytokines such as TNF-α and IL-6.40 M2 cells have increased expres-
sion levels of mannose, scavenger and galactose-type receptors; these cells also differentially
regulate the IL-1 system with low IL-1β but high IL-1ra. Polarised M2 cells initiate Th2
responses, clear parasites, immunosuppression, tissue remodelling and also tumour develop-
ment.40–42 Interestingly, chemokines can also drive this polarisation, CCL2 has been linked
with cancer progression and has been shown to induce an M2-like phenotype suggesting a
link between these systems.43 Polarised macrophages also differ in glucose metabolism which
is likely to reflect the functional roles of these subsets, as M1 macrophages need to act quickly
in response to acute infections whereas M2 macrophages patrol tissues over longer periods
carrying out tasks such as tissue remodelling and repair. M1 macrophages therefore utilise
an anaerobic glycolytic pathway which enables these cells to quickly generate energy in the
hypoxic tissue environment.44 To provide sustained energy, M2 cells use oxidative glucose
metabolism to deal with the long term demands of tissue repair.40 Macrophages also use iron
metabolism to contain infections and aid tissue repair, for example, M1 macrophages express
higher levels of ferritin in order to remove iron, an essential mineral for bacterial growth, from
the microenvironment.45 Alternatively, M2 cells express high levels of ferroportin which acts
to promote cell growth by secreting iron into the microenvironment, aiding the M2-tissue
repair paradigm.45 Interestingly, macrophages play a role in the immune regulation at the
fetal-mother interface in the placenta.46 Here, macrophages exhibit an immunosuppressive
role with an M2-like phenotype in order to prevent rejection of the foetus as a foreign body;
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M2 cells also interact with NK cells and induce regulatory T cells (Tregs) and so most likely
have a role in remodelling the vascular interface.40,47
1.2.1 Monocyte and Macrophage Role in Pathology
1.2.1.1 Inflammation and Liver Fibrosis
Inflammation is an immune response to detection of pathogens or to injury. The process
involves the innate immune system engulfing pathogens via phagocytosis, the release of pow-
erful lytic enzymes and chemical free radicals, such as ROS.11 This is part of a normal
functioning immune system in response to an environment which is constantly presenting
a pathogenic threat to the organism.10 This response can unfortunately result in damage
to surrounding cells and tissues as many of the innate immunity’s defence mechanisms are
non-specific.10 Many diseases are partially or predominantly caused by chronic inflamma-
tion, these include atherosclerosis, rheumatoid arthritis, cancer and organ failure caused by
fibrosis. As monocytes and their more advanced progeny, macrophages, have large phenotyp-
ical variety, these subsets often have multiple and sometimes opposing roles in inflammatory
conditions.2
Fibrosis is a result of chronic inflammation leading to the formation of excessive scar tissue,
nodule formation and, in the case of liver fibrosis, altered hepatic function (see Figure 1.4).3
When tissue is damaged by inflammation, fibroblasts secrete extracellular matrix (ECM)
proteins (mostly type I and III collagens) and if this area is regularly damaged the ECM
develops into scar tissue.3 Tissues eventually become fibrotic over time, this is life-threatening
in the case of liver cirrhosis which is a end-stage outcome of disease such as alcoholics liver
disease (ALD) and non-alcoholics fatty liver disease (NAFLD). The liver has a unparalleled
ability to regenerate in a short amount of time and there is some evidence that even late-
stage fibrosis is reversable; this creates a need to develop novel anti-inflammatories to stop
fibrogenesis and anti-fibrotics to aid regression.4
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Figure 1.4: Sinusoidal cross-sectional diagram of the liver, showing hepatic stellate cells (blue,
responsible for collagen secretion pathologically in fibrosis). Hepatocytes are arranged in cords
surrounded by a fenestrated endothelial lining. Macrophages (purple) patrol the intervening space
and can activate stellate cells to produce collagen, leading to fibrosis. Reproduced with permission
from Piast et al.48
Monocytes and macrophages have been shown to facilitate an integral role in the progression
and also resolution of liver fibrosis. Monocytes and macrophages can non-specifically damage
surrounding liver tissue in inflammation, again triggering collagen deposition as part of the
wound healing process.3,49 The ‘tissue-repair’ M2 macrophages on the other hand can be both
fibrogenic, through excessive deposition of collagen and fibrolytic through anti-inflammatory
functions.4 For example, fibrolytic macrophages in murine liver have been shown to be derived
from circulating Ly6C+ monocytes (inflammatory murine blood monocytes) transmigrate and
differentiate into Ly6C− macrophages, expressing high amounts of matrix metalloprotease
(MMP).50 Furthermore, evidence of the detrimental effects of M1 polarisation in the liver in
the context of NAFLD and protective effects of M2 macrophages provide a strong driving
force for subset specific therapeutic development in certain disease states.51
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1.2.1.2 Tumour-Associated Macrophages
The tumour micro-environment contains many cell types which are involved in the progres-
sion and lifecycle of the tumour; tumour associated macrophages (TAMs) are descended
from monocytes which have been ‘captured’ by the tumour to facilitate tumourigenesis.52
Blood monocytes are more likely to be activated towards an M2 phenotype in the tumour
microenvironment due to hypoxic conditions and Th2 cytokines such as IL-10. Interestingly,
the monocytes are recruited to the tumour site by inflammatory cytokines where the cells
then experience Th2 immunoregulatory signals to progress into the TAM phenotype.
52,53
Circulating blood monocytes are recruited via CCL2, whereby the monocytes transmigrate
across the endothelium into the tumour microenvironment. This has been demonstrated by
CCL2 expression levels in tumuors correlating with the increased influx of monocytes to the
tumour.52,54 TAMs support the tumour as they do not present cytotoxic activity towards
tumour cells, they produce growth factors towards cancer and endothelial cells (ECs) and
also have immunosuppressive functions.55,56 Further studies have revealed a central role of
macrophages in the angiogenic switch of abnormal cells into a malignant tumour, and this
effect is reversed in mice lacking the key macrophage growth factor, colony-stimulating fac-
tor - 1 (CSF-1).57 Macrophage heterogeneity also translates into TAMs where considerable
TAM phenotypical variety exists, with phenotypical modulations having a role in tumour
metastatic progression.58 This modulation typically ends with TGF-β production by the
tumour leading to M2 polarisation in a tumour-promoting direction.59
1.2.1.3 Myeloid-Derived Suppressor Cells
Monocytes have further responsibility for pathogenesis through their link to immature myeloid
cells which have been identified as having a role in many dieases, although most notably in
cancer. In the steady state, these immature myeloid cells (IMCs) quickly develop into ma-
ture granulocytes, monocytes or dendritic cells (Figure 1.5). However, in cancer for example,
IMCs are expanded via blockage of the natural differentiation pathway.60 These cells have
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Figure 1.5: Hematopoietic stem cells begin in the bone marrow and upon exposure to differentiating
cytokines and growth factors (such as GM-CSF, macrophage colony-stimulating factor (M-CSF),
SCF, IL-3 and FLT3), these cells progress into immature myeloid cells (a). The immature myeloid
cells enter the peripheral blood as monocytes or granulocytes before transmigrating into normal
tissues and differentiating into macrophages, dendritic cells or other granolucytes. In some disease
associated microenvironments the immature myeloid cells can differentiate towards disease causing
phenotypes such as MDSCs in infection, trauma and cancer, or towards TAMs (b). Reproduced
with permission from Gabrilovich et al.60
immunosuppresive functions and represent a heterogeneous population of myeloid cells, some
with granulocytic and some with monocytic morphology.61 Interestingly, human MDSCs do
not express typical monocyte markers such as CD14 which reflects the immaturity of these
cells, instead, they are defined as CD14−CD11b+CD33+ cells which have also been shown to
express CCR2.60,62–64 MDSC subsets have been identified in various roles, such as in infec-
tion, trauma responses, in the tumour environment and in lymphoid tissues; factors produced
by inflammation and tumours prevent MDSC differentiation leading to pathogenesis.60,65,66
The expansion of the MDSC population in response to cancer can be tenfold, as has been
demonstrated in murine studies, and these cells have a strong ability to inhibit T cell prolif-
eration, aiding tumour growth.60,67 The mechanism by which MDSCs suppress T cell activity
in disease is thought to be via arginine metabolism through both iNOS and arginase 1.62,68
This leads to an arginine shortage in the MDSC microenvironment which has been linked to
a reduction in T cell proliferation and also an increase in T cell apoptosis.69,70 Therapeutic
strategies include initiation of MDSC differentiation into more mature myeloid cells, inhibi-
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tion of immunosuppressive pathways and direct elimination of MDSCs.60,71–73 Development
of tools that can help understand MDSCs in vivo function are needed, as well as targeted
therapeutics.
1.2.2 Classical, Intermediate and Non-classical Monocytes
Monocytes were previously delineated through functional phenotypes such as pro- or anti-
inflammatory. This arose due to experiments performed in mice which discovered differential
expression of the inflammatory surface marker Ly6C (GR1).10 Human monocytes, however,
have increased heterogeneity from this murine model in the form of relative expression of
CD14 and CD16. The inflammatory classifications in mice can be unhelpful as there can be
a significant amount of functional crossover of these broad subsets. It was therefore decided in
2008 to refer to only three types of human monocyte based on CD surface receptor expression:
classical, intermediate and non-classical monocytes.8 ?? highlights the CD receptors used for
distinguishing these subsets; it is based on relative expression of CD14 and CD16. Murine
monocyte subsets are also listed which highlights the homology between the species, however
the species have some functional differences which has confused some of the literature. For
example, it was previously suggested that classical and intermediate monocytes resemble
mouse Ly6C+ inflammatory monocytes and the non-classical monocytes resemble the anti-
inflammatory Ly6C− mouse monocytes.8 However, much research has revealed the non-
classical monocytes can be pro-inflammatory but through distinct mechanisms to both murine
and human subsets.10
The major function of the CD14 marker is in LPS binding as part of the innate immune
system and so any cell that presents this marker is identified as a monocyte. A subset of
cells that also express CD16 (an Fc receptor for antibody-dependent cell-mediated cytotox-
icity) were later identified as a class of monocytes with distinct functional behaviours from
ordinary CD14+ monocytes.75 Classical monocytes are able to phagocytose erythrocytes and
are greatly adherent to surfaces, however, the CD16+ subset was found unable to effectively
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Figure 1.6: Monoclonal antibody labelling of CD14 and CD16 reveals three populations of monocyte
displaying a characteristic overall “banana” shape.74 The CD14+ cells and the CD14− CD16+ also
differ in size, with CD14− CD16+ monocytes generally being smaller in size (13-18 um) than the
larger CD14+ monocytes. Reproduced under a Creative Commons licence from Stansfield et al.74
phagocytose erythrocytes, were largely non-adherent and express higher levels of MHC class
II complex for antigen presentation.
Following on from this research, the CD16+ population was further divided into two subsets
which now make up the aforementioned non-classical and intermediate monocytes.76 In flow
cytometric analysis the three monocyte subsets exhibit a “banana” shaped distribution with
respect to CD14/CD16 expression; Figure 1.6 shows this labeling strategy and highlights
the three subsets. Interestingly, this distinctive distribution may actually show a progression
of the classical monocyte differentiating to a non-classical monocyte, with the intermediate
subset acting as a bridging population.77 For example, a phase I clinical trial investigating
the effects of M-CSF and interferon on monocytosis found that classical monocytes were
present at the beginning, followed by mixtures of classical and intermediate at eight days
post-treatment and finally, after fifteen days the population was almost entirely consistent
of non-classical monocytes.78 Transcriptional analysis of CD16+ and CD16− monocytes es-
tablished that CD16+ monocytes represent a more advanced stage of immune cell and have
more macrophage character, expressing adhesion molecule CL62L and chemokine receptors
such as CX3CR1.
79 CD16− monocytes possess more similarity to myeloid precursors, for ex-
1.2. Monocytes 18
ample, CCR2 expression and the lack of surface adhesion molecules. Futhermore, CD16+
monocytes were found to be arrested by, and migrate towards, fractalkine (CX3CL1) as an
exclusive mechanism for CD16+ monocyte recruitment.80 A patient study also demonstrated
similar phenotypic chemokine trafficking differences between the subsets; CCR2 expression
was observed to be higher in classical and intermediate monocytes and low in non-classical
monocytes.9 This was reversed for CX3CR1 expression with the classical monocytes express-
ing low levels and the intermediate and non-classical being high in CX3CR1; this suggests
a phenotypic switching as the monocytes progress through the subsets via the intermediate
transitional subset. The distinct molecular recruitment mechanisms of monocyte subsets
leads to potential for therapeutic development towards context specific disease states.
Further evidence suggestive of phenotypic progression from classical to non-classical mono-
cytes stems from surface marker expression of the intermediate monocytes residing at levels
between the extremes of classical and non-classical (See ??).10,81 Studies by Geissman et al.
have highlighted functional differences between the subsets and also provide more evidence for
the transitional nature of the intermediate monocyte.82 Efforts to draw functional homologs
between human and murine monocyte subsets were undertaken in that human classical and
intermediate monocytes resembled murine “pro-inflammatory” monocytes. Indeed, like their
murine counterparts, classical and intermediate monocytes both were unable to attach to the
endothelium of blood vessels nor exhibit any crawling behaviour. The CD14−CD16+ popula-
tion however, quickly attached and crawled along the endothelium akin to Ly6Clo monocytes.
The classical and intermediate monocytes were also found to differ in inflammatory function;
CD14+CD16− easily phagocytosed latex beads and released ROS in response to bacterial
stimuli, the double positive intermediate cells did not reflect this behaviour. The various
behaviours and cytokine/chemokine production of monocyte subsets found in this study are
summarised in Table 1.1.82 This study also highlighted why grouping subsets functionally
can be unhelpful, for example, non-classical monocytes did not exhibit pro-inflammatory
behaviours in response to bacterial cues (ROS production, phagocytosis) and even exhibited
some anti-inflammatory behaviour (IL-1 receptor antagonism). However, in response to vi-
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ral nucleic acid detection non-classical monocytes exhibited distinct inflammatory cytokine
production. These findings suggest that the multiple subsets have independent roles in the
clearance of pathogens rather than a ‘pro’ or ‘anti’ inflammatory phenotype.
The trafficking and development of the human monocyte subsets is now widely accepted to
originate from the bone marrow as classical CD14++ monocytes before differentiating into in-
termediate, and non-classical monocytes in blood circulation (Figure 1.7).10,83 The behaviours
of the monocyte subsets then become quite different; classical and intermediate monocytes
function together by invading tissues through CCL2/CCR2 signalling and/or CCL5/CCR5
signalling via a VLA-1/VCAM-1 dependent manner. The non-classical monocytes do not
circulate as the other subsets, instead they patrol the vessel wall for long periods and only
transmigrate in response to CX3CR1/CX3CL1 activation in a lymphocyte functional antigen
1 (LFA-1)/intercellular adhesion molecule 1 (ICAM-1)-dependent manner.10
Figure 1.7: Classical monocytes exit the bone marrow in a CCR2 dependent manner and enter
the bloodstream. The classical monocytes can be recruited into tissues by CCL2/CCR2 and/or
CCL5/CCR5 signalling or this subset transitions to intermediate monocytes; this subset can undergo
tissue invasion by the same mechanisms as their classical counterparts. The intermediate monocytes
can also transition into non-classical monocytes which proceed to patrol the vessel wall. These cells
transmigrate via CX3CL1/CX3CR1 signalling. Post-transmigration, the classical and intermediate
monocytes differentiate into M1 macrophages (inflammatory), non-classical monocytes differentiate
into M2 macrophages (anti-inflammatory). It is speculated that the classical and intermediate
monocytes can also differentiate into M2 macrophages. MC - monocyte, endothelial cell (EC), TC
- T cell, Mφ. Reproduced with permission from Yang et al.10
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Table 1.1: Comparison of functional behaviour and cytokine/chemokine production across the
three monocyte subsets.82 This research highlights the differing roles the subsets can play, with
non-classical monocytes exhibiting both pro-inflammatory (unique TLR7-TLR8-MYD88-MAP2K
dependent pathway) and anti-inflammatory IL-1 antagonism. Adapted from Cros et al.82
Classical
CD14+CD16−
Intermediate
CD14+CD16+
Non-classical
CD14dimCD16+
Endothelium
patrolling
no no yes
Phagocytose
beads
high high low
ROS produc-
tion
high none none
TNF-α none high low
IL-1β low high high
CCR2 high med low
IL-10 high med none
IL-8 high med low
IL-6 high high low
CCL3 high high low
IL-1 receptor
antagonist
none low high
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1.2.2.1 Diseases Associated with Monocyte Subsets
Many diseases have been associated with monocytes and their subsets, interestingly, expan-
sion of the CD16+ populations are often observed in response to these diseases or infections.84
Generally, the intermediate subset is expanded, often with expansion of the non-classical sub-
set as well and diseases include sepsis, tuberculosis (TB), hepatitis B and C, and auto-immune
diseases.84–90 This expansion of the intermediate subset was often accompanied by a reduc-
tion in classical populations, suggesting a progression of the classical monocytes towards the
intermediate monocytes.84,90
Figure 1.8: Flow cytometric analysis of CD14 and CD16 in RA patients’ monocytes compared with
healthy control groups. A clear increase in CD16+ monocytes can be seen in RA patients with
32.8% of the dual-positive CD14/CD16 population of RA patients compared to 6.9% of healthy
control patients; this suggests a role for CD16+ monocytes in RA. Patients were grouped into
rheumatoid arthritis (RA) or healthy control (HC) according to levels of C-reactive protein: active
RA corresponding to CRP ≥ 30 mg L−1. Reproduced with permission from Kawanaka et al.91
In rheumatoid arthritis, CD14+CD16+ monocytes were shown to be expanded in patients
with the active disease (Figure 1.8).91,92 Interestingly, this population was depleted in re-
sponse to RA therapy suggesting that treatment with glucocorticoids can actually selec-
tively deplete this disease associated population.93,94 A molecular mechanism for recruitment
and/or expansion of the CD16+ population has been suggested as a result of TGF-β (ex-
pressed in synovial fluid) induction of CD16+ on monocytes.95 However, it is unclear whether
CD16+ monocytes are recruited to the synovium in RA or the classical CD14++CD16− mono-
cytes migrate towards the inflamed site and differentiate into CD16+ subsets in response to
TGF-β.96
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Atherosclerosis is a disease of the arterial wall where excessive amounts of lipids accumu-
late on the endothelium leading to coronary heart disease. Monocytes have been identified
as contributing to the inflammation present around atherosclerotic plaques.97 Two broad
subsets of CD16+ and CD16− were defined in this murine study which found that CD16−
monocytes were dependent on CCR2 for recruitment at the introduced plaque but CD16+
monocytes utilised CX3CR1 for this purpose. Intermediate monocytes have been associated
with low levels of the beneficial high-density lipoprotein (HDL) and high levels of the dele-
terious low-density lipoprotein (LDL).98 Larger studies into coronary artery disease (CAD)
have shown an increase in intermediate monocytes suggesting a broader role for this subset
in CAD.96 Again, whether this intermediate population is recruited to the plaques inde-
pendently, or arrives as a classical monocyte before transitioning to the disease associated
intermediate monocyte, is unclear. This provides an opportunity for further investigation of
the phenotypical role in this disease and thus therapeutic development in a subset specific
manner
Monocyte subsets have been identified in having diverse roles in liver fibrosis, in this organ,
resident macrophages known as Kupffer cells are continually replenished by blood mono-
cytes.99,100 These populations are also modified to a great extent by infiltrating blood mono-
cytes in response to liver injury.101 A study into monocyte subset expansion in response
to liver injury and the subsequent effect on liver fibrosis demonstrated that CD14+CD16+
monocytes were expanded in liver sections which were fibrotic.99 This actually increased in
a dose-dependent manner in terms of the progression from healthy, to fibrotic, to cirrhotic
which correlated with a gradual increase in the intermediate/non-classical subset. These
subsets were also found to exhibit increased production of pro-inflammatory cytokines such
as TNF-α which leads to further recruitment of blood monocytes and potentially increased
inflammatory cytokine production. Furthermore, CD14+CD16+ monocytes in patients with
chronic liver disease were also found to be in a highly activated phenotype in terms of pro-
inflammatory cytokine production relative to the same subset in healthy control patients. A
difference in paracrine activity was also observed in the CD14+CD16+ subset as these cells
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were shown to induce activation of hepatic stellate cells towards increased collagen deposition
in ex vivo experiments, this behaviour was not observed in classical monocytes.99 This fibro-
genesis activation was most likely via TGF-β expression by CD14+CD16+ monocytes and this
pro-inflammatory, pro-fibrogenic phenotype was associated with increased CCR2 expression
on this subset.99 Other murine studies complicate this issue as while liver macrophages are
associated with liver fibrosis, these cells also play a key role in fibrosis regression.102 In human
livers, fibrotic diseases have been linked to an expansion of intrahepatic monocytes relative to
healthy controls.103 The authors suggest two mechanisms of intermediate monocyte recruit-
ment in the liver: recruitment from blood, as this subset underwent higher transendothelial
migration than classical monocytes, and differentiation in the liver from classical monocytes
in response to TGF-β and IL-10. These intermediate monocytes were characterised by many
pro-inflammatory and pro-fibrotic markers such as increased phagocytic activity, antigen
presentation, and up-regulation of pro-inflammatory and pro-fibrogenic cytokines, such as
TNF-α and CCL2. Intermediate monocytes therefore represent a key fibrogenic subset of
monocytes which increases inflammation and progression of liver fibrosis.103
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1.3 Chemokines and CCL2
1.3.1 Chemokine Structure, Function and Families
First identified in 1977, chemokines are small heparin-binding binding proteins which are
structurally related to cytokines and are responsible for cell trafficking in a process called
chemotaxis.104,105 There are many different chemokines with around half as many chemokine
receptors. Chemokines are generally small proteins with a molecular weight of around 8-
12 kDa, containing four cysteine residues which are highly conserved across the chemokine
family.106 There are four classes of chemokine which are grouped according to the number of
cysteine residues nearest the N-terminus and their location in the peptide sequence: CXC,
CC, CX3C and C (see Figure 1.9).
106 For example, ‘CXC’ refers to the two cysteines nearest
the N-terminus separated by a single amino acid, whereas ‘CC’ refers to two adjacent cysteines
nearest the N-terminus. Chemokines are secreted by many cell types to recruit monocytes,
however, the chemokine receptors are mostly found only on leukocytes. The majority of
chemokines are found dissolved in serum, though there are some exceptions such as CX3CL1
(fractalkine) which is a membrane protein presented on the surface of ECs and is responsible
for non-classical monocyte transmigration.10 While chemokines are structurally related, even
within sub-families, they are functionally diverse.
The three-dimensional structure of chemokines has three domains containing a highly flexi-
ble N-terminus which is held in place by disulfide bonds, a loop which extends around the
molecule before entering three antiparallel β -pleated sheets and finally an α -helix that lies
over the sheets; this arrangement is known as a ‘Greek key’ (Figure 1.10).107 The sequence
homology of chemokines ranges from highly conserved to varied but interestingly the three di-
mensional structure is relatively similar, regardless of the amino acid sequence differences.108
Crystallographic and NMR studies have shown that chemokines exist as multimers in solu-
tion, with the majority being dimeric. The mode of dimerisation also separates into the sub-
families, for example, CXC chemokines dimerise along the edges of the first β -pleated sheet,
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Figure 1.9: The four sub-families of chemokines and their overall defining structures. Each
chemokine sub-family contains three β -pleated sheets and an α-helix at the C-terminus.
Chemokines are grouped into the number of chemokines found proximally to the N-terminus, CXC,
CC, C and CX3C. The CXC chemokines have two cysteines separated by a single amino acid, CC
chemokines have adjacent cysteine residues and the C chemokines have only one cysteine near the
N-terminus. The CX3C chemokines are different in that the cysteines are separated by three amino
acids and also have a carbohydrate-rich mucin stalk, as well as a short cytoplasmic domain (being
a membrane protein). Adapted from Rollins et al.106
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resulting in a parallel arrangement of the molecules.109 The CC chemokines, on the other
hand, dimerise through interactions between short β sheets near the N-termini which gives a
larger cylindrical structure than CXC dimers.110 The importance of dimerisation for initiation
of chemotaxis has been controversial although it would seem this is a prerequisite for sig-
nalling, either in situ dimerisation or upon interaction with glycosylaminoglycans (GAGs).111
This dimerisation behaviour is variable across chemokines even from the same sub-family,
for example, it was found that CCL2 and CCL8 exhibit strong heterodimerisation in NMR
studies with a comparable reduction in homodimerisation. Interestingly, electrospray ionisa-
tion fourier transform ion cyclotron resonance mass spectrometry (ESI-FTICR) revealed that
the glycosylaminoglycan Arixtra can greatly enhance the heterodimerisation ability of many
of the CC chemokines (Figure 1.11).111 It is speculated that heterodimerisation and GAG-
heterodimerisation removes the redundancy of the CCR2 chemokines and is an important
regulatory process in signalling.112
Figure 1.10: Schematic three-dimensional structure of chemokines showing the location of cysteines
and the disulfide bridges which anchor the N-terminus to the the β -pleated sheets. Reproduced
with permission from Deshmane et al.104
The N-terminal amino acid sequence has been shown to be crucial for homo and heterodimeri-
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Figure 1.11: Relative abundances of CC chemokine homo- and heterodimers, measured via
ESI-FTICR MS. Dimers found in the absence of Arixtra GAG are shown in A and dimers formed
in the presence of Arixtra are shown in B. Generally, heterodimerisation is enhanced in the pres-
ence of GAG except in the case of CCL2-CCL13, of particular note is the effect on CCL8-CCL11
heterodimers where no heterodimers were observed in the absence of GAG but a dramatic increase
was observed in teh presence of GAG. Reproduced with permission from Crown et al.111
sation of chemokines. In the CCR2 chemokines studied by Crown et al., five of the first ten
amino acids in the sequence are identical and other studies have demonstrated that a proline
at the 8-position is crucial for dimerisation.111,113 In this study, a group of CCL2 variants
were made including: Y13A, V9A, P8A, V9E and T10E; it was found that all constructs were
still able to dimerise to varying extents except from P8A which was wholly monomeric. In
this study and in others, the P8A construct has been shown to exhibit equimolar chemotactic
activity to wild-type CCL2 in chemotaxis assays in vitro which provides strong evidence that
CCL2 is able to bind and activate CCR2 as a monomer.112,113 In the vascular space, flow
conditions mean that generating a chemotactic gradient for cellular recruitment is impaired,
resulting in the need for GAG-heterodimerisation in order to present a monomer of CCL2 for
CCR2-binding and subsequent transmigration of the monocyte. In the extravascular space,
fixed media allows a chemotactic gradient to be established and so monomeric CCL2 is able
to recruit monocytes akin to the behaviour observed from mutant P8A CCL2 in vitro.112 In
a broader context, these distinct functional behaviours appear to have evolved to modulate
signalling, for example, the CCR2 chemokine, CCL7, has a serine substitution at the proline-
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8 position and does not dimerise on GAGs. On the other hand, CX3CL1 is embedded in EC
membranes in the vascular wall which recruits patrolling non-classical monocytes.10,112
1.3.2 CCL2-CCR2 Signalling Axis
CCL2 selectively binds the chemokine receptor CCR2 which initiates internalisation and
a signalling cascade leading to monocytic cell recruitment via chemotaxis. CCR2 is a G
protein-coupled receptor (GPCR) comprising of seven-transmembrane domains which are
helical and have both intra- and extracellular loops.114 The N-terminus and three loops
are presented extracellularly and three intracellular loops with the C terminus are held in
the cytoplasm.114,115 The intracellular loops couple to heterotrimeric G-proteins which are
bound via the G-α and G-β subunits, together forming a junction with the G-γ subunit
(Figure 1.12).116 Upon chemokine binding, G protein-coupled receptor kinases (GRKs) phos-
phorylate Ser and Thr residues on the intracellular loops and the C-terminus. This causes a
conformational change in the G-protein subunits, leading to G-α uncoupling from the com-
plex, giving rise to downstream signalling events. The G-βγ complex also dissociates from
the receptor and leads to further signalling. At this stage, continuous stimulation by lig-
and binding leads to receptor desensitisation and ultimately internalisation via β arrestin
binding.117 Endocytosis is initiated by β arrestin binding to the phosphorylated receptor,
this then also binds adaptin-2 (AP-2), this complex then links with a clathrin lattice, giv-
ing rise to a clathrin-coated pit.114,118 The receptor is then internalised in a clathrin-coated
vesicle through cleavage from the membrane in a dynamin-dependent manner.114,119 The in-
ternalised ligand-receptor complex then progresses into an early endosome which can then
be recycled back to the surface for further ligand binding or is trafficked to lysosomes for
receptor degradation (Figure 1.12).114 The signalling pathways that lead to chemotaxis are
not wholly understood but a number of molecules have been identified such as: mitogen acti-
vated protein kinase (MAPK), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), phos-
phoinositide phospholipase C (PLC)/protein kinase C (PKC) and gene expression through
the JAK/STAT pathway (janus kinase (JAK) and signal transducer and activator of tran-
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scription (STAT)).120 The cell processes that follow these pathways include gene expression,
cell polarisation and ultimately chemotaxis.
Clathrin-independent internalisation pathways have also been described, such as through
lipid rafts/cavaeloe mechanisms but these are less well characterised than the typical clathrin
mediated pathway.114 Caveolin is a protein which is found in flask-shaped membrane invagi-
nations that are also rich in lipids such as cholesterol and sphingomyelin.114,116 Research into
this internalisation pathway for chemokine receptors is limited, with only CCR5 and CXCR4
being identified in lipid rafts.114 Post-internalisation, the receptor is held in a caveosome
which can then fuse with early endosomes.121 It has been suggested that caveolae mitigate
compartmentalisation of chemokine signalling and may also contribute the rapid recycling
of receptors back to the membrane for further agonist binding.114,116 With respect to CCR2
internalisation, caveolin dependent pathways have been demonstrated in astrocytes, however,
further research is needed into the prevalence of these pathways in monocytes.122
The chemokine receptors have been shown to amass at the leading edge of the cell during
migration, which is thought to occur through receptor dimerisation and movement through
the bilayer in lipid rafts.120 GPCRs can exist as higher order oligomers and it has been
reported that chemokine receptors utilise dimerisation to modulate functional responses.115
The previously mentioned redundancy of chemokines may actually be part of a subtle refine-
ment of response as receptor heterodimers have been shown to influence receptor specificity
and subsequent signalling.115,123 The aggregation state of chemokine receptors has actually
been shown to influence the speed of response and the nature of the response itself (see Fig-
ure 1.13).124 For example, calcium mobilisation is almost instantaneous upon ligand binding
meaning that this likely occurs as the receptor exists as a monomer because dimerisation of
large chemokine receptors is a relatively slow process. Elevation of the response then depends
on G-βγ subunit release, leading to PLC and PI3K activation.124 Dimerisation does appear
to be necessary for activation of the JAK-STAT pathway, which is a slower process.124,125
Finally, receptor desensitisation and internalisation requires a critical mass of higher order
oligomers, this recruitment is a much slower process often taking over 60 seconds. This pro-
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(a) Signalling pathways of 7TM GPCRs such as CCR2.116
(b) Trafficking of activated 7TM receptors.116
Figure 1.12: In the steady state, 7TM receptors have a coupled heterotrimeric G-protein unit at the
intracellular C-terminus, with a GDP bound to the α subunit (Figure 1.12a). Upon agonist activa-
tion, GTP binds the G-α subunit which dissociates and begins a signalling cascade through cAMP
and PKA, leading to chemotaxis. Figure 1.12b shows how the receptor is trafficked post-activation;
GRK phosphorylation of the receptor leads to recruitment of β -arrestin for subsequent clathrin-
mediated endocytosis. The receptor complex is then either degraded in lysosomes or recycled back
to the surface. Reproduced with permission from Pierce et al.116
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cess is mitigated through receptor phosphorylation and subsequent arrestin binding which
are both slow processes for which G-protein dissociation is a prerequisite.124,126 However,
much of this research has been performed on an array of chemokine receptors and some on
other non-chemokine 7TM receptors meaning the consensus is not complete.
Figure 1.13: Chemokine receptor states and association with response times and signal transduction
pathways. Calcium flux and PIP3 mobilisation are near instantaneous after ligand binding and
so occur through monomeric receptors (due to the lag period for receptor orientation for efficient
dimerisation). Also, PI3K is directly activated by G-protein subunit release, which is a rapid process.
It has also been demonstrated that dimerisation is necessary for JAK-STAT pathways, making
this a slower signalling event.125 Finally, higher order clusters form, with receptor desensitisation
through receptor phosphorylation and subsequent arrestin binding; the clusters are then internalised.
Adapted from Thelen 2001.124
1.3.2.1 Alternative CCL2 Receptors
A number of so-called, atypical chemokine receptors (ACKRs) have been identified which bind
and often internalise chemokines but do not initiate the typical G-protein signalling cascade
found in conventional chemokine receptors such as CCR2. The Duffy antigen receptor for
chemokines (DARC) is an example of an ACKR, which is expressed on erythrocytes and
some ECs, this receptor lacks any G-protein coupling motif and so it was initially thought to
be a scavenger receptor for chemokines.127,128 One function of DARC on red blood cells is to
hold chemokines on the surface of the cell which acts to regulate chemokine concentrations in
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the blood and therefore inflammatory responses.129 DARC is thought to possess a sink and
reservoir function, for example, when chemokines are released into serum they rapidly bind
DARC on red blood cells (RBCs), the liver then depletes the concentration of chemokine
resulting in release of DARC-bound chemokine back into the serum, equilibrating serum
levels.129 Another role for DARC is in the process of transendocytosis of chemokines to the
luminal surface of some ECs.129 Here, chemokines secreted in tissues are bound by basal
DARC which is then migrated through the membrane, likely within lipid rafts, before being
presented on the apical surface of the EC.129,130 Varying chemokine ligands appear to lead to
alternative DARC internalisation mechanisms in ECs. DARC has been shown to colocalise
with CCL2 within endosomes containing caveolin, presumably this function has evolved to
provide greater modulation of chemokines.131–133
Another atypical chemokine receptor which binds CCL2 is D6, also known as a scavenger
receptor. This receptor is an interesting example due to its similarity to other chemokine
receptors, sharing a heptahelical structure and around 60% similarity to the other chemokine
receptors.129,134 Where D6 differs from the typical chemokine receptors is in the C-terminus
and a small deviation in the second intracellular loop which contains a DRYLAIV motif but
in the case of D6 the motif is DKYLEIV.129,134 The alterations in the C-terminus and the
second intracellular loop render D6 incapable of typical G-protein signalling and therefore
calcium flux or chemotactic function which has resulted in this receptor being denoted a silent
scavenger.135 The receptor is present on many cell types including lymphatic endothelial cells,
leukocytes and hepatocytes.129 As opposed to DARC, D6 does not have any transcytosis
function in lymphatic endothelial cells, however it is capable of internalising ligand towards
endosomal compartments.136 Furthermore, the receptor has been shown to recycle back to
the surface membrane in immortalised cell lines, and undergoes phosphorylation of the C-
terminus and subsequent β-arrestin recruitment.137 In vitro studies such as this and also D6
knockdown experiments demonstrate that chemokine ligands are not depleted in media by
cells which also lack conventional chemokine receptors.129 A large number of in vivo studies
have highlighted an anti-inflammatory role for D6, as mice deificient in the receptor generally
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exhibit a pronounced inflammatory response to injury relative to wild-type (WT) mice.129
1.3.3 The Function of CCL2 in Homeostasis and Pathology
CCL2 is thought to be largely responsible for recruiting classical monocytes from the bone
marrow into the peripheral blood and from there, into tissues (Figure 1.14) via CCR2. CCL2
is a ubiquitously secreted protein upon activation by pro-inflammatory cytokines or direct
stimulation via microbial molecules.11 The role of CCL2 in influencing the immune response
has been shown to also be mitigated through T cell immunity. For example, a number
of studies related CCL2 expression with a polarised Th2 response and also an enhanced
production of IL-4.104,138,139 The levels of CCL2 were highly increased in mouse models of
granuloma and this effect was coincident with a switch from Th1 to Th2 responses.
138 Upon
consideration of this evidence, it would appear that CCL2 is responsible for not only monocyte
migration but also has a central role in adaptive immunity and subsequent inflammation.
1.3.3.1 CCL2 Role in Infection
CCL2 expression is associated with infections and inflammation, therefore it is necessary
to understand the function of CCL2 is in vivo.140,141 In a study of CCL2 deficient mice,
responses to infection were initiated by injecting complete Freund’s Adjuvant (CFA) and
keyhole limpet hemocyanin (KLH) into the skin.142 The numbers of circulating monocytes
reaching the infection site were reduced on a number of days and this greatly affected mono-
cyte numbers in the lymph nodes. This was due to the monocyte chemoattractant protein
1 (MCP-1) production at the infection site being transferred into the lymphatic system which
was thought to aid antigen presentation in the lymph nodes. Therefore, CCL2 is responsible
for initial recruitment to the infection site and then subsequent transfer to the lymph node.
Intravital microscopy demonstrated that CCL2 deficiency impaired the ability of monocytes
to arrest in the inflamed lymph nodes although it did not prevent rolling.142 Interestingly,
the CCL2/CCR2 axis can have positive and negative consequences for infection, for exam-
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Figure 1.14: Two models of recruitment of monocytes into the peripheral blood from bone marrow:
chemokinesis and chemotaxis. In the chemokinesis model, monocytes undergo greater movement
which increases the probability of collision with blood vessels, the cells then cross the endothelium
in a CCR2 independent manner (a). In the chemotaxis model, CCL2 binds to surface-bound GAGs
which then initiates transmigration into the peripheral blood. It is thought that the latter model
is particularly important in flow conditions, for example, for circulating monocytes to extravasate
into tissues. Reproduced with permission from Shi et al.11
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ple, in many bacterial infections CCR2 is responsible for both recruitment of monocytes to
the infection and production of pro-inflammatory cellular responses, such as iNOS.11 CCL2
has been identified in having a role in the previously discussed ‘anticipatory inflammation’
whereby monocytes are expanded according to circadian rhythmns; the circadian clock gene,
Rev-erbα has been shown to modulate the function of macrophages by down-regulating the
expression of CCL2.143 In the case of L. monocytogenes, CCR2 deficiency led to a greater
level of infection than wild-type mice; this behaviour was reflected in other studies involving
CCL2 and CCL3 mediated recruitment of Ly6C+ mice.144,145 Other microbials such as in-
fluenza complicate the issue as CCR2-deficient mice generally lead to diminished recruitment
of monocytes which actually lowered the mortality rate.146 However, it was also found that
CD8 T cell responses were not initiated leading to reduced clearance of the virus; CCL2
production was then partially inhibited leading to both lower mortality rates and an in-
crease in pathogen clearance. This study was further validated by evidence that CCR2 is
crucial for the recruitment of antigen-specific IFN-γ producing cells. This would suggest
that CCR2-positive monocytes are responsible for linking the innate and adaptive immune
responses.147
1.3.3.2 CCL2 Role in Inflammation and Liver Fibrosis
The CCL2/CCR2 axis also has a significant role in inflammation and many diseases caused
by chronic inflammation. A role for CCL2 has been shown in cardiac fibrosis where CCL2
deficient mice were shown to have reduced numbers of infiltrating monocytes in response to
being treated with pro-inflammatory cytokines.148 Interestingly, not only was the extent of
fibrosis lowered in CCL2 deficient mice but the absence of these monocytes led to greater
breakdown of collagen in the heart by MMP-9. The effects of the loss of CCL2 were ex-
hibited in a number of ways, including lowered pro-inflammatory cytokine production and
the mitigation of T cell responses, suggesting a central role for CCL2 in inflammatory and
fibrotic diseases. In other inflammatory diseases such as atherosclerosis, monocytes have
been identified as having a central role in both progression and disease resolution through
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subset-specific behaviour. In this context, CCL2 and CCR2 are both highly expressed around
atherosclerotic plaques and the ligand can induce early atherosclerotic lesion formation.149
As discussed in section 1.2.1.1, liver fibrosis and eventual cirrhosis is a condition caused by
chronic inflammation which leads to excessive collagen deposition and ultimately scarring.
The CCL2/CCR2 axis has been identified as a key mediator of progression and even regres-
sion of fibrosis. In non-alcoholics fatty liver disease (NAFLD), serum levels of CCL2 were
found to be significantly higher in sufferers of NAFLD, this also positively correlated with
disease progression.150 This complements the previously discussed research which indicated
CCL2 is not only responsible for monocyte recruitment but also a potent initiator of inflam-
mation across many cell types. Interestingly, CCR2-deficient obese mice have been shown
to exhibit a reduced inflammatory profile and reduction in liver fibrosis compared with WT
mice.151 Mice deficient in CCR2 actually displayed a slightly lower propensity for obesity
than WT and this was also reflected by lowered insulin resistance. Promotion of angiogene-
sis in liver fibrosis has also been linked with CCL2 in mice treated with a CCL2 inhibitor.152
In this study, liver fibrosis was initiated by CCl4 injury and surprisingly, inflammation did
not seem to be affected, however the formation of new blood vessels was markedly reduced.
Similar studies with other CCL2 inhibitors have found a reduction in murine inflammatory
monocyte subsets towards injured liver tissues; this has also coincided with a decrease in
cytokine production (such as IFN-γ).153 CCL2 inhibition prevents the accumulation of Gr1+
murine monocytes to the liver which actually enhanced regression of liver fibrosis, relative to
uninhibited mice, suggesting potential for monocyte subset selectivity.154 The authors specu-
lated this was due to a shift in equilibria towards regenerative monocyte-derived macrophages
as a result of reduced numbers of inflammatory monocyte-derived macrophages. This area is
slightly controversial as restorative macrophages are known to differentiate from Gr1+ mono-
cytes, however, it is possible the restorative macrophages were derived from infiltrating Gr1−
monocytes or expansion of endogenous macrophages.154
This complex role of monocytes/macrophages in liver fibrosis and the association with the
CCL2/CCR2 axis was demonstrated by Gilgenkrantz et al.155 The expression levels of many
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pro-inflammatory cytokines were found to be significantly reduced in CCR2-deficient mice,
such as CCL2, TNF-α IL-6 and IL-1β. Initially, liver fibrosis progressed to a lesser extent in
CCR2 deficient mice, most likely due to a reduction in infiltrating inflammatory monocytes.
However, resolution of the fibrosis was also reduced in CCR2-deficient mice compared to the
wild-type mice which possessed the receptor. This suggests that the CCL2/CCR2 axis is
responsible for both recruiting monocytes which lead to fibrosis but these monocytes then
later aid in regression. Another interesting aspect of this work is that the initial fibrosis was
not wholly reduced in CCR2-deficient mice; this is thought to be a result of the ligand CCL2
having two distinct modes of progressing fibrosis, namely the recruitment of monocytes and
also the activation of fibrogenic hepatic stellate cells. This work suggests that a blanket
approach on CCR2 inhibition is unlikely to be effective in the treatment of liver disease.
1.3.3.3 CCL2 Role in Cancer
Cancer is primarily a genetic disease in which many cancerous tumours can be traced back to
a mutation or mis-regulation of a particular gene.156 While the gene for CCL2 or the receptor
CCR2 have not been directly identified as such, the central role of the CCL2/CCR2 axis in
many host immunology activities means CCL2 can have multiple roles in the same tumour
setting. This could be activation of anti-tumour responses in T cells, promoting growth
or inhibiting growth, depending on the context (for example, CCL2 attracting cytotoxic
immune cells whilst also activating angiogenesis). Anti-tumour properties of CCL2 have
been described in vivo, these properties are a result of monocyte recruitment to the tumour
site.157,158
The primary role for CCL2 in cancer, however, appears to be that of pro-tumour growth
as evidenced by the numerous studies associating CCL2 with progression of many different
cancers.156 For example, breast cancer studies have revealed that high CCL2 levels in tumour
biopsies are associated with a poor prognosis and significantly shorter relapse-free survival
times.160 One mechanism elucidated for this behaviour is that tumours express CCL2 in order
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Figure 1.15: Possible pathways for CCL2 mediated malignancy in tumour growth. The tumour
microenvironment releases CCL2 which recruits monocyte from the blood which then differentiate to
a pro-tumour phenotype, such as a TAM (A). Angiogenesis is also stimulated by CCL2 production
and TAMs begin matrix degradation allowing for vessel and tumour growth (B). Finally, CCL2
induce pro-metastatic factor production leading to metastatic cell egress from the tumour to other
areas of the body (C). Reproduced with permission from Soria et al.159
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to recruit monocytes to the tumour, this then leads to secretion of growth and angiogenic
factors leading to cancer progression (see Figure 1.15).156,161 TAMs begin as blood mono-
cytes which are recruited to the tumour site and elicit immunosuppressive phenotypes; rises
in CCL2 expression has been associated with increases in TAM numbers, which also coin-
cides with poor prognosis in breast cancer.162 Initially many studies indicated that CCL2 is
responsible solely for the recruitment of cancer-progressing cells such as MDSCs, MSCs, and
TAMs but more recently CCL2 is beginning to be shown to have a direct role in immunosup-
pression and tumour progression.163–166 For example, a key pre-requisite of tumour growth
is degradation of the ECM, CCL2 has been shown to promote MMP expression in mono-
cytes, T cells and tumour cells.159 In cancer metastasis, CCL2 has been shown to have an
important role in the epithelial-to-mesenchymal transition (EMT) in which ‘Snail’ is a tran-
scription factor that allows cancer cells to acquire mobility.163 The study found that CCL2 is
an effector molecule which directly enhances the metastatic potential of Snail+ tumour cells.
Stimulation of PBMCs with Snail+ supernatant led to an increase in immunosuppressive
Treg cells and MDSC induction and this effect was prevented when the cells were also treated
with CCL2-small interfering RNA (siRNA). This study implicitly identifies CCL2 as having
multiple roles in tumour progression across a wide spectrum of cell types. Interestingly, an-
other study using CCL2 antibodies in breast cancer also showed a reduction in metastases
upon treatment but surprisingly when treatment was withdrawn prematurely, survival rates
dramatically decreased relative to untreated mice.167 This provides a warning of targeting
the CCL2/CCR2 axis for cancer therapy as rebound effects can occur due to a boost of
infiltrating monocytes which leads to angiogenesis, immunosuppression and metastasis.
1.3.4 CCL2/CCR2 Therapies and CCL2 Conjugates
Evidently the CCL2/CCR2 axis is an attractive target for therapeutic development and many
inhibitors of this pathway have been developed. Generally, conventional small molecule an-
tagonists of the receptor, CCR2, have been synthesised and a handful have undergone clinical
trials; however, every CCR2 antagonist has either not been approved or is still in clinical tri-
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als.1 There are major and minor binding pockets in the extracellular surface of chemokine
receptors (Figure 1.16b), generally chemokines will first be tethered to the receptor by inter-
actions with both the major and minor binding pockets, benefiting from a number of strong
supramolecular interactions (Figure 1.16a).168 With the correct orientation the flexible N-
terminus of the chemokine can insert into the helical bundle which initiates the conforma-
tional change in the receptor (Figure 1.17).1,169 The importance of the flexible N-terminus
in chemokines has been demonstrated by endogenous antagonists whereby N-terminal trun-
cated chemokines are able to bind the receptor but are unable to activate signalling.1 The
majority of small molecule chemokine receptor antagonists are allosteric modulators which
interact with the major/minor binding pockets but do not prevent agonist binding. Instead,
these compounds stabilise the inactive receptor allowing the agonist to bind but preventing
the agonist from inducing signalling.1 A more recent strategy is antagonists that bind in
the intracellular C-tail which allows agonist binding but prevents the C-tail from initiating
signalling.170
In total, seven chemokine receptor antagonists have entered clinical trials, the majority are
small molecule allosteric modulators but neutralising antibodies have also been reported.1 A
selection of small molecule antagonists are presented in Scheme 1.1, generally the compounds
are basic, contain a cyclic amine and a substituted amide. The Merck candidate MK-0812
(1) exhibits a low half-maximal inhibitory concentration (IC50) at 5 nm and was entered
into phase II clinical trials for rheumatoid athritis and multiple sclerosis.1,171 Unfortunately
the candidate did not exhibit any significant therapeutic benefits relative to placebo and
Merck has since ceased referencing the program.1 Incyte has also generated a number of
CCR2 antagonists, the most advanced of which is INCB 3284 (2), these compounds share
a 3-aminopyrrolidine core and exhibit high potency at IC50 = 3.7 nM.
172 This compound
progressed to phase II clinical trials for multiple sclerosis and lupus, however, no activity was
observed in these trials.172 Incyte also jointly developed a series with Pfizer, resulting in PF-
4254196 (3) which is almost structurally identical to the Merck candidate 1.1,173Johnson &
Johnson developed a number of CCR antagonists, the leading CCR2 candidate JNJ-17166864
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(a) Chemokine ligand tethering before signalling activa-
tion.168
(b) Major and minor binding pockets of
chemokine receptors.1
Figure 1.16: Receptor chimera and radioligand binding have demonstrated that N-terminal teth-
ering of the receptor to CCL2 occurs through strong binding affinities (Figure 1.16a). The weaker
affinity to the extracellular loops is then overcome through this initial tethering step which allows
downstream signalling. The tethering step can be avoided with high agonist concentrations.168
Figure 1.16b shows that chemokine receptors possess a major and minor binding pocket, whereby
the flexible N-terminus of the ligand binds the major binding pocket followed by association with
the extracellular loops of the receptor surrounding the minor binding pocket. Reproduced with
permission from Pease et al.1
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Figure 1.17: The binding states of chemokine receptors in response to varying binding molecules. A
- chemokine. B - small mol agonist. C - Small mol. antagonist (allosteric). D - small mol. allosteric
antagonist on intracellular loop. Reproduced with permission from Pease et al.1
(4) was modified from a previous CCR2/CCR5 antagonist through structure-activity rela-
tionship (SAR) studies to remove its potency for CCR5! (CCR5!).174 The quaternary
amine confers poor oral bioavailability meaning this candidate was dosed by nasal spray in
an allergic rhinitis clinical trial but data was not released following this trial.175
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A number of CCL2-neutralising antibodies have also been reported in the contexts of rheuma-
toid arthritis and cancer.176 For example, in prostate cancer pre-clinical models have shown
that anti-CCL2 therapies administered in combination with docetaxel led to reduced tumour
burden and also tumour regression.177 The authors reported previously to this study that
bone marrow endothelial cells (BMECs) are a significant source of CCL2 and there is evi-
dence this system encourages metastasis into bone marrow.178 Therefore, CCL2 neutralising
antibodies were administered to mice bearing prostate tumours which led to a 73% reduction
in tumour burden after three weeks of treatment. When these agents were administered as
a combination therapy the tumour burden was decreased to a greater extent than docetaxel
alone and even had lasting effects after treatment was withdrawn.177 These findings were
echoed in another study whereby blockade of CCL2/CCL12 with antibodies was effective
at reducing tumour volumes in a number of cancer lines when used in combination with
CD8+ T cell immunotherapy in vivo.179 Previously, immunotherapy has been shown to be
less effective against cancer than anticipated and a major reason for this is thought to be
the immunosuppressive properties of CCL2, either through recruitment of immunosuppres-
sive phenotypes of monocytes or direct polarisation of T cells towards immunosuppressive
phenotypes.179 Interestingly, this study found that combination of CCL2/CCL12 blockade
with immunotherapy led to cure of cancer in 50% of subjects, however, whilst the number
of activated CD8+ T cells was increased, no effect on MDSCs was observed. It was also
found that blockade of CCL2/CCL12 resulted in a proinflammatory tumour microenviron-
ment with ∼2-fold greater concentrations of cytokines such as TNF-α and IFN-γ. In the case
of glioma, however, a significant effect of MDSC and TAM recruitment has been observed in
pre-clinical models of anti-CCL2 therapies, with anti-tumour effects particularly increased in
combination with chemotherapies.180
Investigations into rheumatoid arthritis have not been as successful when utilising both CCL2
and CCR2 blocking antibodies. A moderately sized clinical study into the therapeutic effects
of anti-CCL2 in patients suffering from RA showed that whilst treatment was well toler-
ated, no significant beneficial effects were observed.181 Furthermore, another clinical study,
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this time on CCR2-blocking antibodies, did show a reduction in recruited monocytes asso-
ciated with RA but no reduction in synovial biomarkers nor any clinical improvement was
observed.182 Reasons for this have been provided by Tak et al. whereby CCR2 and CCR5
blocking antibodies do prevent CCL2/CCL5 mediated monocyte recruitment, it does not
prevent recruitment via other pathways into the RA synovium.183
1.3.5 Existing CCL2 conjugates
A number of CCL2 conjugates have been prepared to allow either functional behaviour to be
evaluated or in the development of novel therapeutics. One example of a fluorescent CCL2
conjugate was developed using protein expression to incorporate a fused mCherry fluorescent
protein at the C-terminus of CCL2.5 The authors demonstrated that the CCL2-mCherry
conjugate exhibited similar potency in initiating chemotaxis and calcium mobilisation com-
pared to wild-type (recombinant) CCL2. This is an interesting result as human CCL2 has a
mass of ∼8 kDa and mCherry has a much larger mass of ∼30 kDa, meaning CCL2 is able
to transport large moelcules with little effect on signalling or uptake. Live cell imaging also
demonstrated that CCL2 is concentrated inside the cells and that monocytes are able migrate
towards a concentration gradient of the conjugate, as well as being able to rapidly repolarise
towards a moving source of chemokine (Figure 1.18). CCL2 is presumably degraded in lyso-
somes and the receptor is recycled back to the surface for further chemotaxis and ligand
internalisation.5 Further time-lapse experiments found that exposure of monocytes to the G-
protein inhibitor pertussis toxin resulted in cessation of chemotaxis towards CCL2-mCherry
however, fluorescence did increase over time suggesting coupling to G-proteins is not essen-
tial for fluorescence uptake.5 The authors also showed that uptake was not via D6 scavenger
receptors or pinocytosis, and continued to show that treatment with a small molecule CCR2
antagonist prevents both chemotaxis and fluorescence uptake. The findings presented in this
study highlight the power of utilising functional fluorescent ligands to reveal information
about chemokine signalling pathways which is difficult to achieve with conventional antibody
methods.
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Figure 1.18: Time-lapse images of monocytes responding to CCL2-mCherry conjugates in a chemo-
tactic manner. The chemokine was introduced by micropipette resulting in a dilution into media
followed by re-concentration inside the monocytes. Monocytes can be seen projecting towards a
concetration gradient of the conjugate and the cells also appear to localise internalised conjugate
towards the luminal side of the migrating cell. Reproduced with permission from Volpe et al.5
An example of using chemokines to deliver therapeutics has been developed by Osprey Phar-
maceuticals, whereby a truncated form of the Shigella dysenteriae holotoxin (SA1) was con-
jugated to CCL2 through recombinant protein fusion.6 The CCL2-SA1 toxin induces cell
death in any CCR2-bearing leukocyte, therefore a method for targeting specific subsets of
many leukocytes (for example, classical and intermediate monocytes) has been developed.
The SA1 toxin enzyme is a ribosome inactivating protein which prevents protein synthesis
resulting in cell death; SA1 also depurinates DNA which initiates apoptosis.6 The group
showed that the CCL2-SA1 conjugate was internalised by monocytes bearing CCR2 and
this uptake resulted in reduced protein synthesis and subsequent cell death. In a model of
kidney nepropathy, this led to significant reductions of infiltrating monocytes/macrophages,
reduced glomerular lesions and proteinuria. A non-native CCL2 variant was used (including
an alanine addition at the N-terminus) but no chemotactic migration data was reported.6
This CCL2-variant has been reported elsewhere to have reduced chemotactic potency relative
to wild-type CCL2 and so it may have been the case the authors desired to modulate the
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effective concentration of CCl2 to match that of the SA1 toxin. A number of conclusions can
be drawn from this research: the relatively large SA1 enzyme is able to escape endosomes as
the inhibitory function is dependent on cytoplasmic distribution, highly cytotoxic compounds
can be safely administered to monocytes selectively via CCR2 internalisation.
The previously discussed CCL2 conjugates were both fused recombinantly expressed pro-
teins, the issue with using these methodologies to develop CCL2 conjugates is that a new
fusion protein must be engineered from first principles each time a new conjugate is desired;
this is time-consuming, expensive and the types of molecules that can be conjugated are
also limited to peptides. The peptide synthesis company, Almac Chemokines, synthesise a
variety of fluorescently labeled chemokines via solid phase peptide synthesis (SPPS). A fluo-
rescent CCL2 conjugate from Almac has been used by Graham et al. in the characterisation
of atypical chemokine receptors, this study benefited from using a functional analogue of
the ligand of interest rather than antibody labeling.184 In an effort to develop a variety of
chemoine conjugates, Handel et al. reported a general method for conjugating chemokines.7
The method uses genetically encoded peptide tags that can be labeled using phosphopan-
tetheinyl transferase enzymes (PPTases) which allows a specific serine to be substituted with
a coenzyme A-fluorophore conjugate. This allows a variety of substrates to be used as long
as the substrate can be synthesised with the coenzyme A tag. This strategy is shown in
Scheme 1.2, including a 12-amino acid peptide as the S6 PPT tag which is then conjugated
through a specific serine resulting in a phosphoester linkage to a fluorophore. The chemokine
conjugate exhibited a around a ten-fold decrease in potency; the cause of this decrease is
unclear and was not discussed.7 The fluorescent chemokines produced also displayed GAG
binding ability and allowed studies to investigate these interactions to be carried out.
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1.4 Peptide Formation and Conjugation Strategies
1.4.1 Fusion Proteins and Linkers
Protein conjugates are important in the development of targeted therapeutics and imaging
agents to specific cell-types and one example is the use of recobinant fusion proteins. The
proteins are usually separated by a linker peptide sequence which can take three forms: flex-
ible, rigid or cleavable linkers, these act as spacers between the fused proteins and sometimes
also provide functionality. The purpose of the linker can be crucial as direct fusion of the
two desired proteins can lead to misfolding and poor yields of fused proteins in recombinant
expression.185,186 Flexible linkers allow greater movement and rotation of the fused proteins
through the use of small amino acid residues which are stable in aqueous media and therefore
do not greatly interact with the fused proteins.185 Sequences usually employ repeating units
of glycine, serine and threonine, the number of repeats allows the separation of the fused
proteins to be modulated and the serine or threonine residues provide greater stability in
water through hydrogen bonding networks. A common example of a flexible linker of this
kind is (GGGGS)n, where the integer n dictates the separation distance of the proteins.
185
α-helical inducing sequences are used as rigid linkers which contain repeating alanine residues
interrupted by glutamic acid or lysine and maintain spatial separation of fused proteins. The
ability of rigid linkers which form α-helices to successfully separate fused proteins has been
determined by Fo¨rster resonance energy transfer (FRET).187 The sequence A(EAAAK)nA
produced an α-helical structure which was further stabilised by lysine-glutamic acid salt
bridges and was used between enhanced blue fluorescent protein (EBFP) and enhanced green
fluorescent protein (EGFP). The repeats of the rigid linker sequence were then increased and
the FRET signal was measured resulting in an inverse relationship between sequence repeats
and FRET efficiency, indicating that fused proteins were separated.187 Another type of rigid
linker uses proline-rich sequences due to the cyclic nature of this amino acid conferring rigidity
rather than formation of rigid secondary structures.185
1.4. Peptide Formation and Conjugation Strategies 49
Figure 1.19: Types of fusion protein linkers between a targeting protein and an agent which can
include fluorescent proteins or functional proteins. The flexible linkers allow the tethered proteins
to freely translate and rotate, this can encourage the fused proteins to interact with each other
which can be stabilising or destabilising. Some designs may require prevention of this interaction
which can be achieved with rigid linkers, often based on α-helical linkers. Cleavable linkers can
be flexible or rigid but are unstable under physiological or intracellular conditions, separating the
fusion protein under specific conditions. Adapted from Chen et al.185
Figure 1.20: Methodology to produce a disulfide cleavable linker using fusion proteins synthesised via
recombinant protein expression. An initial dithiocyclopeptide is formed with a protease-sensitive
sequence, this is cleaved to reveal the disulfide linker which is reduced to finally separate the
proteins in biological environments. The protease sensitive sequence is a simpler approach as no
initial cleavage step is required before use, although this requires the biological enviornment being
used to contain the relevant protease. Adapted from Chen et al.185
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The presence of the fusion protein can affect function and so intracellular cleavable linkers
have been developed which possess reasonable stability in plasma but instability inside a cell
which allows the targetting protein to separate from the payload.185 This results in decoupling
of the metabolic and distributive fates of the fused proteins leading to enhanced bioactivity
and increased cellular dispersion. A common strategy for an intracellular cleavable linker
is the disulfide bond, this exploits the reductive environment found within cells which have
relatively high concentrations of glutathione (1 mm) and other cysteine proteases, meaning
that disulfide bonds are rapidly reduced, liberating the fused proteins.188 In the case of
recombinant fusion proteins, disulfide linkers are reasonably difficult to make as a cyclic
peptide is used which contains a disulfide, the backbone of the oligopeptide is then hydrolysed
using sequence specific proteases leaving the disulfide linker intact (??).185 Thrombin sensitive
dithiocyclopeptides (LEAGCKNFFPRSFTSCGSLE) are one method of preparing disulfide-
linked fusion proteins.189 The investigators successfully made the fusion protein and the
disulfide linker was shown to reduce in vivo.
Other peptide cleavable linkers use sequences that help to target the fusion protein towards
a specific area of the body or disease state. For example, MMPs are overexpressed in cancer
and inflammation, some peptide linkers therefore contain sequences which are hydrolysed
by MMPs such that the fusion protein is liberated at the desired disease site.185 One such
method is the use of latency-associated peptide (LAP) to insulate the active fused protein
from degradation in the body or acting on sites away from the pathological site.185 In one
study, LAP was fused to IFN-β using an MMP-sensitive PLGLWA sequence flanked by
flexible glycine rich oligopeptides, allowing the interferon to associate with LAP.190 The
half-life of the fused interferon was considerably longer than native interferon, dissociation
of LAP from the interferon was then promoted at disease sites due to the specific MMP
cleavage. Another strategy is to use peptide linkers which are not sensitive to endogenous
enzymes but towards pathogen expressed proteases; E. coli using the MazE-MazF antitoxin-
toxin system have been engineered to create a fusion protein separated by cleavable linker
sequences sensitive to either human immunodeficiency virus (HIV) or hepatitis C virus (HCV)
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proteases.191
1.4.2 Chemical Peptide Conjugation Strategies
Fusion proteins have been a powerful route to generate protein conjugates for imaging, thera-
peutic and functional applications and by modifying linker nature the in vivo activity of these
conjugates can be modulated to suit the application. There are numerous drawbacks to this
approach, however, the most obvious is that conjugate species are limited to peptides meaning
that small molecule therapeutics, small molecule fluorophores, oligonucleotides and polymers
are unavailable as conjugates with this strategy. Furthermore, each fusion protein must be
de novo designed, a plasmid genetically engineered, and a modified organism manufactured
which expresses the fusion protein for any slight modification in sequence or conjugate. The
nature of the linker, while highly variable, is often designed computationally to have the
desired property such as flexibility and there is no guarantee that this will be observed. The
methods to produce certain species can also be convoluted such as disulfide linker forma-
tion from cyclopeptides. Chemical conjugations allow the linker and fluorophore/therapeutic
chemistry to be performed before any need to include the protein.
Protein modification is most useful when a single species is obtained post-conjugation, this
means chemo- and regioselectivity is a prerogative. This simplifies purification and allows
for greater control over dosing and most likely the reliability of any results obtained. For
example, carboxylic acids or reactive derivatives are often used as substrates for conjugation
towards lysine side chains or other amines, as is the case in commercially available protein
labelling kits. The high abundance of the lysine residue and other amines results in oligo-
substitution of the protein with little control over the location of conjugation. This has
a number of potentially deleterious effects: loss of bioactivity as substitutions may be in
important binding regions and a mixture of difficult to separate products. The conjugation
reaction itself therefore requires a number of properties to ensure that as few products are
obtained as possible and that the reaction is site-selective. It must also be bio-orthogonal,
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this means the reaction must work in aqueous media which is buffered or contains many
salts, proceed at ambient temperatures and pH.192 As proteins in solution are usually at
relatively low concentrations, the reaction must be efficient in order to achieve full conversion
in reasonable reaction times, otherwise unfavourable kinetics will prevent completion.192
Cysteine readily undergoes alkylation with electrophiles and widely used example are α-
halocarbonyls and maleimides which produce physiologically stable cnjugates (Scheme 1.3).192
Examples of this reaction in protein conjugates can be found in mass spectrometry and
peptide mapping, biomimetic glycoprotein formation, and glycosylation of dihydrofolate re-
ductase to improve thermal stability.192–195 Iodoacetamides can undergo side reactions with
lysine residues, therefore use of chloroacetamides can avoid this undesired reaction.192 Due
to reactivity issues surrounding haloacetamides, other substitution reactions are used in pro-
tein conjugation with cysteines, nominally 1,4-conjugate additions to α,β-unsaturated enone
systems (Scheme 1.3).192 These Michael additions are termed thiol-ene conjugations and are
highly chemoselective for thiols meaning cysteine is an ideal target. Substrates for the Michael
addition with cysteines are predominantly maleimides and vinyl sulfones.192 Maleimides have
been used to conjugate glycosides to myoglobin through a cysteine to impart greater oxy-
gen affinity.196 Other bifunctional Michael acceptors have been used to pegylate IFN-α-2b
selectively at reduced disulfides as well as on antibody fragments targeting CD4.197 An in-
herent issue with using cysteine is the redox reactivity of sulfur (see Scheme 1.4 with protein
conjugations usually perfromed under aerobic conditions.192 In order to carry out cysteine
conjugations, the cysteine must first be reduced using common thiol reducing agents such
as dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP) which can lead to cross-
reactivity, the reducing agents must ne removed by dialysis or chromatography.198 These
time-consuming techniques can result in re-oxidation of the cysteine and so poor yields are
common. Furthermore, regioselectivity issues of endogenous cysteines can occur resulting in
diminished yields and potentially impaired bioactivity.
One of the most widely used cysteine conjugation reaction is the formation of disulfides as
conjugation strategy and as a cleavable linker.188,192,199,200 Activated disulfides can improve
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control and reduce reaction times which are associated with this reaction. A well known
example of this strategy is Ellman’s Reagent, this compound is a disulfide aromatic dimer
which reacts with available thiols and is used in colorimetric assays to measure thiol con-
tent.201 Methanethiosulfonate derivatives and other activated thiols follow a similar strategy
and have found uses in many applications including post-translational modifications and
other biomimetic applications.192,202 If no endogenous cysteines are available, site-directed
mutagenesis can install a cysteine amino acid at an appropriate position in the protein to
allow rapid conjugation without affecting bioactivity of the protein.188
The use of non-natural amino acids can improve regioselectivity isues inherent with cysteine
conjugations if the protein contains more than one cysteine. This also offers the added benefit
of introducing many different conjugation strategies with enhanced chemical reactivity and
versatility.203 In chemical peptide synthesis, incorporation of non-natural amino acids is
relatively straightforward, however, this technique is limited to shorter chain proteins of
around 100 amino acids or less. Synthetic biology advances have allowed the use of non-
natural amino acids in recombinant protein expression through several methods such as
auxotrophic bacterial strains, stop codon suppressor tRNAs and codon length expansion
from natural triplet codons.203
These techniques have allowed many non-natural amino acids to be incorporated into proteins
with the notable addition of azide or alkyne containing amino acids which has introduced
the domain of CuAAC ‘Click chemistry’ into protein conjugations. The formation of tria-
zoles has been known for decades but it was in 2002 where this copper catalysed reaction
between an azide and an alkyne was popularised through independent discoveries by the
Meldal and Sharpless groups.204? Click chemistry refers to a group of chemical transforma-
tions which meet certain criteria including ease of use, no side products, very high yielding,
bio-orthogonal and unaffected by substituents.205 Cu(I) is the active catalytic species, this
can present some problems due to the redox chemistry of copper and it’s rapid dispropor-
tionation in air. The Sharpless group reported in situ generation of Cu(I) via use of Cu(II)
salts such as the cheap copper source, copper (II) sulfate, is the optimal method of gener-
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ating copper I. Copper sulfate is reduced in situ in the presence of air, this excess reducing
agent can then re-reduce any re-oxidised copper as part of a redox cycle. Shortly after this
research, the Fokin group, in collaboration with Barry Sharpless, reported the use of poly-
triazoles as rate-accelerating ligands for the CuAAC reaction.206 The most successful ligand
was tris-(benzyltriazolylmethyl)amine (TBTA) which is a tris-triazole capable of tetraden-
tate coordination to Cu(I) which is thought to envelop the metal ion providing a stabilising
effect.206 The high affinity for copper insertion into alkynes is then enough to displace one
of the triazole arms and begin the catalytic cycle (Scheme 1.6). This ligand has been su-
perseded by tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), a hydroxylated version of
TBTA which is more water soluble than the lipophilic ligand.207
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Sharpless and Fokin et al.204,206
The mechanism for the CuAAC catalytic cycle has been the subject of some disagreement,
initially it was thought to involve formation of a copper-acetylide species akin to the Sono-
gashira coupling reaction, the azide then coordinates to the copper ion (Scheme 1.6).205
The azide then attacks the acetylide to form a strained six-membered ring containing a het-
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eroatomic allene-type system. This quickly collapses down to the five-membered 1,2,3-triazole
ring, selectively forming the 1,4-isomer, before eliminating the product to free the Cu(I) ion
to begin the cycle again. Practical and theoretical experiments suggested this was not the
correct mechanism, thus density functional theory (DFT) calculations which incorporated a
second copper ion demonstrated a marked reduction in the activation energy of the catalytic
cycle (Scheme 1.6).205 These results suggested a second copper ion coordinates to the copper-
acetylide species which stabilises this complex and encourages recruitment and attack of the
azide. Interestingly, the rate accelerating nature of copper ligands such as THPTA is further
rationalised by this second copper ion association with the copper acetylide as these ligands
are bidentate meaning one THPTA ligand can coordinate the first copper in the acetylide
complex and then aid the recruitment of the second copper ion.205
Many practical considerations are necessary to achieve optimal conditions for the cycloaddi-
tion to operate successfully. The reaction is highly exothermic with ∆H0 approximately 250
kJ mol−1, however, this is associated with a high activation energy of around 130 kJ mol−1
which gives very low rates of reaction when a catalyst is not used.205 The reason regioisomers
are formed in the absence of copper is that the HOMO and LUMO energy levels for azides and
alkynes are very similar meaning there is no preference for one arrangement. The action of the
copper ion forces nucleophilic attack of the most-substituted alkyne carbon to the terminal
nitrogen in the azide which sets the 1,4-substitution preference. The rate of the CuAAC reac-
tion is increased by a factor of 107 relative to the uncatalysed process and is almost unaffected
by the electronic or physical nature of azide or alkyne substituents.205 Formation of a copper-
acetylide species activates the alkyne towards nucleophilic attack through pi-back donation
of the copper into the pi∗ orbital of the alkyne.205 Other metals besides copper have been
reported in the azide-alkyne cycloaddition, for example, ruthenium-based cyclopentadienyl
complexes which resemble the Grubbs catalyst. The main issues with ruthenium catalysis are
sensitivity to solvents, the steric nature of azide substituents and most importantly, elevated
temperatures which prevent the routine use of this metal in bioconjugations.205
The most common source of copper (I) utilised in bioorthogonal reactions is the aforemen-
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Scheme 1.6: Initial proposed catalytic cycle based on a single copper ion species determined by
DFT calculations (A). The copper(I)-acetylide is first formed via pi-alkyne coordination to copper
before deprotonation and an exothermic formation of the acetylide (Step A). The azide then co-
ordinates at the substituted end which enhances the electrophilicity of the terminal nitrogen and
also increases nucleophilicty of the alkyne (Step B). A C-N bond is then formed to give a strained
copper-mettalacycle, this step is endothermic and in some cases this species can be isolated (Step
C).205 This strained system then collapses to give the 1,2,3-triazole with 1,4-isomerism (Step D)
before the triazole leaves the cycle to reform the copper catalyst (Step E). The next scheme (B)
shows the revised catalytic cycle based on further DFT modelling and some kinetic observations
which indicated a second copper ion likely coordinates to the copper-acetylide. Adapted from Fokin
et al.205
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tioned in situ reduction of copper (II) sulfate with sodium ascorbate.205 Copper (I) sources
have also been reported which include copper salts such as bromide, iodide, chloride and ac-
etate. Copper iodides should be avoided as copper-iodide-copper bridging has been observed
resulting in poly-Cu-acetylide aggregate formation, therefore copper bromide and acetate
salts are preferential.205 Coordination complexes of copper (I) acetonitrile are also used wich
are more resistant to oxidation in air.205 The use of rate-accelerating ligands are also impor-
tant, not only do these ligands enhance the rate but they have also been shown to stabilise
the Cu(I) oxidation state in aerobic conditions.205,208 The previously mentioned TBTA poly-
triazole has been successfully used in partially aqueous bioconjugations and this activity
has been enhanced through the development of the THPTA ligand.205,208 The ligand-solvent
interactions can be very important, for example, in DMSO mixtures THPTA is not particu-
larly effective whereas tris(2-benzimidazolylmethyl)amine operates efficiently, this is in stark
contrast to it’s behaviour in water.205,207 Generally, for conventional chemical synthesis the
reaction is very robust and the reaction will proceed efficiently even against some of these
factors, however, biological applications are more demanding due to the low concentrations
involved and requirement for reaction completion (due to purification difficulty) meaning
that greater attention to these issues is required for success.
Biological applications of CuAAC are numerous and varied, not only has this chemistry
been used to form conjugates but the triazole ring has been used in many native proteins
to improve biological stability.209 Due to the instability of certain bonds found in peptides,
triazoles have found function as replacements for both amide and disulfide bonds which in
certain examples has enhanced the drugability of peptides as therapeutics.209 Triazoles are
bioisosteres of the amide bond, for example, both are of a similar size and most importantly
each group has a similar dipole moment.209,210 This dipole moment causes the sp2 nitrogen
atoms in the ring to be weak hydrogen bond acceptors. This is complemented by the C-
5 proton being highly polarised and has similar hydrogen bond donating properties as an
amide NH-proton.209,210 The difference between these systems is that the amide bond can
be hydrolysed by proteases whereas the triazole is very stable under most conditions found
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in biology. For example, triazoles have been successfully used as peptide bond surrogates in
the cyclic peptide (PVPY) to inhibit tyrosinase.211
To enhance the bioorthogonality of the CuAAC reaction, Finn et al. reported modified
conditions which enabled live cell surfaces to be successfully labeled with fluorophores.212
Copper is known to be toxic to cells as free Cu(I) is oxidised by oxygen and produces ROS
leading to cell damage and eventually cell death and so copper-free click conditions are
usually used instead.212 This is less convenient though as the alkyne must be under ring
strain which is very difficult to incorporate into biological or even chemical species. The
successful strategy therefore included use of THPTA and aminoguanidine to allow micromolar
concentrations of copper sulfate to be used which did not result in significant cell death. The
Cu-ascorbate reduction system produces large amounts of ROS and the THPTA ligand has
been shown to intercept ROS as well as accelerate copper-mediated peroxide degradation.213
The aminoguanidine allows the capture of dehydroascorbate which would otherwise react
with protein side chains. Azido-functionalised peracylated mannose was then uptaken by
both CHO and jurkat cells and presented on the cell surface, the azide then successfully
underwent cycloadditions with rhodamine-alkyne derivatives allowing the progress of the
reaction to be monitored by live-cell imaging.212 The investigators also demonstrated that
increasing the copper sulfate concentration resulted in increased toxicity, however, this could
be counteracted by THPTA incorporation in a dose-dependent manner.
1.4.3 Cleavable Linkers
The term cleavable linker refers to a chemical species which is covalently bonded between
two molecules, of usually different functions, which is stable under ambient conditions but
becomes unstable either in the body or inside a cell.214 The purpose of the cleavable linker
is to ensure the two molecules are bonded together until they reach the desired destination
in the organism or cell and then covalently separate such that functional responses can then
occur which were reduced while the molecules were bonded together. Cleavable linkers must
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meet criteria such as cleavage under mild conditions, use of bioorthogonal reagents, highly
yielding at biologically relevant concentrations and biocompatibility of waste products.214
The linker is cleaved only under specific conditions depending on its design, this can be
enzymatically, photolytically or chemically cleaved. Due to the versatility of cleavable linkers,
uses of these molecules are widespread and include drug delivery, proteomics, imaging and
DNA sequencing.214 For example, in drug delivery some drugs are not particularly water
soluble or are unable to cross cell membranes therefore drug delivery uses targeting ligands
which deliver the drug across membranes and the linker then cleaves liberating the drug
inside the cell. A good example of this are antibody drug conjugatess (ADCs) where an
antibody is used to target a particular receptor or cell-type which causes disease resulting
in the drug being delivered to the disease causing cell, the cleavable linker is needed as it is
unlikely the drug will still be effective with the large antibody still attached.215 Furthermore,
the drug may be highly cytotoxic and so excessive side-effects would persist with the free
drug which are avoided through the selective nature of the ADC. Drug delivery ligands
are widely varied including antibodies, peptides, proteins, aptamers, liposomes, dendrimers
and polymers.214 In imaging applications, cleavable linkers sensitive to enzymes involved in
cancer have been used with MRI contrast agents which allow the presence of tumours to be
detected in body.214,216 Fluorescence imaging allow biological processes to be characterised,
for example, through the use of FRET to detect the event or with fluorophore-quencher
systems.214
Many peptide-based cleavable linkers are known but for the purposes of this review, this
section will focus on the disulfide linker. This linker takes advantage of high concentrations
of glutathione inside cells which rapidly reduce the disulfide bond leading to separation of
the linked molecules; this has led to applications in drug delivery and imaging.217? ,218 For
example, campothecin is an anti-cancer drug which is highly lipophilic and also very cyto-
toxic meaning it exhibits poor pharmacokinetics and side effects.219 This compound has been
conjugated to folic acid via a disulfide-containing peptide linker which allowed selective deliv-
ery to cancer cells which over-express the folate receptor resulting in uptake via endocytosis.
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The conjugate exhibited greater solubility than free campothecin due to the presence of the
polar peptide and specificity of the targeting folic acid ligand resulted in excellent inhibition
of cancer proliferation.219 The use of disulfides does not always enhance the therapeutic ef-
fects of drug conjugates, particularly when the targeting ligand is also therapeutically active
is was the case in trastuzumab conjugates.220 Trastuzumab is a monoclonal antibody ther-
apy for HER-2 positive breast cancers, however, some patients do not respond well to this
treatment and so conventional chemotherapies are sometimes co-administered. Conjugates
of trastuzumab are therefore desirable as the chemotherapy is targeted toward the HER-2
positive cancer cells which improves efficacy and limits side-effects. Trastuzumab was conju-
gated to antimitotic agent DM1 through non-cleavable sulfide and cleavable disulfide bonds;
interestingly, the sulfide linked conjugate exhibited higher activity than the disulfide linked
conjugate.221 In the case of antibody maytansinoid conjugates (AMCs), disulfide linked con-
jugates exhibited no significant difference in the cytotoxic activity of the therapy towards
antigen positive cells compared to non-cleavable thioether conjugates.222 This study high-
lights a useful property of chemically synthesised disulfide linkers which is that the stability
in the presence of reducing agents can be improved by introducing steric bulk around the
disulfide bond in the form of adjacent methyl or geminal dimethyl groups.215 In this study,
differences in the nature of the disulfide (no methyl, methyl, or dimethyl) resulted in lower
reduction rates for more hindered species, however, this had little effect on the efficacy of
the conjugate towards antigen-positive cancer cells over the thioether linked conjugate.215,222
The disulfide linked AMCs was markedly improved in bystander killing assays over thioether
acpAMC, where antigen-negative cells were also inhibited. This effect was also exhibited
dose-dependency in terms of the number of antigen-positive cells which is beneficial in vivo
as tumour microenvironment localised cell cytotoxicity will occur. The bystander killing ef-
fect was most pronounced in the more hindered disulfide conjugates due to the regioselective
reduction which prevents maytansinoid-glutathione species forming allowing egress of the
drug out of the cell (??).215,222
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Adapted from Widdison et al.215
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1.5 Aims
1.5.1 CCL2 as a Delivery Vehicle to Monocytes
The introduction presents a clear need for tools which are able to selectively target monocytes
and also bear subset specificity. This need has been shown in many diseases such as can-
cer, liver fibrosis and atherosclerosis, with a multitude of monocyte subsets having varying
roles in these diseases. The chemokine, CCL2, presents an attractive pathway to utilise for
this purpose as it is not only highly selective for monocytes but there is also a spectrum of
expression level of the receptor CCR2 across the various monocyte/macrophage subsets. A
beneficial aspect of using CCL2 as a delivery vehicle is that this is a natural biological path-
way which is even complicit in many of the diseases which are being treated. For example,
CCL2 is secreted as part of the inflammatory response which is accompanied by increased
CCR2 expression meaning the capacity for delivery may be enhanced towards pathologies
related to chronic inflammation. The use of a naturally occurring peptide also renders a re-
duced chance of an immunogenic reaction compared to non-natural peptide delivery methods.
Furthermore, CCL2 is a small protein and so this increases extravasation properties making
these conjugates more effective at penetrating disease sites in tissues or tumours compared
to larger proteins such as antibodies.215 The benefit of the CCL2 internalisation pathway is
that this area has benefited from a large amount of research and whilst the dynamics are not
wholly understood, it is better characterised than the multitude of antibody internalisation
pathways. Furthermore, a number of variants of CCL2 have been identified and some of these
have altered function, these variants could therefore be evaluated to alter function such as
binding affinity, in vivo activity, chemokine signalling and half life.
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1.5.2 Development of Novel Fluorescent CCL2 Conjugates
The objective of this project is to develop a platform of chemokine conjugates as a proof of
concept towards developing successful therapeutic conjugates in the future. Many approaches
towards therapeutic peptide conjugates are essentially ‘black box’ experiments where the
success or failure of a peptide conjugate’s function is not well understood. Alternatively,
developing fluorescent conjugates of CCL2 will provide information into the function and
behaviour of the conjugates which can be applied to a therapeutic. The use of fluorophores
allows imaging experiments to be performed giving insight into the internalisation and sub-
cellular distribution of conjugates. Flow cytometry can also be performed on primary white
blood cells to identify the selectivity of the conjugates and demonstrate any modulation
of activity resulting from the nature of the CCL2 variant or the conjugate. Fluorescence
also provides information in migratory experiments as both the signalling properties of the
CCL2 conjugates can be identified as well as internalisation behaviours. This high level of
characterisation is important in the development of a biological delivery platform for a variety
of applications.
Figure 1.21: The single letter amino acid sequences used for CCL2 variants, red amino acids identify
residues not present in the wild-type sequence. nCCL2 refers to a wild-type sequence at the N-
terminus, CCL2 (Ala−1) refers to the alanine addition at the N-terminus and P8A-CCL2 refers
to the P8A substitution at the N-terminus. All variants bear the AM{pG} sequence at the C-
terminus, this includes the AM spacer used in the CCL2-SA1 conjugate and {pG} is a propargyl
glycine residue for CuAAC.
Current CCL2 conjugates and the strategies used translate poorly to other applications, for
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example, the CCL2-mCherry fusion protein and the CCL2-SA1 fusion protein must be de-
signed for each conjugate and the fusion proteins then developed as a genetic sequence and
then expressed. Furthermore, fusion proteins are limited to peptide linkers and conjugates,
and the incorporation of the commonly used disulfide linker is a laborious and inefficient
process. The fluorescent chemokines developed by Almac Chemokines are a good example of
the research that can be performed with functional fluorescent chemokine. The best example
in the literature of chemokine conjugation is the S6-PPTase tag developed by Handel et al.
which allows conjugation of any molecule bearing the Ppant arm, although it does require an
oligopeptide sequence to be included at the C-terminus of the chemokine.7 Issues with these
conjugations include some loss of activity and the need for the coenzyme A incorporation
which may be difficult in some systems and may also reduce activity of therapeutics. Trans-
lating this reaction to larger species, such as oligonucleotides, may also be difficult if these
prevent the action of the PPTase enzyme. To avoid these problems and offer an alternative
strategy with higher conjugate flexibility this project therefore aims to develop CCL2 con-
structs which possess an alkyne-containing non-natural amino acid at the C-terminus for use
in CuAAC conjugations. This only requires a small modification to the C-terminus of CCL2
which is known to be non-essential for CCR2 binding and is an approach successfully used
by the aforementioned conjugates (a schematic representation is shown in Figure 1.22). This
alkyne-bearing amino acid can be introduced easily through SPPS chemistry, representing a
minor change in structure.
To the best of our knowledge, the nature of the linker between CCL2 conjugates has not
previously been varied and so we aim to use non-cleavable and cleavable linkers between
CCL2 and the fluorophores. This should allow modulation of the sub-cellular distribution
of fluorophores through the use of disulfide cleavable linkers or non-cleavable alkyl-based
linkers. Furthermore, this project will investigate the effects of varying the lipophilicity
of the fluorophore on behaviour of the conjugates which is an important consideration in
developing therapeutic CCL2 conjugates.
A number of CCL2 variants have been reported which have differences in binding affinity due
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Figure 1.22: Schematic of CCL2 conjugates which will be made in this project, the chemokine
will provide monocyte-selective uptake through CCR2-specific endocytosis. The conjugates will
be formed using CuAAC giving the 1,4-triazole allowing attachment of various fluorophores and
linker species. Non-cleavable linkers will be mainly alkyl based and cleavable linkers will utilise
disulfide chemistry which should enhance endosomal escape. The effect of fluorophore polarity
will also be examined and so fluorophores will be either hydrophilic of hydrophobic. Finally, a
disulfide separated FRET pair will be synthesised allowing disulfide reduction to be detected and
both fluorophores to be independently tracked. CCL2 ribbon structure reproduced from PDB, code
1DOL.223
to small modifications to the N-terminal sequence. This project will use the wild-type CCL2
sequence (at the N-terminus) as a direct comparison of conjugated CCL2 vs wild-type human
CCL2 sourced from Peprotech. The three CCL2 sequences which will be used are shown in
Figure 1.21, the C-terminal modification includes a propargyl glycine for the CuAAC and
an ala-met dipeptide which was reportedly used in the Osprey CCL2-SA1 patent.6 As this
system was successful this AM spacer will be used between the CCL2 C-terminus and the
propargyl glycine. This study was interesting because a CCL2 variant was used which was
first reported in 1995 by Clark-Lewis et al. called CCL2 Ala−1 which exhibited an over
100-fold loss of chemotactic activity relative to wild-type CCL2.224 Unfortunately, McIntosh
et al. did not report any migration data for the CCL2-SA1 conjugate and so it is unclear
whether this reduced activity was reproduced in this system or why this less active sequence
would be selected.6 This project will therefore investigate fluorescently labeled conjugates of
this sequence to ascertain if there is a disconnect between G-protein signalling and ligand
internalisation in the CCL2 Ala−1 variant which could allow high concentrations of CCL2 to
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be internalised without triggering chemotactic activity. The third CCL2 variant used is the
alanine substitution of proline at the 8-position (P8A) reported by Handel et al., which is
able to induce chemotaxis in vitro but loses chemotactic activity in vivo.113,225 This is due
to the inability of P8A-CCL2 to dimerise on GAGs which is essential for chemotaxis out of
the blood vessel. This P8A-CCL2 is an appealing variant for therapy as it may represent a
‘silent’ delivery vehicle where affinity for the receptor is retained but chemotactic activity is
absent.
The aims of the project are therefore as follows:
1. To synthesise fluorophores which vary in lipophlicity and contain an azide for subse-
quent CuAAC conjugations.
(a) Develop disulfide linkers and incorporate these linkers into both hydrophobic and
hydrophilic fluorophore azides for comparison with the non-cleavable linker con-
jugates.
(b) Synthesise a FRET pair containing a disulfide linker between donor and acceptor
allowing the intracellular reduction of the disulfide to be detected and separated
fluorophores to be tracked.
2. Design CCL2 sequences amenable to undergo CuAAC reactions with the above azides.
(a) Form three CCL2 variants including native CCL2 (WT-CCL2), CCL2 Ala−1 and
P8A-CCL2 each including an alkyne tag for CuAACs.
(b) Optimise CuAAC reactions to successfully conjugate the above fluorophores and
FRET pairs to alkyne-tagged CCL2.
3. Characterise biological activity of fluorescent CCL2 variants.
(a) Compare chemotactic activity of CCL2 variants with wild-type human CCL2.
(b) Characterise internalisation efficiency of CCL2 variants in relevant cells.
(c) Demonstrate that chemotaxis and internalisation is CCR2 specific in each CCL2
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variant.
4. Compare properties of the various fluorophore and linker systems in cellular experi-
ments.
(a) Measure chemotactic activity and internalisation behaviour of the conjugates.
(b) Perform microscopy to demonstrate sub-cellular distribution differences between
different fluorophore and linker systems.
(c) Determine CCR2-selective uptake of CCL2 variants and the various conjugates in
primary mixed cell populations and characterise any subset specificity.
Chapter 2
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2.1 Biological Methods
2.1.1 Cell Culture
THP-1 (human monocytic cell line derived from the peripheral blood of a male with acute
monocytic leukemia) cells and Jurkat cells were cultured in RPMI-1640 (plus 10% FCS, 1%
penicilin, streptavidin, glutamate) in T-75 flasks at a density of 0.5 x 106 cells per mL. Prior
to experiments, live cells were purified with lymphoprep gradient (StemCell Technologies,
centrifuged at 800 g, 20 min), then washed with PBS and resuspended into chemotaxis or
culture media.
2.1.2 Transwell Migration Assay
Corning HTS Transwell-96 Tissue Culture Systems were used as follows. Lower reservoirs
contained chemotaxis buffer (RPMI-1640 plus 0.1 % BSA, 150 µL) with or without the
chemoattractant. THP-1 cells (0.3 x 106 cells) were seeded onto the membrane in the upper
chamber in chemotaxis buffer (75 µL) and incubated for 4 h at 37 ◦C, 5% CO2. Cells were
then taken directly into flow cytometry.
CCR2 inhibition was carried out as follows: CCL2 pre-incubation was obtained by incubating
THP-1’s (3.999 x 106 per mL) in 250 nm CCL2 (recombinant human CCL2 from Peprotech
Ltd.) for 30 min at 37 ◦C before washing with PBS (1 mL) and resuspending in chemotaxis
media at the same density.
Inhibition with INCB 3284 (Tocris Bioscience) was carried out by incubating THP-1 cells in
chemotaxis buffer containing either 470, 47 or 4.7 nm, in agreement with a reported IC50 =
4.7 nm, for 30 min and taken without washing into the chemotaxis plate.
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2.1.3 Timecourse
THP-1 cells (0.1 x 106) were incubated in chemotaxis buffer (150 µL RPMI-1640 plus 0.1 %
BSA) containing the CCL2 conjugate at the specified concentration for either 0.5, 1, 2, 3 or
4 h before flow cytometry in the AB Biosystems Attune (2.1.4).
2.1.4 Flow Cytometry - Chemotaxis and Timecourse
The Boyden transwell chemotaxis assays were quantified on an AB Biosystems Attune flow
cytometer with acoustic focussing and an auto-sampler. Each well was auto-pipetted 3
times before sampling, either 25 x 103 events were collected or 75 µL was extracted. The
fluorescence was captured using a 488 nm HeNe laser. Data was analysed using Attune 2.1
cytometric software.
2.1.5 Primary Blood Cell Isolation
Human blood was taken from healthy donors into heparin-coated vacuum tubes (10 mL
aliquots). The blood was obtained under ethics reference ERN 10 0660.
Peripheral Blood Mononuclear Cells
The blood was layered onto Lymphoprep solution (20 mL, StemCell Technologies) in sterile
sterling tubes (50 mL) and centrifuged at 1000 g for 20 min without brakes at ambient
temperature. The PBMC layer was extracted and washed with MACS buffer (100 µL, PBS
+ 2% FCS + 1 mm EDTA) and centrifuged at 1000 g for 5 min and washed again with
MACS buffer (500 g, 10 min) before resuspension in MACS buffer at a density of 1 x 103
mL−1 and kept on ice until treated.
Neutrophil Isolation
Whole blood was treated with 2% w/v dextran (Pharmacosmos, DK) in a 1:6 ratio for 30 min
at ambient temperature to sediment erythrocytes. The leukocyte-rich plasma was aspirated
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and layered onto a 56/80% w/v Percoll gradient at a ratio of 5:3 and centrifuged at 220 g
for 20 min without brakes. The neutrophil layer was extracted and washed in MACS buffer
(centrifuged 450 g, 10 min) before resuspension in MACS buffer at a density of 1 x 103 mL−1
and kept on ice until treated.
2.1.6 Flow Cytometry - PBMC Monoclonal Antibody Labelling
100 x 103 PBMCs were transferred to FACS tubes in 100 µL of MACS buffer. The cells
were then treated with the chemokine conjugates: CCL2 Ala−1-alk-H (200 nm), WT-alk-H
(30 nm), P8A-alk-H (30 nm), P8A-SS-H (30 nm), P8A-SS-L (30 nm) for 1 h at ambient
temperature. In initial experiments (Figure 5.24) cells were treated with a live/dead marker
(LIVE/DEADTM dead cell stain kit, ThermoFisher Scientific L10119) for 30 min before
washing twice in MACS buffer. In later experiments, the cells were washed twice in MACS
buffer, excluding the live/dead labelling step and resuspended in MACS buffer containing
the monoclonal antibodies (listed in Table 2.2 and Table 2.3). The cells were labelled for
30 min on ice, washed twice and resuspended in MACS buffer (100 mL) for FC sampling.
Flow cytometry was carried out on a Dako CyAn ADP flow cytometer (laser lines: 405
nm, 488 nm and 633 nm) and the data analysed using Summit software (Beckman Coulter,
Buckinghamshire, UK).
The tables below summarise the monoclonal antibody panels used to gate the monocyte
and lymphocyte subsets in compensation (Table 2.1), monocyte subsets (Table 2.2) and
lymphocyte subsets (Table 2.3).
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Table 2.1: Antibodies utilised for fluorescence compensation for both monocyte and lymphocyte
panels. Suppliers: † - Biolegend, ‡ - BD Biosciences, ? eBioscience.
Antibody Isotype Control Source Clone Dilution
CD45-BV421† IgG1 K-BV421 Mouse H130 1:10
CD45-BV510† IgG1 K-BV510 Mouse H130 1:10
CD45-FITC† IgG1 K-FITC Mouse H130 1:10
CD45-PE-CF594‡ IgG1 K-PE-CF594 Mouse H130 1:10
CD45-PECy7? IgG1 K-PECy7 Mouse H130 1:10
CD45-APC† IgG1 K-APC Mouse H130 1:10
CD45-APC-eFluor780? IgG1 K-APC-Cy7 Mouse H130 1:10
Table 2.2: Antibodies utilised for the monocyte subset panel. Suppliers: † - Biolegend, ‡ - BD
Biosciences, ? eBioscience.
Antibody Isotype control Source Clone Dilution
HLA-DR-eFluor450? IgG2a K-eFluor450 Mouse H130 1:10
CD16-PE-CF594‡ IgG1 K-PE-CF594 Mouse 3G8 1:10
CCR2-APC† IgG2a K-APC Mouse K036C2 1:5
CD14-APC-eFluor780? IgG1 K-APC-eFluor780 Mouse 61D3 1:10
Table 2.3: Antibodies utilised for the lymphocyte subset panel. Suppliers: † - Biolegend, ‡ - BD
Biosciences, ? eBioscience.
Antibody Isotype control Source Clone Dilution
CD3-BV510† IgG2a K-BV510 Mouse OKT3 1:10
CD56-PECy7? IgG1 K-PECy7 Mouse CMSSB 1:10
CCR2-APC† IgG2a K-APC Mouse K036C2 1:5
2.1.7 Fixed Cell Imaging
THP-1 cells or PBMCs (1 x 105 in 100 µL) were incubated in either chemoattractant media
containing the CCL2 conjugate or chemoattractant media alone for negative controls. Cells
were incubated for 2 h before being mounted onto glass slides via cytospinning (300 rpm,
3 min), washing with PBS + 0.05% Tween-20 and fixed with para-formaldehyde (4%) for
5 min. Coverslips were then mounted onto microscopy slides with Prolong Gold anti-fade
containing DAPI (Life Technologies). Slides were then imaged on a Zeiss Axio Observer-Z1
using LED illumination at 405 and 488 nm with Apotome optical sectioning. The following
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filters were used for green fluorescence: excitation (440 - 470 nm), beamsplitter (495 nm)
and emission (520 - 550 nm). The following filters were used for DAPI: excitation (G 365
nm), beamsplitter (FT 395 nm) and emission (BP 445 - 450 nm). The image was focused
on the centre of the cells and five z-slices were acquired at 0.37 µm intervals, the maximum
intensity projection was then averaged through the z-direction.
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2.2 Chemical Methods
2.2.1 CCL2 CuAAC Conjugations
CuAAC of Alkyl-linked Fluorophores
Stock solutions of CuSO4, THPTA, Na ascorbate and BODIPY 10 were prepared in PBS.
Solid CCL2 was dissolved in PBS and the concentration was determined using UV absorption
and the Beer-Lambert law (molar absorption coefficient = 8490 dm mol−1 cm−1, calculation
performed on www.protcalc.sourceforge.net/ based on number of W and Y residues). The
reaction mixture was prepared as follows unless stated otherwise: PBS was added first,
followed by CuSO4 (1 eq.), Na ascorbate (25 eq.), THPTA (5 eq.), CCL2 (1 eq.) and finally
BODIPY 10 (20 eq.). The reaction was left for the time stated in chapter 4, the CCL2
product was separated from smaller molecules using size exclusion chromatography (PD-25
column, GE Healthcare) eluting in the first 0.7 mL. The concentration of the conjugate was
then determined by UV absorption spectroscopy, mass spectrometry determined product
mass, and the protein was diluted by a suitable factor with PBS and the solution made up
to 0.5% BSA to aid stability. The conjugate was aliquoted and stored at -20 ◦C.
Lipophilic BODIPY 8 conjugates were prepared using the same method except substituting
tris(2-benzimidazolylmethyl)amine ((BimH)3) (0.5 eq.) for THPTA and also being carried
out in 30% DMSO in PBS. An extra dialysis step was performed prior to size exclusion
chromatography, this utilised Slide-A-LyzerTM MINI dialysis tubes with a 3.5 kDa MWCO
using PBS at 4◦C overnight.
CuAAC of Disulfide-linked Fluorophores
An Atmosbag glove bag was perfused with nitrogen according to the user manual and sol-
vents were degassed via nitrogen bubbling for 30 min. Stock solutions of CuBr, (BimH)3 and
the fluorophore were prepared in DMSO. Solid CCL2 was dissolved in PBS and the concen-
tration was determined using UV absorption and the Beer-Lambert law (molar absorption
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coefficient = 8490 dm mol−1 cm−1). The reaction mixture was prepared as follows unless
stated otherwise: DMSO was added first, followed by DMSO, CuBr (1 eq.), (BimH)3 (0.5
eq.), CCL2 (1 eq.) and finally the fluorophore (20 eq.). The reaction was left for the time
stated in chapter 4 before removal of DMSO via dialysis (as above) and size exclusion chro-
matography (PD-25 column, GE Healthcare) eluting in the first 0.7 mL. The concentration
of the conjugate was then determined by UV absorption spectroscopy, mass spectrometry
determined product mass, and the protein was diluted by a suitable factor with PBS and the
solution made up to 0.5% BSA to aid stability. The conjugate was aliquoted and stored at
-20 ◦C.
2.2.2 MALDI Mass Spectrometry
Samples were desalted using a C-18 ziptip (Millipore) into 1:1 acetonitrile:0.1% TFA. Sinap-
inic acid (10 mg mL−1, 4:6 water:acetone) was used as the matrix in a ratio of 3:1 ma-
trix:sample (v:v). MALDI-TOF-MS was recorded on a Waters Micromass MALDI micro
MX mass spectrometer.
2.2.3 UV-Vis Spectroscopy
UV-Vis spectra were recorded on a Shimadzu UV-1800 spectrometer sampling a wavelength
range from 220 - 800 nm at 1.0 nm intervals. The concentration of unlabelled CCL2 was
calculated using absorption at 280 nm based on tryptophan/tyrosine absorption according to
the Beer-Lambert law (molar absorption coefficient = 8490 dm mol−1 cm−1). Post-labelling
the concentration was determined using BODIPY absorption at the absorption maxima using
the molar absorption coefficient determined in chapter 3.
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2.2.4 Fluorimetry
Fluorescence spectra were recorded on a Shimadzu RF-5301 PC spectrofluorimeter with a 5
nm slit width in 1.5 mL quartz cuvettes. Samples were maintained at 15 nm and dissolved
in either PBS (pH 7.4, 10 mm, 100 mm NaCl), CH2Cl2 or DMSO.
2.2.5 Quantum Yield Calculation
Quantum yields were calculated using the relative quantum yield equation (2.1) using fluo-
rescein as the known standard (Φ = 0.95).226 The UV-Vis absorbance for both the BODIPY
and fluorescein standard were identical at the relevant excitation maxima allowing relative
fluorescence intensities to be compared.
Φ = Φst
I
Ist
Ast
A
η2
η2st
(2.1)
Where Φ = quantum yield, I = integrated emission, A = absorbance, η = solvent refractive
index, ‘ST’ refers to the fluorescein standard.
2.2.6 FRET Efficiency Calculation
The FRET efficiency for the FRET pair 45 was calculated using the methods described by
Asunuma et al.227 2.2 describes the decrease in donor emission using BODIPY azide 8 as the
donor-only molecule (ID) and the donor emission from the FRET pair (IDA).
ΦT1 = 1− IDA,506
ID
(2.2)
The second method (2.3)relates to increase in acceptor emission within the FRET pair using
BODIPY azide 8 as the donor-only compound and rhodamine 38 as the acceptor-only com-
pound. Where AA is absorbance of the acceptor-only, AD is absorbance of the donor-only, IDA
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is emission of the FRET pair at the acceptor maxima and IA is emission of the acceptor-only
compound.
ΦT2 =
(
AA
AD
)(
IDA,580
IA − 1
)
(2.3)
2.2.7 Organic Synthesis
General Methods
All reactions were carried out in oven-dried (140 ◦C) single-necked round bottomed flasks fit-
ted with rubber septa and under positive pressure of argon, unless stated otherwise. Organic
solutions were concentrated under reduced pressure at 40◦C and 50-500 mbar and residual
solvent removed under high vacuum (˜1 mbar). Thin-layer chromatography (TLC) was per-
formed using aluminium plates coated with a 0.25 mm layer of silica gel. Reaction progress
was followed by TLC analysis and visualized by UV light and/or submersion in standard
TLC stains (KMnO4, anisaldehyde, vanilin) followed by heating with a hot-air gun (˜300
◦C,
10 s). Flash column chromatography was performed on silica gel (particle size 40-63 µm
mesh). All materials were obtained from commercial sources and used without further purifi-
cation unless stated otherwise. Dichloromethane (CH2Cl2), tetrahydrofuran (THF), toluene
(PhMe), acetonitrile (CH3CN), diethyl ether (Et2O), methanol (CH3OH) were all purified us-
ing a Chromasolv solvent purification system. N,N -dimethylformamide was dispensed from a
septum-fitted bottle and stored under nitrogen. IR spectra were recorded as neat thin films.
Each band is described as s (strong), m (medium), w (weak) in reference to the intensity and
with the suffix ‘br’ (broad), where appropriate. 1H and 13C NMR were recorded in deuterated
solvents at 400 and 100, or 300 and 75 MHz, respectively. Chemical shifts are reported as
δ values (measured in ppm) referenced to TMS, δH 0.00 ppm. The term ‘m’ refers to peaks
which originate from single or equivalent nuclei but coupling constants could not be assigned.
In analysing AB systems where the resonances form well separated groups, these are reported
as ‘AB’. Peak assignment was analysed from 2D NMR experiments: COSY90, HMBC and
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HSQC. Mass spectra were obtained on a liquid-chromatography time-of-flight (LCT) mass
spectrometer using electrospray ionisation (ESI) with a methanol mobile phase. HRMS were
recorded on an LCT spectrometer utilising a lock-mass incorporated into the mobile phase.
Melting points were recorded using open capillary tubes.
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10-(5-bromopentyl) -5,5- difluoro -1,3,7,9- tetramethyl -5H - dipyrrolo [1,3,2]di-
azaborinine (7). Bromohexanoyl chloride (0.77 mL, 5.0 mmol) was dissolved in dry CH2Cl2
(50 mL) and the mixture was cooled to 0.0 ◦C. 2,4-dimethylpyrrole (0.95 g, 10 mmol) dis-
solved in dry CH2Cl2 (20 mL), was added dropwise over 30 min before stirring at ambient
temperature for 3.5 h. The mixture was then cooled to 0 ◦C and neutralized by the addition
of dry triethylamine (2.8 mL, 20 mmol). After 30 min, boron trifluoride etherate (2.5 mL, 10
mmol) was added slowly and the mixture was stirred at ambient temperature for 1 h. The
solvent was evaporated in vacuo and the residue was purified on a silica gel column eluting
with CH2Cl2 : petroleum ether (2:1). The resulting solid was recrystallised from heptane to
give 7 as a red-brown solid (0.60 g, 30% yield). MP 134-135 ◦C, lit. 134-136 ◦C. IR (thin
film)/cm-1 νmax; 2928 s, 2868 s, 1546 s, 1438 s, 1305 s, 1195 s, 982 s, 797 s;
1H NMR (300
MHz, chloroform-d) δH 6.05 (s, 2H, C3), 3.42 (t, J = 6.5 Hz, 2H, C12), 2.93 (dd, J = 10.0,
5.8 Hz, 2H, C8), 2.51 (s, 6H, C1), 2.40 (s, 6H, C5), 2.01 – 1.78 (m, 2H, C11), 1.73 – 1.53
(m, 4H, C9/10); 13C NMR (100 MHz, chloroform-d) δC 154.0 (C2), 145.9 (C7), 140.2 (C4),
131.4 (C6), 121.7 (C3), 33.4 (C12), 32.2 (C11), 30.9 (C9/10), 28.6 (C9/10), 28.2 (C8), 16.4
(C5), 14.5 (C1); HRMS-ESI; [M+H]+ calc’d for C18H25BN2F2Br 397.1262 found; 397.1273.
Values consistent with reported data (NMR, MS, MP).228
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10-(5-azidopentyl)-5,5-difluoro -1,3,7,9- tetramethyl-dipyrrolo [1,3,2] diazabori-
nine 8. Bromo-BODIPY 7 (100 mg, 0.25 mmol) was dissolved in DMF (10 mL) before
adding sodium azide (24 mg, 0.38 mmol) and stirring under N2 at ambient temperature for
16 h. The mixture was then taken into water (20 mL) and extracted with CH2Cl2 (20 mL,
3x), dried with MgSO4 and evaporated. The compound was then dissolved in ether (30 mL)
and washed with water (20 mL, 2x) and brine (20 mL), dried with MgSO4 and evaporated
to give an orange solid (83 mg, 93% yield). MP 175-178 ◦C. IR (thin film)/cm-1 νmax 2928 s,
2870 s, 2093 s, 1547 s, 1472 s, 1197 s, 1074 s, 982 s, 820 w; 1H NMR (300 MHz, chloroform-d)
δH 6.01 (d, J = 19.7 Hz, 2H, C3), 3.25 (dt, J = 12.3, 5.8 Hz, 2H, C12), 2.91 - 2.78 (m, 2H,
C8), 2.50 (s, 6H, C1), 2.37 (s, 6H, C5), 1.74 – 1.47 (m, 6H, C9-11); 13C NMR (100 MHz,
chloroform-d) δC 153.9 (C2), 146.1 (C7), 140.2 (C4), 131.4 (C6), 121.7 (C3), 51.2 (C12) 31.4
(C9), 28.7 (C10/11), 28.2 (C8), 27.4 (C10/11), 16.4 (C5), 14.5 (C1); HRMS-ESI; [M+Na]+
calc’d for C18H24BN5F2Na 382.1991 found; 382.1998. Values consistent with reported data
(NMR, MS).229
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Sodium 10-(5-azidopentyl)-5,5-difluoro -1,3,7,9- tetramethyl -5H - dipyrrolo [1,3,2]
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diazaborinine-2,8-disulfonate (10). AzidoBODIPY 8 (65 mg, 0.18 mmol) was dissolved
in dry CH2Cl2 (3.0 mL) and was cooled to -25
◦C with addition of a few crystals of BHT.
Chlorosulfonic acid was added dropwise over 15 min and stirred for a further 30 min. The
solution was then allowed to warm to ambient temperature and stirred for another hour.
Methanol (5.0 mL) was then added followed by sodium bicarbonate (62 mg, 0.73 mmol) and
stirred for 20 min. The solvents were removed in vacuo and purified via column chromatog-
raphy eluting with CH2Cl2:MeOH (80:20) to give the product as an orange solid (60 mg, 59%
yield). MP 220-223 ◦C. IR (thin film)/cm-1 νmax 3669 m, 3326 br, 2980 s, 2901 s, 2102 w,
1637 br, 1537 s, 1405 s, 1228 s, 1055 s, 896 s; 1H NMR (300 MHz, methanol-d4) δH 3.41 –
3.35 (m, 2H, C12), 3.30 - 3.22 (m, 2H, C8), 2.82 (s, 6H, C5), 2.77 (s, 6H, C1), 1.79 - 1.58 (m,
6H, C9-11); 13C NMR (100 MHz, methanol-d4) δC 153.6 (C2), 150.5 (C7), 139.6 (C4), 134.4
(C3), 130.6 (C6), 50.8 (C12), 30.9 (C9-11), 28.2 (C9-11), 28.0 (C8), 26.8 (C9-11), 13.4 (C1),
13.0 (C5); HRMS-ESI; [M+Na]+ calc’d for C18H22BN5F2S2O6Na3 586.0766 found; 586.0757.
NO2N
S S OH
O
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Synthesis of 3-((5-nitropyridin-2-yl)disulfanyl)propanoic acid (13). (2,2)’-bis-dithio-
5-nitropyridine (0.80 g, 2.7 mmol) was dissolved in 80 mL MeOH:CH2Cl2 (1:1). A solution of
3-mercaptopropionic acid (120 µL, 0.88 mmol) in CH2Cl2 (1.0 mL) was added drop-wise to
the reaction mixture with continuous stirring at ambient temperature, resulting in a bright
yellow solution. The formation of a major UV active spot at an Rf identical to that of
3-mercaptopropionic acid (Rf = 0.45) indicated the presence of the desired product. The
solvents were removed in vacuo and a small portion of CH2Cl2 was added, resulting in pre-
cipitation of an orange solid (thiolate side-product) which was filtered. The filtrate was
concentrated and purified via flash column chromatography, eluting with 3.0% MeOH in
CH2Cl2 giving the product as a pale yellow solid (0.20 g, 87% yield). MP 94-96
◦C. IR (thin
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film)/cm-1 νmax; 3086 s, 2918 s, 1705 s, 1587 s, 1514 s, 1339 s, 1095 s, 854 s, 747 s;
1H NMR
(300 MHz, DMSO-d6) δH 9.24 (d, J = 2.5 Hz, 1H, C7), 8.60 - 8.50 (m, 1H, C6), 8.02 (d, J =
8.9 Hz, 1H, C5), 3.07 (t, J = 6.9 Hz, 2H, C2), 2.63 (t, J = 6.9 Hz, 2H, C3); 13C NMR (101
MHz, methanol-d4) δC 176.5 (C1), 167.2 (C8), 144.9 (C7), 142.3 (C4), 132.6 (C6), 119.6 (C5),
33.7 (C3), 33.5 (C2); HRMS-ESI; [M+H]+ calc’d for C8H8N2O2S2 261.0004 found; 261.0009.
HO S
O O
1
2
3
4 5
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3-(acetylthio)propanoic acid (18). 3-iodopropionic acid (100 mg, 0.50 mmol) was dis-
solved in DMF (10 mL), followed by potassium thioacetate (86 mg, 0.75 mmol). The reaction
mixture was stirred at ambient temperature for 6.0 h at which point the starting material
was no longer present by thin-layer chromatography (TLC) and formation of a product was
observed (Rf = 0.35, 5.0% MeOH in CH2Cl2). The mixture was with 1.0 m HCl (20 mL)
twice followed by washing with brine (30 mL). The crude reaction mixture was purified via
column chromatography eluting with 2.0% MeOH in CH2Cl2 which gave the product as a
colourless oil (42 mg, 47% yield). IR (thin film)/cm-1 νmax; 2935 w, 1685 s, 1423 s, 1354 s,
1133 s, 949 s, 685 s; 1H NMR (400 MHz, chloroform-d) δH 3.11 (t, J = 6.9 Hz, 2H, C3),
2.70 (t, J = 6.9 Hz, 2H, C2), 2.34 (s, 3H, C5); 13C NMR (100 MHz, chloroform-d) δC 195.5
(C4), 177.4 (C1), 34.1 (C2), 30.5 (C5), 23.8 (C3); HRMS-ESI; [M-H]+ calc’d for C5H7O3S
147.0116, found; 147.0109. Values consistent with reported data (NMR, MS).230
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S-(1-azido-13- oxo-3,6,9-trioxa -12- azapentadecan-15-yl) ethanethioate (19). 3-
thioesterpropionic acid 18 (20 mg, 0.14 mmol) was dissolved in THF (8.0 mL), followed
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by triethylamine (33 µL, 0.24 mmol), commercially available 11-azido-3,6,9-trioxaundecan-1-
amine (24 µL, 0.12 mmol) and HBTU (51 mg, 0.14 mmol). The reaction mixture was stirred
at ambient temperature under an argon atmosphere. Monitoring the reaction by TLC showed
consumption of the acidic starting material and formation of a major product (Rf = 0.10,
3.0% MeOH in CH2Cl2). The solvents were then removed in vacuo and the crude reaction
mixture was purified via column chromatography eluting with 4.0% MeOH in CH2Cl2. This
gave the product as a colourless oil (24 mg, 57% yield). IR (thin film)/cm-1 νmax; 3359 br,
2935 w, 2108 w, 1687 s, 1649 s, 1549 s, 1294 s, 1130 s, 945 s; 1H NMR (300 MHz, chloroform-
d) δH 6.33 (s, 1H, NH), 3.71 – 3.53 (m, 10H, C2-6), 3.61 – 3.56 (m, 2H, C7), 3.50 - 3.41
(m, 2H, C8), 3.40 - 3.32 (m, 2H, C1), 3.07 (t, J = 7.0 Hz, 2H, C10), 2.42 (t, J = 7.0 Hz,
2H, C11), 2.33 (s, 3H, C13); 13C NMR (100 MHz, chloroform-d) δC 196.0 (C12), 170.6 (C9),
70.7 (C2/-7), 70.6 (C2/-7), 70.4 (C2/-7), 70.3 (C2/-7), 70.1 (C2/-7), 69.8 (C2/-7), 50.7 (C1)
38.6 (C8), 36.1 (C11), 30.6 (C13), 24.9 (C10); HRMS-ESI; [M+Na]+ calc’d for C13H24N4O5S
371.1365 found; 371.1366.
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S -(5-(5,5-difluoro -1,3,7,9- tetramethyl -5H - dipyrrolo [1,3,2] diazaborinin-10-yl)
pentyl) ethanethioate (21) 5-bromopentyl-BODIPY 7 (100 mg, 0.25 mmol) was dissolved
in acetone (20 mL) then treated with potassium thioacetate (28 mg, 0.25 mmol) and the
mixture was stirred under reflux conditions for 3.0 h. The solvent was removed in vacuo
and resuspended in CH2Cl2 before washing with water (3.0 times). The solvent was removed
in vacuo to give the product as an orange solid (89 mg, 91% yield). MP 146-149 ◦C, lit.
146-148 ◦C. IR (thin film)/cm-1 νmax; 2927 s, 2865 s, 1687 s, 1545 s, 1472 s, 1307 s, 1194
2.2. Chemical Methods 85
s, 973 s, 714 s; 1H NMR (300 MHz, chloroform-d) δH 6.04 (s, 2H, C3), 3.43 – 2.76 (m, 4H,
C8/12), 2.51 (s, 6H, C1), 2.39 (s, 6H, C5), 2.33 (s, 3H, C14), 1.75 – 1.46 (m, 6H, C9-11); 13C
NMR (100 MHz, chloroform-d) δC 195.8 (C13), 153.9 (C2), 146.1 (C7), 140.3 (C4), 131.4
(C6), 121.6 (C3), 31.4 (C9/-11), 30.7 (C14), 29.4 (C9/-11), 29.3 (C9/-11), 28.8 (C8/12), 28.2
(C8/12), 16.4 (C5), 14.4 (C1); HRMS-ESI; [M+Na]+ calc’d for C20H27BN2F2SNa 415.1803
found; 415.1814. Values consistent with reported data (NMR, MS, MP).228
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(5-(5,5-difluoro-1,3,7,9-tetramethyl -5H - dipyrrolo [1,3,2] diazaborinin-10-yl) pen-
tane -1- thiol (22) Pentylthioester-BODIPY 21 (80 mg, 0.20 mmol) was dissolved in EtOH
(oxygen removed) followed by addition of potassium carbonate (33 mg, 0.24 mmol) and
heated at 30◦C for 4.0 h. Product formation was confirmed by TLC (Rf = 0.90, CH2Cl2),
the mixture was then acidified with sat. NH4Cl and extracted with CH2Cl2. The solvent was
removed in vacuo and the resulting mixture was purified by column chromatography, eluting
with 55:45 CH2Cl2:petroleum ether to give the product as an orange solid (54 mg, 77% yield).
MP 118-120 ◦C, lit. 120-121 ◦C. IR (thin film)/cm-1 νmax; 3379 br m, 2927 w, 2853 s, 1547
s, 1408 s, 1224 s, 1158 s, 974 s, 803 s; 1H NMR (300 MHz, chloroform-d) δH 6.05 (s, 2H, C3),
3.08 – 2.84 (m, 2H, C8), 2.61 – 2.53 (m, 2H, C12), 2.51 (s, 6H, C1), 2.41 (s, 6H, C5), 1.75
– 1.55 (m, 6H, C9-11), 1.34 (t, J = 7.8 Hz, 1H, SH); 13C NMR (100 MHz, chloroform-d) δC
153.9 (C2), 146.1 (C7), 140.2 (C4), 131.4 (C6), 121.7 (C3), 33.5 (C12), 31.3 (C9/-11), 28.9
(C9/-11), 28.3 (C8), 24.4 (C9/-11), 16.4 (C5), 14.4 (C1); HRMS-ESI; [M+Na]+ calc’d for
C18H25BN2F2SNa 373.1697 found; 373.1690. Values consistent with reported data (NMR,
MS, MP).228
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N-(2-(2-(2-(2-azidoethoxy) ethoxy) ethoxy) ethyl) -3- ((3-nitropyridin-2-yl) disul-
fanyl) propanamide 23. Disulfide 13 (110 mg, 0.43 mmol) was dissolved in a solution of
dry THF (15 mL) then treated with triethylamine (105 µL, 0.78 mmol), 11-azido-3,6,9-
trioxaundecan-1-amine (77 µL, 0.39 mmol) and HBTU (160 mg, 0.43 mmol). The solution
was left to stir at ambient temperature for 16 h. Monitoring by TLC revealed formation
of a major product (Rf = 0.60, 5.0% MeOH in CH2Cl2) and the solvent was then removed
in vacuo. The reaction mixture was purified via column chromatography eluting with 3.0%
MeOH in CH2Cl2, the gradient was increased to 10% MeOH in CH2Cl2 after elution of the
first compound. The product was recovered as a yellow oil (146 mg, 81% yield). IR (thin
film)/cm-1 νmax; 3315 br w, 3064 w, 2882 w, 2194 m s, 1723 s, 1657 s, 1589 s, 1518 s, 1441
s, 1343 s, 1269 s, 1097 s, 855 s, 749 s; 1H NMR (300 MHz, DMSO-d6) δH 9.35 - 9.15 (m,
1H, C16), 8.65 – 8.49 (m, 1H, C14), 8.16 - 7.98 (m, 1H, C13), 3.63 – 3.56 (m, 2H, C2/-7),
3.56 – 3.47 (m, 10H, C2/-7), 3.42 - 3.35 (m, 4H, C1 & C2/-7), 3.20 (q, J = 5.8 Hz, 2H, C8),
3.08 (t, J = 7.0 Hz, 2H, C10), 2.52 - 2.48 (m, 2H, C11); 13C NMR (100 MHz, DMSO-d6) δC
170.2 (C9), 167.9 (C15), 145.4 (C16), 142.8 (C12), 133.1 (C14), 120.0 (C13), 70.2 (C2/-7),
70.2 (C2/-7), 70.0 (C2/-7), 69.7 (C2/-7), 69.5 (C2/-7), 50.5 (C1), 39.1 (C8), 34.9 (C11), 34.8
(C10); HRMS-ESI; [M+Na]+ calc’d for C16H24N6O6S2 483.1096 found; 483.1095.
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N-(2-(2-(2-(2-azidoethoxy) ethoxy) ethoxy) ethyl) -3-((5-(5,5- difluoro -1,3,7,9-
tetramethyl- 5H - 4λ4,5λ4- dipyrrolo [1,2-c:2’, 1’-f ] [1,3,2] diazaborinin-10-yl)
pentyl) disulfanyl) propanamide 24. Azido disulfide 23 (110 mg, 0.24 mmol) was dis-
solved in a solution of MeOH/CH2Cl2 (1:1, 30 mL). BODIPY thiol 22 (61 mg, 0.17 mmol)
was then added to the solution and stirred at ambient temperature for 16 h leading to for-
mation of a fluorescent product (Rf = 0.40, 3.0% MeOH in CH2Cl2). The solvent was then
removed in vacuo and the crude mixture was purified via column chromatography eluting
with 2.0% MeOH in CH2Cl2. The product was recovered as a yellow oil, however, some
residual azide starting material was present by nuclear magnetic resonance (NMR) and so
the mixture was further purified via HPLC using an isocratic gradient of 65% MeCN in water,
the product eluted after a retention time of 16 min (C18 column, 1.0 mL min−1) to give an
orange solid (16 mg, 40% yield). MP 105-107 ◦C. IR (thin film)/cm-1 νmax; 3320 br w, 2912
w, 2104 s, 1663 s, 1545 s, 1488 s, 1341 s, 1245 s, 1149 s, 990 s, 717 s; 1H NMR (300 MHz,
chloroform-d) δH 6.23 (br s, 1H, NH), 6.05 (s, 2H, C3), 3.74 – 3.60 (m, 12H, C16/-22), 3.58 –
3.51 (m, 2H, C16/-22), 3.51 – 3.41 (m, 2H, C16/-22), 3.43 – 3.35 (m, 2H, C23), 2.94 (m, 4H,
C8 & C14), 2.70 (t, J = 7.1 Hz, 2H, C12), 2.58 (t, J = 7.3 Hz, 2H, C13), 2.51 (s, 6H, C1),
2.41 (s, 6H, C5), 1.85 – 1.69 (m, 2H, C9/-11), 1.67 – 1.55 (m, 4H, C9/-11); 13C NMR (100
MHz, chloroform-d) δC 170.8 (C15), 153.9 (C2), 146.1 (C7), 140.3 (C4), 131.4 (C6), 121.7
(C3), 70.7 (C16/-22), 70.6 (C16/-22), 70.6 (C16/-22), 70.3 (C16/-22), 70.1 (C16/-22), 69.8
(C16/-22), 50.7 (C23), 39.2 (C16/-22), 38.2 (C12), 35.9 (C13), 33.7 (C14), 31.5 (C9/-11),
28.9 (C9/-11), 28.7 (C9/-11), 28.3 (C8), 16.5 (C5), 14.5 (C1); HRMS-ESI; [M+Na]+ calc’d
for C29H45BF2N6O4S2 677.2903 found; 677.2903.
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sodium 10- (5-bromopentyl)- 5,5-difluoro - 1,3,7,9 - tetramethyl- 5H -4λ4, 5λ4 -
dipyrrolo [1,2-c: 2’,1’-f ] [1,3,2] diazaborinine -2,8- disulfonate 46. BODIPY bromide
7 (100 mg, 0.25 mmol) was dissolved in dry CH2Cl2 (5.0 mL) and was cooled to -25
◦C with
addition of a few crystals of butylated hydroxytoluene (BHT). Chlorosulfonic acid (35 µL,
0.53 mmol diluted in 1.1 mL CH2Cl2) was then added dropwise over 15 min and stirred for a
further 30 min. The solution was then allowed to warm to ambient temperature and stirred
for 1.0 h. Methanol (5.0 mL) was then added followed by sodium bicarbonate (95 mg, 1.1
mmol) and stirred for 20 min. The solvents were removed in vacuo and purified via column
chromatography eluting with MeOH in CH2Cl2 (20:80) to give the product as a brown solid
(130 mg, 83% yield). MP 209-212 ◦C. IR (thin film)/cm-1 νmax; 3668 m, 2981 w, 2902 w,
1638 w, 1453 s, 1406 s, 1394 s, 1250 s, 1229 s, 1066 s, 1056 s, 896 s, 793 s; 1H NMR (300 MHz,
methanol-d4) δH 3.58 – 3.45 (m, 2H, C12), 3.33 (dt, J = 3.3, 1.6 Hz, 2H, C8), 2.82 (s, 6H,
C5), 2.77 (s, 6H, C1), 2.04 – 1.90 (m, 2H, C9/-11), 1.79 - 1.71 (m, 4H, C9/-11); 13C NMR
(100 MHz, methanol-d4)) δC 153.6 (C2), 150.5 (C7), 139.7 (C4), 134.4 (C3), 130.6 (C6), 32.7
(C12), 32.0 (C10/11), 30.5 (C9), 28.1 (C8), 28.0 (C10/11) 13.4 (C5), 13.0 (C1); HRMS-ESI;
[M+Na]+ calc’d for C18H22BBrF2N2Na2O6S2 622.9857 found; 622.9858.
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S-(5-(5,5-difluoro-1,3,7,9-tetramethyl- 5H -4λ4,5λ4-dipyrrolo [1,2-c:2’,1’-f ] [1,3,2]
diazaborinin-10-yl) pentyl) 4-methylbenzenesulfonothioate 28. BODIPY bromide
7 (100 mg, 0.25 mmol) was dissolved in dry acetone (15 mL) followed by the addition of
potassium p-toluenethiosulfonate (140 mg, 0.60 mmol). The mixture was heated under re-
flux conditions for 4.0 h resulting in formation of a major product (Rf = 0.70, CH2Cl2).
The solvent was removed in vacuo and purified via column chromatography eluting with
petroleum ether:CH2Cl2 (1:2) to give the product as an orange solid (69 mg, 72% yield). MP
151-153 ◦C. IR (thin film)/cm-1 νmax; 2929 w, 1718 s, 1545 s, 1470 s, 1406 s, 1318 s, 1160
s, 985 s, 813 s; 1H NMR (300 MHz, chloroform-d) δH 7.90 – 7.74 (m, 1H, C15), 7.32 (d, J
= 8.1 Hz, 1H, C14), 6.04 (s, 2H, C3), 3.09 – 2.94 (m, 2H, C12), 2.91 – 2.77 (m, 2H, C8),
2.50 (s, 6H, C1), 2.42 (s, 3H, C17), 2.34 (s, 6H, C5), 1.72 – 1.60 (m, 2H, C11), 1.55 – 1.46
(m, 4H, C9-10); 13C NMR (100 MHz, chloroform-d) δC 153.9 (C2), 145.8 (C7), 144.9 (C16),
142.0 (C13), 140.2 (C4), 131.4 (C6), 129.9 (C15), 127.0 (C14), 121.7 (C3), 35.7 (C12), 31.1
(C9), 28.9 (C10/11), 28.4 (C10/11), 28.0 (C8), 21.6 (C17), 16.4 (C5), 14.5 (C1); HRMS-ESI;
[M+Na]+ calc’d for C25H31BF2N2O2S2 527.1786 found; 527.1788.
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2-((5-(5,5-difluoro-1,3,7,9-tetramethyl- 5H -4λ4,5λ4 -dipyrrolo [1,2-c:2’,1’-f ] [1,3,2]
diazaborinin-10-yl) pentyl) disulfanyl)ethan-1-amine 30. BODIPY 28 (20 mg, 0.04
mmol) was dissolved in MeOH:CH2Cl2 (1:1 5.0 mL) followed by the addition of cysteamine
(4.5 mg, 0.04 mmol) and triethylamine (7.0 µL, 0.05 mmol). The solution was stirred at am-
bient temperature for 15 h leading to formation of a fluorescent product (Rf = 0.1, CH2Cl2).
The solvents were removed in vacuo, resuspended in CH2Cl2 and washed with saturated
potassium bicarbonate solution (3 times). The organic phase was dried with MgSO4, filtered
and the solvent was removed in vacuo to give the product as an orange solid (18 mg, 95%
yield). MP 133-135 ◦C. IR (thin film)/cm-1 νmax; 2925 w, 2862 w, 1548 s, 1509 s, 1409 s,
1370 s, 1224 s, 1079 s, 985 s, 714 w; 1H NMR (300 MHz, chloroform-d) δH 6.02 (d, J = 19.3
Hz, 2H, C3), 3.03 – 2.90 (m, 4H, C8& C14), 2.79 – 2.66 (m, 4H, C12& C13), 2.49 (s, 6H,
C1), 2.41 (s, 6H, C5), 1.82 – 1.71 (m, 2H, C11), 1.67 – 1.55 (m, 4H, C9-101), 1.45 (br s,
2H, NH2);
13C NMR (100 MHz, chloroform-d) δC 153.9 (C2), 146.1 (C7), 140.2 (C4), 131.4
(C6), 121.7 (C3), 42.6 (C13/14), 40.6 (C13/14), 38.5 (C12), 31.5 (C9), 29.8 (C10/-11), 28.7
(C10/-11), 28.3 (C8), 16.5 (C5), 14.5 (C1); HRMS-ESI; [M+H]+ calc’d for C20H30BF2N3S2
426.2021 found; 426.2023
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2-(2-(2- (2-(2- azidoethoxy) ethoxy) ethoxy) -N -(2-((5- (5,5-difluoro -1,3,7,9-
tetramethyl- 5H - 4λ4,5λ4- dipyrrolo [1,2-c: 2’,1’-f ] [1,3,2] diazaborinin-10-yl)
pentyl) disulfanyl) ethyl) acetamide 32. BODIPY 30 (280 mg, 0.67 mmol) was dis-
solved in dry THF (25 mL), followed by the addition of 11-azido-3,6,9-trioxaundecanoic acid
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(130 µL, 0.61 mmol), triethylamine (160 µL, 1.2 mmol) and HBTU (250 mg, 0.67 mmol).
The reaction mixture was stirred at ambient temperature for 16 h and monitoring by TLC
revealed formation of a fluorescent product (Rf = 0.10, 2.0% MeOH in CH2Cl2). The solvent
was removed in vacuo and the crude product was purified via column chromatography elut-
ing with 2.0% MeOH in CH2Cl2 which gave the product as an orange solid (280 mg, 71%
yield). MP 109-111 ◦C. IR (thin film)/cm-1 νmax; 3332 br, 2922 w, 2880 w, 2106 m, 1720
s, 1660 s, 1544 s, 1442 s, 1407 s, 1344 s, 1197 s, 1097 s, 989 s, 832 w; 1H NMR (300 MHz,
chloroform-d) δH 7.17 (br s, 1H, NH), 5.98 (s, 2H, C3), 3.92 (s, 2H, C16), 3.66 – 3.53 (m,
8H, C14/17-21), 3.49 - 3.42 (m, 2H, C17/-21) 3.37 – 3.24 (m, 2H, C22), 2.91 - 2.80 (m, 2H,
C8), 2.74 (dd, J = 8.7, 4.4 Hz, 2H, C13), 2.64 (t, J = 7.1 Hz, 2H, C12), 2.44 (s, 6H, C1),
2.33 (s, 6H, C5), 1.74 – 1.61 (m, 2H, C11), 1.61 – 1.45 (m, 4H, C9-10); 13C NMR (100 MHz,
chloroform-d) δC 170.1 (C15), 153.8 (C2), 146.1 (C7), 140.3 (C4), 131.4 (C6), 121.6 (C3), 71.0
(C14/16/-21), 70.9 (C14/16/-21), 70.7 (C14/16/-21), 70.6 (C14/16/-21), 70.4 (C14/16/-21),
70.0 (C14/16/-21), 50.7 (C22), 38.4 (C12), 37.7 (C13/16/-21), 37.6 (C13/16/-21), 31.4 (C9),
28.9 (C10/11), 28.7 (C10/11), 28.2 (C8), 16.4 (C5), 14.4 (C1); HRMS-ESI; [M-Na]- calc’d
for C28H43BF2N6O4S2Na 663.2746 found; 663.2744.
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sodium 10- (1-azido-11-oxo -3,6,9- trioxa- 15,16-dithia -12- azahenicosan-21-yl)
-5,5-difluoro -1,3,7,9- tetramethyl- 5H - 4λ4,5λ4 -dipyrrolo [1,2-c:2’,1’-f ] [1,3,2]
diazaborinine -2,8- disulfonate 33. BODIPY 32 (50mg, 0.078 mmol) was dissolved in
dry CH2Cl2 (3.0 mL) and was cooled to -25
◦C with addition of a few crystals of BHT.
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Chlorosulfonic acid (11 µL, 0.16 mmol, diluted into 0.34 mL of CH2Cl2) was then added
dropwise over 15 min and stirred for a further 30 min. The solution was then allowed to
warm to ambient temperature and stirred for 1.0 h. Methanol (2.0 mL) was then added
followed by sodium bicarbonate (33 mg, 1.1 mmol) and stirred for 20 min. The solvents were
removed in vacuo and purified via column chromatography eluting with MeOH in CH2Cl2
(20:80) to give the product as an orange solid (35 mg, 53% yield). MP 137-140 ◦C. IR (thin
film)/cm-1 νmax; 3317 br, 2927 w, 2865 w, 2104 m, 1662 s, 1548 s, 1472 s, 1370 s, 1307 s,
1200 s, 1081 s, 986 s, 856 s; 1H NMR (300 MHz, DMSO-d−6) δH 3.88 (s, 2H, C16), 3.66 -
3.51 (m, 12H, C13/14/17-22), 3.46 – 3.36 (m, 4H, C17/-22 & C23), 3.13 - 2.99 (m, 2H, C8),
2.85 – 2.71 (m, 4H, C12 & C13/14), 2.67 (s, 6H, C5), 2.61 (s, 6H, C1), 1.85 - 1.73 (m, 2H,
C11), 1.70 - 1.59 (m, 4H, C9/10); 13C NMR (100 MHz, DMSO-d−6) δC 169.8 (C15), 153.0
(C2), 149.1 (C7), 138.1 (C4), 130.2 (C3), 126.7 (C6), 70.7 (C16/-22), 70.4 (C16/-22), 70.2
(C16/-22), 70.1 (C16/-22), 70.0 (C16/-22), 69.7 (C16/-22), 50.4 (C23), 38.0 (C12/-14), 37.9
(C12/-14), 37.4 (C12/-14), 31.3 (C9/10), 28.6 (C9/10), 28.5 (C11), 28.1 (C8), 14.3 (C1), 14.2
(C5); HRMS-ESI; [M-Na]- calc’d for C28H41BF2N6NaO10S4 821.1726 found; 821.1719.
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Synthesis of (N -(9-(2-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)phenyl)-6-
(diethylamino)-3H -xanthen-3-ylidene)-N -ethylethanaminium (38). RhoB base (1.0
g, 2.3 mmol) was dissolved in CH2Cl2, under N2, before adding N-boc piperazine (Sigma,
0.46 g, 2.5 mmol), triethylamine (0.6.0 mL, 4.5 mmol) and HBTU (0.93 g, 2.5 mmol) and
stirring for 24 h. This resulted in formation of a major product (9:1 CH2Cl2:MeOH, Rf =
0.80) and the solvent was then removed in vacuo. This crude mixture was then purified via
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flash column chromatography eluting with 3.0% MeOH in CH2Cl2 to give the product as a
dark purple solid (1.3 g, 98% yield). MP = 136-138 ◦C. IR (thin film)/cm-1; 3661 w, 3356
br, 2988 w, 2901 w, 1636 s, 1595 s, 1465 s, 1337 s, 1259 s, 1127 s, 1066 s, 959 s, 772 s; 1H
NMR (400 MHz, chloroform-d) δH 7.80 - 7.68 (m, 2H, C12-13), 7.62 – 7.49 (m, 1H, C14),
7.39 - 7.28 (m, 1H, C11), 7.25 (d, J = 9.5 Hz, 2H, C7), 6.99 (d, J = 9.5 Hz, 2H, C6), 6.79
(s, 2H, C4), 3.78 – 3.53 (m, 8H, C2), 3.39 -3.25 (m, 8H, C17-18), 1.46 (s, 9H, C21), 1.39 –
1.23 (m, 12H, C1); 13C NMR (100 MHz, chloroform-d) δC 167.8 (C16), 157.8 (C5/8), 156.0
(C9), 155.7 (C8), 154.6 (C19), 135.2 (C10), 132.1 (C7), 130.8 (C15), 130.4 (C11/-13), 130.2
(C11/-13), 130.2 (C11/-13), 127.6 (C14), 114.1 (C6), 113.8 (C5/8), 96.4 (C4), 80.5 (C20),
47.4 (C17/18), 46.1 (C2), 41.9 (C17/18), 28.3 (C21), 12.6 (C1); HRMS-ESI; M+ calc’d for
C37H47N4O4 611.3597 found; 611.3592. Values consistent with reported data (NMR, MS).
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Synthesis of N -(6-(diethylamino) -9- (2-(piperazine-1-carbonyl) phenyl)- 3H -
xanthen -3- ylidene)- N -ethylethanaminium (37). RhoB N-boc piperazine (38, 200
mg, 0.33 mmol) was suspended in water (10 mL) and transferred to a microwave vial. The
suspension was heated to 170 ◦C for 30 min (150 W). The suspension had dissolved an ex-
hibited formation of a major product (Rf = 0.30, 9:1 CH2Cl2:MeOH) and consumption of 37.
The solution was acidified with addition of HCl (0.10 M, 10 mL) and washed with CH2Cl2
(20 mL, 3.0x) to remove any residual starting material. The aqueous phase was then basified
via addition of potassium carbonate to reach pH 10. The aqueous phase was then extracted
with CH2Cl2 (30 mL, 3.0x) until a faint pink colour persisted in the aquoues phase. The
CH2Cl2 extractions were combined, dried with MgSO4 and concentrated in vacuo to give 37
as a viscous purple oil which was used without further purification (107 mg, 64%) MP =
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165-169 ◦C, lit. 218-220 ◦C. IR (thin film)/cm-1; 3374 br, 2978 w, 2934 w, 2877 w, 1645 s,
1589 s, 1530 s, 1468 s, 1414 s, 1395 s, 1339 s, 1275 s, 1248 s, 1161 s, 1074 s, 1009 s, 963 s,
923 s, 840 s, 740 s, 684 s; 1H NMR (300 MHz, methanol-d4) δH 7.70 - 7.62 (m, 2H, C12-13),
7.59 – 7.53 (m, 1H, C14), 7.37 – 7.30 (m, 1H, C11), 7.25 (d, J = 9.4 Hz, 2H, C7), 6.97 (dd,
J = 9.4, 2.3 Hz, 2H, C6), 6.78 (d, J = 2.3 Hz, 2H, C4), 3.73 – 3.54 (m, 8H, C2), 3.41 - 3.21
(m, 4H, C17/18), 2.55 – 2.46 (m, 4H, C17/18), 1.27 - 1.16 (m, 12H, C1); 13C NMR (100
MHz, methanol-d4) δC 169.4 (C16), 159.3 (C8), 157.2 (C3), 157.0 (C9), 136.8 (C10), 133.3
(C7), 132.0 (C15), 131.7 (C11/-13), 131.3 (C11/-13), 131.1 (C11/-13), 128.8 (C14), 115.4
(C6), 114.8 (C5), 97.3 (C4), 46.9 (C2), 45.9 (C17/18), 43.4 (C17/18), 12.8 (C1); HRMS-ESI;
M+ calc’d for C32H39N4O2 511.3073 found; 511.3073. Values consistent with reported data
(NMR, MS).232
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N -(9-(2-(4-(3- carboxypropanoyl) piperazine-1-carbonyl) phenyl) -6- (diethyl-
amino) -3H - xanthen -3- ylidene)- N -ethylethanaminium 40. RhoB 37 (109 mg,
0.21 mmol) was dissolved in dry THF (20 mL) before adding triethylamine (57 µL, 0.42
mmol) and succinic anhydride (53 mg, 0.53 mmol). The reaction mixture was left to stir
overnight and monitored by TLC to show formation of a product (Rf = 0.10, 8.0% MeOH
in CH2Cl2). The solvent was removed in vacuo and purified via column chromatography,
eluting with CH2Cl2:MeOH (90:10) to give the product as a dark purple solid (26 mg, 20%
yield). MP 167-169 ◦C, lit. 166-168 ◦C. IR (thin film)/cm -1 νmax 3325 br, 2944 w, 1641 s,
1636 s, 1456 s, 1017 s, 903 s, 781 s; 1H NMR (300 MHz, methanol-d4) δH 7.80 - 7.74 (m, 2H,
C12-13), 7.72 – 7.67 (m, 1H, C14), 7.57 – 7.49 (m, 1H, C11), 7.28 (d, J = 2.9 Hz, 2H, C7),
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7.15 - 7.05 (m, 2H, C6), 6.96 (s, 2H, C4), 3.74 – 3.62 (m, 8H, C2), 3.47 - 3.35 (m, 8H, C17/18),
2.56 (t, J = 7.0 Hz, 2H, C20/21), 2.43 (t, J = 7.0 Hz, 2H, C20/21), 1.31 (t, J = 7.1 Hz, 12H,
C1); 13C NMR (100 mHz, methanol-d4) δC 179.8 (C22), 173.7 (C19), 169.6 (C16), 159.3 (C8),
157.2 (C3), 157.0 (C9), 136.6 (C10), 133.2 (C7), 132.2 (C15), 131.7 (C11), 131.2 (C12/13)
129.0 (C14), 115.4 (C6), 114.9 (C5), 97.4 (C4), 46.9 (C2), 45.7 (C17/18), 45.4 (C17/18), 33.4
(C20/21), 30.2 (C20/21), 12.8 (C1); HRMS-ESI; [M+H]+ calc’d for C36H43N4O5 611.3233
found; 611.3224. Values consistent with reported data (NMR, MS, MP).232
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tert-butyl (1-azido-15- ((3-nitropyridin-2-yl)disulfanyl) -13- oxo -3,6,9- trioxa-
12- azapentadecan-14-yl) carbamate 42. Commercially Npys-Boc-Cys-OH (Sigma, 150
mg, 0.4 mmol) and azide-PEG-amine 47 (96 mg, 0.44 mmol) were dissolved in dry THF (15
mL) followed by triethylamine (110 µL, 0.80 mmol) and HBTU (170 mg, 0.44 mmol) and
stirred at ambient temperature for 16 h. The solvent was evaporated and the resulting yellow
oil was purified via column chromatography eluting with CH2Cl2:MeOH (95:5.0) to give the
product as a yellow oil (220 mg, 96%). IR (thin film)/cm -1 νmax 3301 br, 2977 w, 2870 w,
2103 s, 1711 s, 1667 s, 1582 s, 1517 s, 1342 s, 1120 s, 958 w, 856 s; 1H NMR (300 mHz,
DMSO-d−6) δH 8.92 (dd, J = 4.5, 1.4 Hz, 1H, C16), 8.61 (dd, J = 8.2, 1.4 Hz, 1H, C14),
7.57 (dd, J = 8.2, 4.5 Hz, 1H, C15), 6.52 (d, J = 7.3 Hz, 1H, NH), 4.16 – 3.91 (m, 1H, C10),
3.63 – 3.57 (m, 4H, C2/-8), 3.56 – 3.49 (m, 8H, C2/-8), 3.38 (dd, J = 6.5, 3.4 Hz, 2H, C1),
3.27 (dd, J = 13.1, 4.4 Hz, 1H, C11HA/B), 3.13 (dd, J = 13.1, 7.7 Hz, 1H, HA/B), 1.31 (s,
9H, C19); 13C NMR (100 MHz, DMSO-d6) δC 173.5 (C9), 155.6 (C17), 155.0 (C12), 154.2
(C16), 142.5 (C13), 134.5 (C14), 121.9 (C15), 77.8 (C18), 69.8 (C2/-8), 69.7 (C2/-8), 69.3
(C2/-8), 66.8 (C2/-8), 54.7 (C10), 50.0 (C1), 45.5 (C10), 42.0 (C11), 28.2 (C19); HRMS-ESI;
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[M+H]+ calc’d for C21H33N7O8S2 576.1910 found; 576.1927.
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2-amino-N -(2-(2-(2-(2-azidoethoxy) ethoxy)ethoxy)ethyl) -3- ((3-nitropyridin-2-
yl) disulfanyl) propanamide 43. N-boc cysteine-azide 42 (370 mg, 0.62 mmol) was
treated with 1:1 TFA:CH2Cl2 (6.0 mL) and stirred in air for 1.0 h. Complete consumption
of the starting material was observed by TLC (95:5 CH2Cl2:MeOH, Rf = 0.20). The solution
was treated with toluene (10 mL) and evaporated. The resulting oil was used without further
purification (290 mg, quant.). IR (thin film)cm -1 νmax 3365 br, 3230 br, 2926 w, 2885 w,
2110 m, 1668 s, 1583 s, 1337 s, 1194 s, 1131 s, 801 s; 1H NMR (300 MHz, DMSO-d6) δH 8.99
– 8.90 (m, 1H, C16), 8.67 – 8.61 (m, 1H, C14), 7.99 - 7.89 (br m, 1H, NH), 7.60 (dd, J = 8.2,
4.6 Hz, 1H, C15), 4.49 (tt, J = 15.3, 7.7 Hz, 1H, C10), 3.93 (d, J = 2.2 Hz, 2H, C1/-8), 3.70
– 3.49 (m, 10H, C1/-8), 3.43 – 3.33 (m, 4H, C1/-8), 3.24 (dd, J = 13.5, 8.1 Hz, 4H, C11);
13C NMR (100 MHz, DMSO-d6) δC 169.1 (C9), 155.1 (C12), 154.3 (C16), 142.6 (C13), 134.5
(C14), 122.0 (C15), 70.2 (C2/-8), 69.8 (C2/-8), 69.7 (C2/-8), 69.7 (C2/-8), 69.6 (C2/-8), 69.2
(C2/-8), 51.7 (C10), 50.0 (C1), 38.9 (C11); HRMS-ESI; [M+H]+ calc’d for C16H25N7O6S2Na
498.1205 found; 498.1211.
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2-amino-N -(2- (2-(2-(2- azidoethoxy) ethoxy) ethoxy)ethyl) -3- ((5-(5,5-difluoro
-1,3,7,9- tetramethyl -5H - dipyrrolo [1,3,2] diazaborinin -10- yl) pentyl) disul-
fanyl) propanamide 44. PEG-azide 43 (170 mg, 0.360 mmol) was dissolved in a 1:1
mixture of CH2Cl2:MeOH (30 mL) containing potassium carbonate (50 mg, 0.360 mmol).
BODIPY-thiol 22 (63 mg, 0.18 mmol) was dissolved in 1:1 CH2Cl2:MeOH (3.0 mL) and
added dropwise to the reaction mixture. The solution was then stirred overnight, resulting
in a major fluorescent product (Rf = 0.35, 97:3 CH2Cl2:MeOH). The solution was evap-
orated and the resulting orange oil was purified via column chromatography eluting with
1.0% MeOH in CH2Cl2 before increasing to 2.0% MeOH giving the product as a orange
glassy solid (61 mg, 51%). MP 98-100 ◦C. IR (thin film) cm-1 νmax 3677 br w, 2918 m, 2105
m, 1663 s, 1549 s, 1473 s, 1307 s, 1200 s, 1075 s, 802 s; 1H NMR (300 MHz, chloroform-d)
δH 7.72 - 7.64 (m, 1H, NH), 6.02 (s, 2H, C3), 3.73 – 3.61 (m, 14H, C13/17/-23), 3.57 (t, J
= 5.2 Hz, 2H, C17/-23), 3.52 – 3.42 (m, 2H, C16), 3.39 - 3.30 (m, 2H, C17/-23), 3.21 (dd,
J = 13.7, 3.6 Hz, 1H, C14), 2.95 - 2.88 (m, 2H, C8), 2.78 – 2.68 (m, 2H, C12), 2.50 (s, 6H,
C1), 2.41 (s, 6H, C5), 1.84 (br s, 2H, NH2), 1.76 - 1.70 (m, 2H, C11), 1.66 - 1.54 (m, 4H,
C9-10); 13C NMR (100 MHz, chloroform-d) δC 173.2 (C15), 153.9 (C2), 146.1 (C7), 140.3
(C4), 131.4 (C6), 121.7 (C3), 70.7 (C13/16/-23), 70.6 (C13/16/-23), 70.3 (C13/16/-23), 70.2
(C13/16/-23) 70.1 (C13/16/-23), 69.7 (C13/16/-23), 53.9 (C14), 50.7 (C13/16/-23), 43.3
(C13/16/-23), 39.0 (C13/16/-23), 38.0 (C12), 31.4 (C9), 29.0 (C8/10/11), 28.6 (C8/10/11)
28.3 (C8/10/11), 16.5 (C5), 14.4 (C1); HRMS-ESI; [M+Na]+ calc’d for C29H46N7O4S2Na
692.3012 found; 692.3008.
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N -(9- (2-(4-(1-azido-14- (((5- (5,5-difluoro -1,3,7,9- tetramethyl -5H - dipyrrolo
[1,3,2] diazaborinin-10-yl) pentyl) disulfanyl) methyl) -13,16- dioxo -3,6,9- trioxa
-12,15- diaza nonadecan -19- oyl) piperazine -1- carbonyl)phenyl) -6- (diethy-
lamino) -3H - xanthen-3-ylidene) -N - ethylethanaminium 45. RhoB acid 40 (16
mg, 0.026 mmol) and BODIPY azide 44 (15 mg, 0.022 mmol) were dissolved in CH2Cl2 (4.0
mL) under argon. Triethylamine (7.0 µL, 0.052 mmol) was added to this solution followed
by HBTU (11 mg, 0.026 mmol) before stirring at ambient temperature for 20 h. A major
red fluorescent spot was observed by TLC (Rf = 0.50, 9:1 CH2Cl2:MeOH) and the solvent
was removed in vacuo. The product was purified via column chromatography eluting with
3.0% MeOH in CH2Cl2 to give the product as a pink glassy solid (7.5 mg, 27%). IR (thin
film)/cm-1 νmax 3674 w, 2980 m, 2902 w, 1990 w, 1633 s, 1564 s, 1408 s, 1378 s, 1260 s, 1059
s, 912 s, 793 s; 1H NMR (300 MHz, chloroform-d) δH 7.67 – 7.54 (m, 2H, CHarom), 7.47 (d,
J = 7.0 Hz, 1H, CHarom), 7.35 - 7.20 (m, 5H, CHarom), 7.04 – 6.82 (m, 1H, NH), 6.71 - 6.63
(m, 2H, CHarom), 5.98 (s, 2H, CHarom), 4.60 (br s, 1H, NH), 3.71 – 3.50 (m, 20H, CH2), 3.49
- 3.32 (m, 16H, CH2), 3.22 - 3.10 (m, 2H, CH2), 2.93 - 2.86 (m, 2H, CH2), 2.65 (t, J = 7.0
Hz, 2H, CH2), 2.43 (s, 6H, CH3), 2.34 (s, 6H, CH2), 1.69 - 1.60 (m, 4H, CH2), 1.59 - 1.51 (m,
4H, CH2), 1.41 – 1.14 (m, 12H, CH3);
13C NMR (100 MHz, chloroform-d) δC 173.2, 170.4,
157.7, 156.2, 155.7, 153.8, 146.3, 140.4, 135.2, 132.2, 131.4, 130.2, 130.1, 130.0, 127.6, 121.6,
114.2, 113.8, 95.9, 70.5, 69.9, 69.4, 53.0, 50.6, 47.6, 47.1, 46.1, 45.3, 41.6, 41.1, 39.6, 39.2,
38.2, 31.4, 28.9, 28.5, 28.3, 16.4, 14.4, 12.6; MALDI (matrix: 2,5-dihydroxy benzoic acid);
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[M]+ for C65H87BF2N11O8S2 1262.
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3.1 Introduction
The work described in this chapter produces a range of fluorophores which contain an azide
functional group for use in CuAAC conjugations with alkyne-bearing CCL2. The require-
ments for these fluorophores are they must be suitable for use as FRET pairs and either
the donor or acceptor must exhibit a high degree of synthetic flexibility. This is because
both lipophilic and hydrophilic fluorophores are needed and so ideally this would be a single
fluorophore core which can include lipophilic functional groups and hydrophilic functional
groups. An obvious choice for the fluorophores would be the cyanine dyes which are widely
used FRET pairs and also can be synthesised as both polar and non-polar molecules through
sulfonation of the aromatic rings. Unfortunately, there is very little literature on the synthesis
of these fluorophores and so after extensive literature searching, boron dipyrrin (BODIPY)
was selected as the donor fluorophore (which would also be used for all single fluorophore
work) and rhodamine B was selected as the acceptor fluorophore.
BODIPY represents a class of fluorophores with excellent quantum yields, neutral overall
charge, narrow emission peaks, strong molar absorptivity and forms the basis of many syn-
thetic papers which highlight the scope of reactivity of these molecules.228,233,234 Scheme 3.1
shows the general core structure for BODIPY dyes and highlights the α-, β- and meso-
positions commonly used for substitution of the core. Unsubstituted BODIPYs are not
known in the literature, presumably due to further electrophilic attack on the pyrrolo-ring
from pyrrole starting materials or intermediates.233 The boron-free dipyrromethene interme-
diate is not stable at room temperature in most systems and is not generally observed or
isolated. Some regioisomers of BODIPY-dimethyl compounds have not been reported which
highlights the difficulty in synthesis of some BODIPYs, indicating planning is needed to en-
sure synthetic success. The higher degree of substitution on the BODIPY core translates into
greater stability and so many tetra-, hexa- and heptaalkyl-substituted BODIPYs have been
reported in the literature.233 A trend can be observed in that increased substitution corre-
lates with a red-shift in absorption and emission maxima. Interestingly, phenyl substituents
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at the meso position do not greatly affect absorption or emission maxima but in some cases a
significant impact on quantum yield has been observed.233 This can be rationalised through
the rotational freedom of the aromatic ring, if vicinal methyl groups are present, rotation of
the aromatic ring is limited and therefore fewer relaxation pathways are available, increasing
quantum yield. When the ring can freely rotate, the quantum yield is lowered due to the
increase in non-fluorescent relaxation pathways, these findings highlight the sometimes large
effects relatively small modifications to BODIPY can have on photophysical properties.
BODIPYs with substituents at the meso-position have been widely reported and are usually
prepared from acyl chloride condensation with the relevant pyrrole.228,233 Alternatively acti-
vated carboxylic acids can also be used in this reaction such as anhydrides which result in for-
mation of a carboxylic acid for further reactivity.233 Pyrroles or aromatic substituents which
are particularly reactive may require softer BODIPY formation conditions, these include for-
mation from aromatic aldehydes and pyrroles. This process results in a dipyrrole separated
by an sp3 centre which requires a further oxidation step to generate the dipyrrolo species
before boron complexation.233 This method has allowed the synthesis of α,β-unsubstituted
BODIPYs from an aromatic aldehyde, the corresponding acyl chloride would likely be too
reactive to successfully form the product.233,235
BODIPY has found extensive applications in imaging, chemosensing and light-harvesting sys-
tems which highlights the large range of spectral properties available with modifications to the
fluorescent rings.233,234,236 In cellular imaging, neutral BODIPYs offer cytosolic distribution,
whereas BODIPYs based on esters (which likely unmask to anionic acids due to esterase-
mediated hydrolysis) will localise around the endoplasmic reticulum and positively charged
BODIPYs have been used to label mitochondria.234,237–239 For FRET applications, increased
substitution of the BODIPY core would lead to a red-shifted fluorophore which would be
suitable for spectral overlap with a typical ‘green’ BODIPY. However, these compounds usu-
ally require aliphatic ring fusion to the aromatic core making these compounds very lipophilic
(and thus not water soluble).233 Furthermore, these compounds are often asymmetric which
complicates the synthesis and the extended systems can stabilise the free dipyrrin species
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Scheme 3.1: Properties of simple BODIPY fluorophores. Numbering system of BODIPY positions
and the α, β and meso positions (Top). Phenyl substituents have little effect on absorption and
emission maxima but free rotation of the phenyl ring has a deleterious effect on quantum yield
(Middle). Increasing substitution on the BODIPY rings generally leads to a red-shift in emission
(Bottom). Adapted from Burgess et al.233
3.1. Introduction 104
N
B
N
F FR3 R4
R1 R2
N3
3
N
B
N
F FR3 R4
R1 R2
N3
3
NaO3S SO3Na
N
B
N
F FR3 R4
R1 R2
S
n
NaO3S SO3Na
S N3
n
N
B
N
F FR3 R4
R1 R2
S
n
S N3
n
N
B
N
F FR3 R4
R1 R2
S
n
S
R5
n
N3
O NEt2Et2N
Scheme 3.2: General structures of polar and non-polar fluorophores synthesised in this chapter,
including azide groups and disulfide bonds in cleavably-linked compounds.
meaning the boron species is not held in the complex as tightly (Butterworth group unpub-
lished observations). The acceptor fluorophore therefore utilised rhodamine, derivatives of
which have been used in FRET pairs with BODIPY.240 Rhodamine is cationic which results
in increased water solubility over BODIPY and the complete fluorophore is commercially
available at a relatively low price, unlike the BODIPYs which are only available for specific
applications not for further synthesis. Furthermore, a number of derivatisation strategies
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exist for rhodamine and so functionalisation of the rhodamine towards a FRET pair would
be simpler than generating a red/orange BODIPY from pyrrole starting materials.241 Due to
the cationic nature of rhodamine, this compound may not be able to escape endosomes and
any rhodamines that localised in the cytosol would likely traffic to mitochondria; BODIPY
will therefore be used as the fluorophore which will be reductively detached from CCL2. The
general schematic structures for the fluorophores and FRET pair are displayed in Scheme 3.2.
3.2. Synthesis of Conjugating Substrates 106
3.2 Synthesis of Conjugating Substrates
3.2.1 Synthesis of BODIPY Azides
BODIPY was selected as the first fluorophore to be synthesised due to the fluorochrome’s
favourable spectral properties such as good quantum yield, excellent photostability and chem-
ical stability. We followed the work of Mueller et al. to generate a pentasubstituted BODIPY
core with a pentyl alkyl chain as a spacer.228 The highly substituted core increases the sta-
bility of the core towards downstream reactions and also limits the number of isomers that
can be formed in the reaction. Furthermore, the five-carbon spacer gives the linker flexibility
and reduces steric hindrance between the fluorophore and the propargyl glycine residue on
the CCL2 derivative, which should increase the probability of obtaining complete conversion
to the conjugate. This length of spacer also generally gave the best reaction yields in later
synthetic steps reported in the study.228 The first stage of the synthesis is a two-step, one-pot
procedure using 2,4-dimethylpyrrole (5), this undergoes an SNAr reaction with 6-bromo
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F F
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NH
i) Br-(CH2)5-COCl
0oC -> rt N HN
Br
ii) NEt3, 0oC, 30 min
iii) BF3.OEt2, 0oC ->rt, 1h
    28% (3 steps)
N
B
N
F F
N3
NaN3, DMF
rt, 3 h, quant.
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7
7
8
Scheme 3.3: Synthesis of a lipophilic BODIPY azide (8) from 2,4-dimethylpyrrole using one-pot
conditions. The resulting BODIPY bromide (7) was then treated with sodium azide resulting in 8.
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hexanoyl chloride twice, eliminating HCl and producing the dipyrrin core 6 (Scheme 3.3).
The next step quenches the HCl and also deprotonates the nitrogen of the dipyrrin core using
an excess of cold triethylamine, the deprotonated nitrogen can then coordinate to the lewis
acid boron trifluoride, this results in completion of the boron dipyrrin core (7) with a fluo-
ride leaving group. The experimental procedure was modified to include a recrystallisation
step using heptane as the compound was not pure after column chromatography. Heptane
allows heating to elevated temperatures over shorter chain solvents which can aid the recrys-
tallisation process, resulting in pure BODIPY bromide 7. A reason for typically low yields
of BODIPYs is the stability of the dipyrrin core (without the complexed boron species), if
this core is not particularly stable, the first step in the one-pot procedure can be limiting.
A tenuous trend exists in that the greater the extent of pi-conjugation (an extended ring
system), the greater the stability of the uncomplexed dipyrrin species. However, this can
favour release of any complexed boron making downstream synthesis and subsequent biolog-
ical experiments more difficult (unpublished observations in the group). The yields reported
in this work ranged from 9 - 45% with an average yield of 28%, this is compared with the
33% yield reported by Mueller et al..228 The authors reported the importance of limiting
the boron trifluoride etherate reaction time to 1 h as side products can form after this time
but which substrate this was performed on was not discussed. One attempt was therefore
made to increase the reaction time of the boron trifluoride etherate step from 1 h to 16 h.
A moderate increase in yield to 45% was observed suggesting a longer reaction time can be
beneficial for this substrate, however, these conditions were not attempted again. A number
of factors were observed to improve yields: fresh distillation of dry triethylamine, replacing
pyrrole 5 and boron trifluoride etherate after three months. Whilst this initial step did limit
the amount of material needed for subsequent steps (scale up resulted in lower yields), 250-
500 mg was consistently obtained and so we proceeded with the synthesis without further
optimisation; subsequent steps were therefore performed on relatively small scales (1˜00 mg).
The bromide 7 was then substituted with sodium azide to give the azide 8 in excellent yield.
In order to modulate the endosomal escape capabilities of the fluorophore, the lipophilic
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BODIPY core was substituted with chlorosulfonic acid. This extremely polar bis-substituent
should considerably diminish the ability of the fluorophore to escape endosomes and would
also provide a direct comparison with the aforementioned lipophilic azide. BODIPYs are
known to be acid sensitive: strong acids lead to dissociation of the boron from the fluo-
rochrome resulting in loss of fluorescence and so the chlorosulfonic acid step was initially
performed on BODIPY bromide 7. The first attempt used chlorosulfonic acid at low temper-
ature in an electrophilic substitution reaction (Scheme 3.4). A high polarity fluorescent spot
was observed by TLC suggesting the reaction was successful, however, this was accompanied
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Scheme 3.4: Optimisation of disulfonation of the BODIPY core using chlorosulfonic acid. Initial
attempts on BODIPY-bromide (7) were not successful, most likely as a result of acid sensitivity of
the boron centre. Efforts towards salt formation of disulfonate species on the BODIPY azide were
successful, conditions used are summarised in Table 3.1.
by a non-fluorescent red spot suggesting some dissociation of the boron center in response
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Table 3.1: Conditions attempted in sodium disulfonate substitution reaction, displayed in
Scheme 3.4, B
Reaction Conditions Yield
i) ii)
1 ClSO3H, DCM, -
40◦C, 20 min
NaHCO3, H2O 0%
2 ClSO3H, DCM,
BHT, -25◦C, 1 h
NaHCO3, MeOH 59%
to the acidic product and/or conditions (known in the literature242). Encouraged by this
result, the azide (8) was taken forward and the conditions modified such that the sulfonate
salt (10) was formed, removing the acidic product. Two conditions were attempted, the
initial biphasic strategy reported by Burgess et al. did not work leading to the successful
strategy of Landfester et al..236,243 This included a dropwise addition of chlorosulfonic acid
and the use of BHT as a radical scavenger, followed by addition of sodium bicarbonate in
methanol to give a homogeneous, monophasic solution. This method resulted in good yields
of 59% giving copious amounts of water soluble, highly polar BODIPY for later conjugations
to CCL2.
3.2.1.1 Synthesis of Disulfide Linkers and Fluorescent Disulfide Azides
The potential for endosomal escape of the fluorophores are likely to be enhanced by incorpo-
ration of a disulfide linker species which would be reduced by high intracellular concentrations
of glutathione. The next stage of the project was therefore to develop methods to prepare
mixed disulfide species, which is known to be a difficult and often inefficient process.244 This
was initially carried out on non-fluorescent systems due to the poor scale up capabilities of
the BODIPY synthesis, as well as the acid sensitivity which had been problematic. One
method of generating mixed disulfides is to form mixed disulfides from an aromatic disulfide
homodimer and an alkyl thiol, the aromatic ring acts as a good leaving group to aid in subse-
quent regioselective thiol substitutions. The homodimer is usually used in excess to prevent
the alkyl thiol from forming homodimers through attack on the newly formed product. These
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Scheme 3.5: Formation of the mixed disulfide (13) from the homodimer disulfide, 2,2’-Dithiobis(5-
nitropyridine), 11. The optimised conditions are reported in Table 3.2
Table 3.2: Optimised conditions of disulfide formation described in Scheme 3.5.
Eq. 11:12 Addition of 12 Base Solvent Time / h Yield / %
2:1 bulk 1 m NaOH MeOH 16 0
2:1 bulk 1 m NaOH MeOH 48 0
2:1 bulk 1 m NaOH CHCl3 16 0
2:1 dropwise none MeOH/DCM 1 18
2:1 dropwise none MeOH/DCM 24 32
3:1 dropwise none MeOH/DCM 16 76
3:1 dropwise none MeOH/DCM 16 90
2.5:1 dropwise none MeOH/DCM 16 65
2:1 dropwise none MeOH/DCM 16 66
considerations led to the selection of 2,2’-Dithiobis(5-nitropyridine) (11) as the homodimer,
this is shown in Scheme 3.5 and results are summarised in Table 3.2; in spite of this prepa-
ration the reaction required extensive optimisation to attain a good yield in moderate scale.
The activated aromatic disulfide was relatively labile to nucleophiles and so we tested the
stability of this compound in the presence of alanine. Any thiolate aromatic leaving group
was easily identifiable by TLC as a strong chromophore, fortunately the disulfide remained
intact.
Efforts were then made towards formation of a disulfide-linked azide from the activated
disulfide using alkyl thiols. Commercially available polyethylene glycol (PEG) azide deriva-
tives are a useful starting material for this purpose and so an amide coupling with 3-
mercaptopropionic acid was attempted (Scheme 3.6). Unfortunately, this attempt was not
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successful, most likely due to cross-reactivity of the thiol with HBTU-acid intermediates.
Another strategy was therefore pursued which formed a protected thiol (18) on a simple
iodo-acid substrate (Scheme 3.6, 17) for subsequent coupling to the aformentioned PEG
azide. This was successful which allowed HBTU coupling of the thioester to PEG azide 15
to give the protected thiol azide 19. Hydrolysis of this ester to the resulting thiol unfortu-
nately resulted in oxidation and therefore dimer formation which could not be avoided by
lowering the temperature or dilution. Attempts at reducing the disulfide were also undertaken
using dithiobutylamine and TCEP but neither were successful.
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Scheme 3.6: Direct coupling of 3-mercaptopropionic acid to PEG azide 15 was not successful,
presumably due to thiol nucleophilicity. Building the thioester (18) from 3-iodopropionic acid
failed at a late stage when the thioester (19) was hydrolysed which resulted in disulfide homodimer
formation (20).
The strategy was thus revised such that an activated aromatic disulfide was formed on the
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PEG azide before substitution with a BODIPY thiol (Scheme 3.7). The previously syn-
thesised acidic disulfide, 13, was coupled to the commercially available PEG azide, 15, to
give activated disulfide 23. The BODIPY bromide (7) was then treated with potassium
thioacetate giving the thioester (21) in good yields, following the work of Mueller et al..228
Subsequent ester hydrolysis using potassium carbonate gave the thiol, 22, with careful heat-
ing to only 30◦C which was important to minimise the formation of disulfide homodimers.
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Scheme 3.7: Successful route towards a BODIPY disulfide azide ready for conjugation to CCL2.
BODIPY thiol (22) was prepared from initial thioester formation (21) from BODIPY bromide
(7), akin to the previous route using iodopropionic acid. Coupling of the activated disulfide 13 to
the commercially available PEG azide 15 was achieved using HBTU. The BODIPY thiol 22 then
underwent nucleophilic substitution with 23 to give the desired product 24.
Substitution of the activated disulfide (23) with BODIPY thiol was performed using the same
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conditions the mixed disulfide synthesis discussed earlier with 3-mercaptopropionic acid. As
the disulfide must be used in excess this step resulted in large losses of compound which is
difficult to recover due the similarity in polarity of the disulfide starting material and the
reduced aryl thiol anion. Furthermore, this reaction did provide the product, 24, but this
product was inseparable by column chromatography from the starting material 23. Reverse
phase high performance liquid chromatography (HPLC) was therefore carried out to separate
the two compounds.
With a lipophilic BODIPY azide separated by a cleavable linker synthesised, a hydrophilic
version of this system was now needed as a direct comparison in future experiments. As a
result of the difficulty in forming lipophilic BODIPY 24, we decided to synthesise a disul-
fonated BODIPY thiol and substitute this with the activated disulfide (23). Beginning with
BODIPY bromide, treatment with the successful chlorosulfonic acid conditions generated the
disulfonated product 25 in excellent yield (Scheme 3.8). Production of the thioester 26 from
bromide 25 was not successful, the reasons for this were not clear but one issue with synthe-
sising disulfonates is that the high polarity renders any conventional chemical purifications
methods very difficult. This meant that the similarity in polarity between these compounds
made separation difficult. A final attempt to form the desired thiol product was performed
though disulfonation of the liophilic thioester 21 to give 26. It was difficult to determine
the success of this reaction by NMR as the spectra was noisy suggesting the presence of
contaminants or side-products, it was decided to take this crude mixture forward into the
next thioester hydrolysis step. Unfortunately, formation of the thiol 27 was not observed,
possibly because the thiol nucleophile could react with the chlorosulfonic acid.
The successful method to synthesise the lipophilic BODIPY disulfide clearly had some in-
herent issues such as separation difficulties with the final product and the wasteful nature of
installing the activated disulfides on two occasions. Another strategy to form mixed disul-
fides was therefore explored to provide better polarity separation of reactants and products,
as well as improved yields. This method used potassium toluenethiosulfonate which can
be used as a nucleophile to attack alkyl halides such as the BODIPY bromide to give an
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Scheme 3.8: Efforts towards synthesis of a disulfonated BODIPY thiol from BODIPY bromide (7)
and the thioester 21.
activated disulfide.244 This proceeded efficiently to give 28 in good yield, meaning an ac-
tivated disulfide could be generated in a single step, avoiding the inefficient pathway used
previously (Scheme 3.9). This compound was then treated with cysteamine which regiose-
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Scheme 3.9: Alternate route to give a disulfide-linked BODIPY azide with a late stage successful
disulfonation of the BODIPY core. BODIPY bromide 7 was heated in the presence of potassium
toluenethiosulfonate which installs an activated disulfide (28) in one step. This disulfide was sub-
stituted with cysteamine giving the disulfide amine 30 ready for HBTU coupling a pegylated azide
acid giving another BODIPY disulfide-linked azide (32) in better yields than the previous route,
this enabled the core to be disulfonated giving 33.
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lectively attacks the alkyl sulfur liberating the aforementioned leaving group. Furthermore,
this reactant was also chemoselective as the amine was not observed to react, even in the
presence of base, this is likely due to the size of the sulfur atom and the the hybridisation
of reactive orbitals meaning better orbital overlap is present between sulfur atoms than the
smaller sulfur-nitrogen analogue. With the disulfide amine 30 prepared, a HBTU coupling
with PEG azido acid 31 gave BODIPY azide 32 in good yield, with a high similarity to the
previous BODIPY disulfide 24. This efficient sequence allowed a final disulfonation reaction
with the same chlorosulfonic acid method to give the highly polar BODIPY disulfide 33.
3.2.2 Synthesis of Rhodamines Derivatives and FRET pair
The use of a FRET pair separated by a disulfide linker allows sensing of intracellular glu-
tathione reduction and subsequent tracking of both fluorophores independently. One fluo-
rophore will be able to freely move according to its own physical properties and the other
would remain covalently attached to CCL2 and therefore subject to the processing the cell
applies to the chemokine. Upon analysis of the literature, common FRET pairs such as the
cyanine class of fluorophore were not selected for use due to the difficulty in synthesis of these
compounds. We therefore decided to use BODIPY as the donor species due to our knowledge
of the chemistry of this class of compounds and the aforementioned spectral properties of
BODIPYs. Rhodamine was selected as the acceptor due to the breadth of scope for synthesis
described by Martinho et al., and the excellent spectral properties of these fluorophores.241
To synthesise the rhodamine derivatives, we followed a strategy developed by Francis et al.
to perform amide couplings on a carboxylic acid positioned away from the xanthene ring.232
It is important to use cyclic amines as less hindered amines lead to spiro-lactam formation
which is non-fluorescent (Scheme 3.10). The spiro-lactone rhoadmine B base is activated
towards nucleophilic attack using trimethyl aluminium as a Lewis acid and piperazine as
the nucleophile.232 Attempts to reproduce this reaction were unsuccessful (Scheme 3.10),
consumption of starting material was observed by TLC but it was difficult to track formation
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Scheme 3.10: Secondary amides of rhodamines lead to lactam formation which results in loss of
fluorescence due to the spiro-ring system removing planarity and pi-conjugation (34 to 35).232
Initial attempts at directly forming the cyclic piperazine amide 37 from rhodamine B base 36 were
not successful. Amide coupling using N-boc piperazine and HBTU gave the protected cyclic amide
37 in excellent yield, this reaction likely proceeds via the open zwitterionic form of rhodamine B
base.
of products and purification by chromatography generated many compounds which could not
be identified by NMR. Presumably, the presence of trimethyl aluminium led to the formation
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of numerous aluminium salts, the result of which gave very polar compounds which were
difficult to separate, there could also have been cross-reactivity issues with the unprotected
piperazine amine. To circumvent these issues we used a mono-boc-protected piperazine in a
HBTU coupling (Scheme 3.10). We hypothesised that the spiro-lactone starting material is
actually in an equilibrium with the open carboxylic form, allowing the acid to undergo amide
couplings, relying on this equilibrium to drive the reaction through to completion. This
resulted in complete consumption of the starting material giving the cationic cyclic amide
38 in excellent yields.
Table 3.3: Optimised conditions of boc deprotection (38 to 37) to avoid salt formation. MW
heating in water gave a single product in 64% yield, simplifying the synthesis.
Conditions Salt Formation
TFA (50% v/v), DCM PF6, halide
HCl (4m) in dioxane PF6, halide
MW 165◦C, water PF6
OEt2N NEt2
N
O
NH
OEt2N NEt2
N
O
NBoc
Table 3.3
OEt2N NEt2
N
O
N
O
SH
38
37
37
39
Scheme 3.11: Boc deprotection with optimised conditions listed in Table 3.3. Efforts towards
coupling to 3-mercaptopropionic acid were not successful (39) likely due to cross-reactivity of the
thiol with activated acids.
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The next step was to deprotect the amine, however, this step was problematic due to the
cationic nature of the compound leading to various salt formations when removing the boc
group (Scheme 3.11). Standard conditions, such as treatment of 38 with trifluoroacetic
acid (TFA), resulted in complete consumption of starting material and the formation of two
polar compounds which could be separated by chromatography. The NMR spectra of these
compounds both corresponded to the product as indicated by loss of the tert-butyl singlet
and downfield shift of the ethylene piperazine protons. Differences in the peak shapes and
chemical shifts of the piperazine protons suggested different environments for these protons,
however, mass spectrometry presented a single ion to the correct mass of 510 Da for both
compounds. We suspected this was due to different salt formations in the two compounds
which resulted in the distinct NMR patterns on the piperazine ring. To verify this, mass
spectrometry was performed in negative mode to identify the nature of any salts which
resulted in a PF6 anion associated with one rhodamine and no peak was observed in the
other compound. This was likely due a low mass anion such as a chloride which is not able
to be detected by mass spectrometry (MS), this ‘harder’ salt would confer higher polarity
to the compound and indeed this compound exhibited a lower relative front (Rf) by TLC.
Similar results were also observed with HCl (4m) in dioxane, presumably due to the presence
of chloride ions.
To circumvent this issue, salt formation was avoided via the use of reagent free deprotection
conditions in the form of heating in solvent. Boc groups decompose under heating and so this
compound was heated by microwave to 165◦C in water resulting in thermal decomposition
of the boc group and only single product formation (Table 3.3). In order to install a thiol
onto the rhodamine portion of the FRET pair, we attempted to couple rhodamine 37 to
3-mercaptopropionic acid (Scheme 3.11). We envisaged this coupling would proceed with
greater efficiency than the PEG-amine attempts because rhodamine 37 is a secondary amine
with higher basicity than primary amines meaning this compound should out-compete any
thiol nucleophilicity. Unfortunately, this was not the case and any clean product was not
recovered. To develop an azide-functionalised FRET pair, the synthetic sequence was again
3.2. Synthesis of Conjugating Substrates 120
OEt2N NEt2
N
O
N
O
O
O
OEt2N NEt2
N
O
NH
OO O
THF, 20 h, rt, 31%
37 40
Scheme 3.12: Formation of zwitterionic rhodamine acid for subsequent amide couplings in FRET
pair synthesis.
modified to include initial linker synthesis, substitution of the BODIPY thiol giving the
disulfide before final coupling of the rhodamine B to limit the use of this compound which
had previously diminished yields or been unwieldy. Another reason for this was that we
found the BODIPYs were sensitive to acidic pH resulting in loss of fluorescence (likely due
to boron dissociation) and so performing a boc-deprotection in the absence of BODIPY was
beneficial. The modular synthesis therefore began with preparing a carboxylic acid derivative
of the rhodamine 37 via reaction with succinic anhydride to form the rhodamine acid 40
(Scheme 3.12). Formation of the zwitterion removes any need for counterions and so this
avoided the salt issue meaning a single product was obtained in good yield. A second synthetic
sequence was then pursued to disulfide-link this rhodamine to a BODIPY, beginning with
an amide coupling of the commercially available Boc-Cys-(Npys)-OH to pegylated azido
amine 15 which proceeded via HBTU activation in excellent yield (Scheme 3.13). The
boc group was removed at this stage to reveal the primary amine 43 in quantitative yields
under standard TFA conditions, this avoided deprotection in the presence of BODIPY. Some
efficiency was sacrificed in the next step as the initial activated disulfide conditions were
used in the formation of 44 meaning that 2 equivalents of 43 were used relative to BODIPY
thiol 21, although this step represents another modular stage of the FRET pair synthesis.
Unfortunately, initial attempts under neutral pH conditions resulted in no observable reaction
and so potassium carbonate was utilised as a base. This resulted in product formation but
was again accompanied by BODIPY disulfide homodimer formation by as much as 30%.
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Scheme 3.13: Successful formation of the BODIPY-rhodamine FRET pair with a highly modular
synthesis. Commercially available Boc-Cys-(Npys)-OH 41 was coupled to PEG azido amine 48
via HBTU in 93% yield. Deprotection of the boc group under standard TFA conditions resulted
in quantitative yields of the amine 43. Substitution of the activated disulfide with BODIPY thiol
was successful but substantial losses in yield were incurred as a result of BODIPY dimer formation.
Coupling of this compound to rhodamine acid 40 (Scheme 3.12) resulted in completion of the FRET
pair synthesis in moderate yields.
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The FRET pair synthesis was then completed through amide coupling of the RhoB acid 40
to BODIPY disulfide 44 via HBTU to give FRET pair 45 in 27% yield.
3.2.3 Fluorescence Spectra and Data
The final stage of fluorophore development was to measure the spectroscopic properties of the
synthesised molecules. Initially, both the BODIPY bromide (7) and rhodamine amine (37)
were measured in a fluorimeter to ensure these compounds exhibited fluorescence spectra
similar to literature reports (Figure 3.1).228 Indeed, BODIPY bromide exhibited fluorescence
excitation and emission maxima around 500 nm which is typical for this class of fluorophore.
Similarly, the rhodamine exhibited spectroscopic properties almost identical to literature
values with maxima centring around 570 nm.232 Furthermore, the fluorescent spectra are
plotted on the same graph which highlights the overlap between BODIPY donor emission
and rhodamine acceptor excitation, which is essential for FRET applications. Although the
overlap is not donor maxima to acceptor maxima, the benefit of having this level of overlap
is the donor and acceptor excitation spectra are wholly distinct and therefore false-positive
FRET signals resulting from crossover should be minimised. The fluorescence spectra of single
fluorophore compounds were measured, disulfonate BODIPY 10 excitation and emission
spectra are displayed in Figure 3.2. This highlights the compound is fluorescent and has
a very similar spectral profile to the bromo-BODIPY 7, fluorescence spectra for the other
single fluorophore compounds are displayed in Figure 3.2 and Figure 3.3.
Determination of FRET was then pursued, this was achieved using a number of methods,
the first of which encompassed exciting the molecule at the donor’s excitation maxima and
measuring emission across the donor and acceptor emission wavelength range. If the com-
pound is capable of FRET, a reduction in donor emission should be observed, which would
be accompanied by an increase in acceptor emission(Figure 3.4). The spectral properties in
DCM exhibited a FRET signal in the emission profile when excited at the donor excitation
maxima, both a reduction in donor emission was observed as well as an increase in acceptor
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Figure 3.1: Fluorescence spectra of BODIPY bromide 7 measured in DCM and rhodamine 37
measured in MeOH. The excitation maxima of both the BODIPY bromide and rhodamine piperazine
match literature values and so the fluorophores are behaving as expected.228,232
emission, suggesting energy transfer from donor BODIPY to acceptor rhodamine. The ex-
citation spectrum (monitoring emission at 589 nm) for this compound showed an expected
major peak in the acceptor region and a minor contribution from the donor region. This
likely indicates some loss of energy through other relaxation pathways, for example, a sig-
nificant reduction in donor emission suggests a strong transfer of energy to the rhodamine
acceptor but this energy may not wholly relax through a fluorescence pathway but could
decay thermally. Furthermore, the energy transfer is an indirect excitation and there are
energy losses associated with the donor BODIPY excitation, the contribution to the FRET
pair excitation spectrum is also dependent on relative molar absorptivities of donor/acceptor
and also quantum yields. It was apparent that solvents were having a pronounced effect on
the FRET signal whereby the signal was stronger in DCM than in methanol as shown by
examination of the decrease in donor emission in DCM relative to methanol.
TCEP treatment could only be carried out in methanol as the reducing agent is stored in
aqueous media and so the lack of miscibility of DCM and TCEP would have affected the
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(a) Fluorescence spectra of non-cleavably linked BODIPY azide 8 in DCM.
λmax, ex = 495 nm, λmax, em = 506 nm, φ = 0.63.
(b) Fluorescence spectra of the disulfonate BODIPY azide 10 in water. λmax, ex
= 494 nm. λmax, em = 506 nm, φ = 0.25.
Figure 3.2: Fluorescence spectra of the alkyl-linked BODIPY azides showing differences in peak
width likely due to ring electronics.
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(a) Fluorescence spectra of BODIPY disulfide azide 24 in DMSO. λmax, ex =
499 nm. λmax, em = 506 nm, φ = 0.61.
(b) Fluorescence spectra of BODIPY disulfonate disulfide azide 33 in DMSO.
λmax, ex = 512 nm. λmax, em = 522 nm, φ = 0.21.
Figure 3.3: Fluorescence spectra of both cleavably linked BODIPY azides 24 and 49. The lipophilic
BODIPY disulfide exhibited a similar spectra to the non-cleavably linked BODIPYs, however, the
hydrophilic BODIPY disulfide exhibited a bathychromic shift of around 15 nm.
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(a) Fluorescence spectra of FRET pair 45 in DCM
(b) Fluorescence spectra of FRET pair 45 in MeOH. λex = 495 nm.
Figure 3.4: Fluorescence spectra of the FRET pair in DCM and MeOH. A clear FRET signal can
be seen through excitation at the donor and a diminished donor emission paired with an increased
acceptor emission. The acceptor emission was reduced upon treatment of the disulfide reducing
agent TCEP which was also accompanied by an increase in donor emission, indicative of loss of
FRET through spatial separation of fluorophores. λmax, donor em = 506 nm, λmax, acceptor em = 589
nm
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Figure 3.5: The effects of increasing concentrations of DMSO in aqueous media on the fluorescence
spectrum of FRET pair 45. The general trend is decreased fluorescence in high water concentrations,
suggesting a solubility effect on fluorescence. λex = 495 nm.
fluorescence spectrum. Interestingly, reduction of the disulfide by TCEP wholly reduced ac-
ceptor emission providing further evidence of FRET due to the loss of energy transfer when
the fluorophores are spatially separated. However, this loss of acceptor emission was only
accompanied by a modest increase in donor emission, this result, and the difference in spectra
between DCM and methanol solvents, suggested that solubility of the relatively lipophilic
FRET pair 45 has a significant effect on fluorescence. This effect was investigated through
measuring the emission spectrum of the FRET pair whilst titrating increasing concentrations
of DMSO into water (Figure 3.5). At low concentrations of DMSO, both the donor and ac-
ceptor emission is decreased, as the FRET pair is relatively lipophilic this is possibly due to
solubility issues in high water concentrations. The behaviour is likely due to aggregation of
this compound as the water content increases, as molecules move to minimise unfavourable
interactions with water, possibly forming small micellar structures. This reduces fluorescence
through auto-quenching of fluorophores in close proximity and as the solubilising DMSO con-
centration increases the fluorescence quickly returns. While these physicochemical properties
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are affecting fluorimetry, it is unlikely to have a significant effect on fluorescent behaviours
in imaging experiments in cells due to the complex media that occupies a cell
The presence of CCL2 will prevent aggregation due to sterics and after disulfide reduction in
the cell, the liberated BODIPY donor will satisfy hydrophobicity needs through localisation
with lipid membranes or other hydrophobic compartments. Studies were then undertaken
into loss of FRET in response to TCEP reduction, altering both the concentration of TCEP
and the reaction time (Figure 3.6). With a high concentration of 1 mm TCEP, even after
1 minute the BODIPY donor emission had increased with a compensatory decrease n rho-
damine acceptor emission. This strongly increased until 60 minutes which suggested that
complete reduction of the FRET pair had occurred. The lower concentration of 0.1 mm
TCEP did not display as rapid a loss of FRET which provides further evidence that this loss
of a FRET signal over time is a result of the TCEP reduction of the disulfide. After 120
minutes the donor emission had not reached the levels of fluorescence observed with 1 mm
TCEP treatement. Stratifying this to how the FRET pair may behave inside a cell, it is
more likely to reflect the 1 mm TCEP treatment as glutathione concentrations are generally
over 1 mm, however, it is unclear what the intracellular concentration of the CCL2 conjugate
will be.
Single fluorophore spectroscopic properties are listed in Table 3.4 and these results are gen-
erally typical for this class of fluorophore. Molar extinction coefficients at the absorption
maxima for the BODIPY fluorophores were around 80000 dm3 mol−1 cm−1 which represents
a strong absorption at these wavelengths which is good for fluorescence microscopy. The ab-
sorption and emission maxima are at wavelengths amenable to overlap with the rhodamine
acceptor and also complement common laser lines used in flow cytometry and imaging. The
Stokes shifts are quite small, however, which may be a slight issue for imaging due to scatter-
ing but the benefit of a small Stokes shift with sharp excitation and emission peaks is reduced
crossover and bleedthrough, which is of benefit in flow cytometry and imaging. Lastly, the
quantum yields for BODIPYs with unmodified cores were excellent at around 60%, however,
disulfonation of the core had a detrimental effect on quantum yield. While this is not ideal,
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(a) Timecourse treatment of 45 with 0.1 mm TCEP.
(b) Timecourse treatment of 45 with 1 mm TCEP.
Figure 3.6: Fluorescence spectra of FRET pair 45 measuring the effects of TCEP treatment over
time. Gradual loss of FRET over time indicates that disulfide reduction is responsible for loss of
FRET. The clear concentration dependency of this loss can also be seen as very little loss of FRET
was apparent with the 0.1 mm TCEP treatment compared to the 1 mm treatment. FRET pair was
at 15 nm. λex = 495 nm.
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the quantum yields are still high enough to be visible in microscopy and the excellent photo-
stability of BODIPYs should ensure the fluorophores with lower quantum yields will remain
emissive. This effect of disulfonation on quantum yield has been shown in some BODIPY
examples in the literature but not in others. The FRET pair 45 was quantified through
two mathematical methods described in the literature which include decrease in donor emis-
sion and increase in acceptor emission.227 The first method ΦT1 measures the emission of
the donor-alone fluorophore relative to the donor-FRET pair emission, as described in 3.1.
The decrease in emission was over 90% showing almost total quenching of the donor emission
which correlates well with the TCEP reduction experiments described previously. The second
method measures the change in acceptor emission in the FRET pair compared to acceptor
alone, relative to a ratio of the absorbance of the individual acceptor and donor fluorophores,
giving ΦT2 (3.2).
ΦT1 = 1− IDA,506
ID
= 0.96 (3.1)
ΦT2 =
(
AA
AD
)(
IDA,589
IA − 1
)
= 0.57 (3.2)
Table 3.4: Spectroscopic properties determined for BODIPY conjugates.  - molar extinction co-
efficient. λmax abs - absorption maxima. λmax - emission maxima. φ - quantum yield. Solvents:
†DCM, ?H2O, ‡DMSO.
Compound  / dm3mol−1 cm−1 λmax abs nm λmax em / nm φ
8 † 82468 495 506 0.63
10 ? 77160 494 506 0.25
24 ‡ 79198 499 506 0.61
33 ‡ 86351 512 522 0.21
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3.3 Conclusion
The aim of this chapter was to synthesise a range of fluorophore azides for subsequent CuAAC
conjugation to an alkyne bearing CCL2 peptide. Successful synthesis of a non-cleavably linked
BODIPY azide has been achieved, this fluorophore has been further functionalised with disul-
fonate groups on the fluorescent rings giving both a lipohilic and a very hydrophilic BODIPY
azide for direct comparison. Crucially, these compounds are neutral and so intracellular lo-
calisation should be less biased towards any particular organelle such as mitochondria than
charged species. The optimised potassium thiosulfonate method reduced the number of steps
to form the lipophilic BODIPY disulfide from six to five steps and did not need HPLC purifi-
cation due to the alternation of non-polar and polar products. These strategies resulted in
formation of a lipophilic and hydrophilic BODIPY azide separated by a disulfide bond which
can act as direct comparisons in terms of intracellular localisation behaviour and retention
times.
A FRET pair based on rhodamine B piperazine and BODIPY was also successfully synthe-
sised after extensive optimisation. The synthetic route had to be revised a number of times
due to handling difficulties and salt formation with the rhodamines and the acid sensitivity
of BODIPY. Fortunately, a highly modular synthetic strategy allowed the linker and azide
regions of the FRET pair to be formed from a derivatised cysteine which were then joined
by BODIPY thiol substitutions at a late stage, and finally amide coupling of rhodamine B
as the final step.
The spectroscopic properties of the fluorophores and FRET pairs have also been determined
which reveal a suite of fluorophores which are suitable for cellular experiments. The BODIPY
and rhodamine fluorophores have spectral overlap between the donor emission and acceptor
absorption peaks, the overlap is partial but this at least separates the donor/acceptor spec-
tra enough to minimise crossover and/or bleedthrough issues. The synthesised FRET pair
is capable of FRET and the FRET efficiency ratios were calculated in terms of decrease of
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donor emission and increase of acceptor emission. The acceptor emission increase is rea-
sonable which may be difficult to detect in fluorescence microscopy, however, the almost
total quenching of BODIPY donor emission resembles an on-off switch system pre- and post-
disulfide reduction. It is unclear whether the fluorophore aggregation observed in fluorimetry
experiments will be detected as the large CCL2 conjugated to the FRET pair and any fluo-
rophores will prevent the fluorophores aggregating together. Cleaved lipophilic fluorophores
will likely localise in hydrophobic environments in the complex media found inside cells,
this may be other proteins, lipid membranes or organelles and so fluorescence should be
maintained irrespective of aqueous solubility.
Chapter 4
Optimisation of Copper-mediated
Azide-Alkyne Cycloaddition Towards
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4.1 Introduction
The previous chapter described the successful synthesis of azido-bearing fluorophores for the
subsequent conjugation towards CCL2 variants through CuAAC; this chapter concerns the
optimisation of the CuAAC reaction for CCL2 conjugation to these fluorophores. The incor-
poration of a C-terminal propargyl glycine provides the alkyne required for CuAAC and this
placement of the glycine follows literature precedent of related CCL2 conjugates.5,104 Two
reports of chemically synthesised CCL2 described alternate methods for synthesising CCL2
using SPPS which provided functional CCL2 in good yield.245,246 The first report involved a
linear fmoc solid phase synthesis, followed by oxidation using both oxidised and reduced glu-
tathione, and a final affinity purification using a CCL2 antibody.245 The N-terminus included
a cyclised pyroglutamate residue due to the glutamine of wild-type CCL2 spontaneously cy-
clising to the pyroglutamate. The second study involved a native chemical ligation between
two smaller peptides: residues 1-35 and 36-76, where the N-terminus of amino acid 36 at-
tacked a thioester at the C-terminus of amino acid 35 to form the ligated CCL2 protein.246
The cysteine oxidation conditions were of a similar nature to the previous CCL2 synthesis
which resulted in successful folding of the protein as confirmed by x-ray crystallography.
From this literature precedent, outsourcing of the CCL2 synthesis to a specialist protein syn-
thesis company, called Peptide Protein Research Ltd., was selected as the optimal strategy.
The three CCL2 sequences included the wild-type sequence, P8A-CCL2 which includes a
substitution of alanine at proline-8, and CCL2 Ala−1 which includes a N-terminal alanine
addition. Each protein sequence included an addition at the C-terminus of CCL2 which is
displayed in Scheme 4.1.
An investigation into biocompatible conjugations by Bode et al. highlighted the need for
stoichiometric equivalents of reagents in CuAAC reactions due to low concentrations.247 Us-
ing catalytic quantities of copper in CuAAC involving low concentration biological molecules
would result in nanomolar concentrations of copper which would render the rate of reaction
negligible. As described by Bode et al., the second order reaction requires rate constants
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Ala-Met-Propargyl glycine
R= QPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCP
KEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT
Scheme 4.1: Peptide sequence of the C-terminal addition of CCL2 for subsequent CuAAC conjuga-
tions.
above 10 mol−1 dm−3 s−1 for 90% yield in an acceptable reaction time.207 The investiga-
tors proceeded to report general conditions for peptide-based CuAAC: CuSO4 (1.0 eq.), Na
ascorbate (25 eq.) and TBTA (5.0 eq.) relative to peptide. The large excess of sodium ascor-
bate ensures continuous reduction of copper (II) in air and also mitigates the production of
ROS species which would oxidise amino acids. Mechanistic investigations were reported by
Finn et al., particularly into the role of solvents in the Click reaction and how the effects
could be influenced by the choice of rate accelerating ligand.207 The authors evidenced that
tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) was better suited to aqueous reactions
compared to TBTA due to solubility, aqueous CuAAC reactions in this chapter would there-
fore use CuSO4 (1.0 eq.), Na ascorbate (25 eq.) and THPTA (5.0 eq.). Finn et al. also
reported that three classes of ligand exist in the CuAAC reaction dependent on behaviour
in DMSO rich or aqueous rich media. Class I ligands (including THPTA and poly-triazole
molecules) exhibited highest reaction rates at 5-fold excess in aqueous media, when utilised
in high concentrations of DMSO the rate decreased significantly. Conversely, class II ligands
(including mixed pyridine/benzimidazole arms) operated most efficiently at 0.5 equivalents
and only in DMSO-rich media. Class III ligands (mostly benzimidazole arms) were not active
in aqueous media. This behaviour was rationalised by the relative copper-binding affinities
whereby benzimidazole is the strongest binder, followed by pyridine and triazole. Therefore,
higher equivalents of triazole ligands are needed to bind the copper efficiently, relative to the
benzimidazole ligands. This copper binding must be balanced in that the ion is not bound
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Table 4.1: Description of the CCL2 conjugate naming system, chemical structures of conjugates
are displayed in Figure 4.1. Three CCL2 variants will be used: WT-CCL2, CCL2 Ala−1 and P8A-
CCL2. Examples of the nomenclature of these conjugates are P8A-alk-H and CCL2 Ala−1-alk-H.
Code Compound Meaning
WT-alk-H 10 alkyl-linked, hydrophillic
WT-alk-L 8 alkyl-linked, lipophillic
WT-SS-H 33 disulfide-linked, hydrophillic
WT-SS-L 24, 32 disulfide-linked, lipophillic
Figure 4.1: Ribbon structures of CCL2 highlighting the chemical structure of the conjugates and
naming system below the structure. The naming convention is summarised in more detail in Ta-
ble 4.1.
too strongly such that the reaction azide/alkyne can displace a ligand arm. The solvent
DMSO, is a strong pi donating compound which strongly binds copper, class I ligands cannot
displace DMSO from the copper centre and so ligands such as THPTA are not suitable,
instead strong copper binding ligands such as the class III benzimidazole ligands exhibit
excellent rates in high DMSO concentrations. This chapter will therefore utilise THPTA in
aqueous rich conjugations in the 1:25:5 molar ratio described above and (BimH)3 in DMSO-
rich conjugations (for lipophilic reagents) in a 1:25:0.5 molar ratio as recommended by Finn
et al.207 Table 4.1 and Figure 4.1 outlines the CCL2 conjugate targets and terminology.
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4.2 Results and Discussion
4.2.1 Conjugation of Fluorophores to CCL2 Ala−1
A specialist protein synthesis company, Peptide Protein Research Ltd. (PPR), was con-
tracted to synthesise three CCL2 variants. As per our instructions, PPR trialled both the
native chemical ligation strategy described by Gilliland et al., and the linear step-wise syn-
thesis reported by Kruszynski et al., using Fmoc-SPPS techniques as well as the oxidation
conditions described therein.245,246 The linear step-wise synthesis was successful and the three
desired peptides were obtained, CCL2 Ala−1 was completed first giving 10 mg at 90% pu-
rity. The other peptides were not as efficient as this, only 4 mg of 90% pure P8A-CCL2 was
synthesised and three samples of WT-CCL2 (1.0, 2.3 and 5.1 mg) were obtained at lower
purities of 74, 76 and 82%, respectively. The declared reasons for the difficulties in synthesis
were cyclisation issues of the N-terminal pyroglutamate in both WT-CCL2 and P8A-CCL2.
The lowered purities of the WT-CCL2 variant could not be improved upon, however, the
major contaminant was an oxidised methionine residue at position 78. The two methionines
are located towards the C-terminus and so it is unlikely these impurities would affect the
biological function of the chemokine. The difference in lead times, quantity and purity of the
three peptides resulted in much of the initial work being performed on CCL2 Ala−1.
The first conjugation attempted was the formation of CCL2 Ala−1-alk-H from BODIPY
10, this was selected due to the excellent aqueous solubility of the fluorophore and the
chemically inert linker. The solubility of the compound ensured that this would not affect the
conjugation and the unreactive alkyl spacer would also not complicate any issues found with
the reaction. The reaction scheme is displayed in Scheme 4.2 which highlights the equivalents
used and bears a slight modification to reported conditions in that the azide is used in large
excess of the alkyne to drive the reaction through to total conversion.247 Obtaining one
product was important as any unlabeled peptide would be difficult to separate from labeled
peptide and the small amount of material used adds practical issues with HPLC.
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Scheme 4.2: Conjugation conditions for CuAAC between CCL2 Ala−1 and BODIPY 10 giving the
desired triazole as a single product (Expected mass 9611 Da). The equivalents are listed showing
the stoichiometric quantity of copper sulfate and the excess of both sodium ascorbate and azide.
The concentration of CCL2 was 100 µm.
Figure 4.2: UV absorbance spectrum of CCL2 Ala−1 before and after the CuAAC reaction. A peak
at 280 nm in the unlabelled spectrum corresponds to tryptophan absorbance, this peak broadens
after the reaction due to a small contribution from BODIPY absorbance and from dilution effects.
A major peak was observed at the BODIPY absorption maxima suggesting that the conjugation
was successful as any free BODIPY would be removed via size exclusion chromatography.
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As discussed in chapter 3, the order of addition of reagents is important in the CuAAC reac-
tion to avoid poly-alkyne-copper aggregates and so the ligand, copper sulfate and ascorbate
were mixed first, followed by the CCL2-alkyne and fluorophore azide. The reason for not
adding the alkyne last was due to this reagent usually representing the largest volume (and
therefore a major dilution) of the reaction mixture. The concentrations used by Bode et al.
ranged between 50 and 100 µm and so this reaction was performed at 100 µm of CCL2-alkyne.
After 4 h the reaction mixture was taken and the protein was separated from small molecule
reagents via size exclusion chromatography. The concentration of the labeled protein was
then determined via UV absorbance and the extent of conjugation was assessed using matrix-
assisted laser desorption ionisation (MALDI) mass spectrometry (Figure 4.2 and Figure 4.3).
The UV spectrum before and after conjugation suggested the BODIPY had indeed conju-
gated to CCL2 due to the presence of both a tryptophan and BODIPY absorbance peak.
The labelled protein was aliquoted and stored at -30 ◦C in 0.1 m PBS and 0.5% BSA (v/v,
a carrier protein). These conditions were used for all subsequent conjugations unless stated
otherwise.
The samples were desalted and concentrated using ZipTips for MALDI-MS compatibility
which consistently yielded strong MS signals even with dilute samples. The MALDI MS is
accurate to 5-10 Da with large molecules and agrees well with the stated mass of 9048 Da,
with the 2+M adduct observable at 4531 Da. A clear mass shift can be observed between
starting material and product which corresponds to the molecular mass of the BODIPY
azide (563 Da). The mass difference between starting material and product, while subject to
instrumental error, may not exactly equal the molecular mass of 10 and this may reflect loss
of sodium ions in the disulfonate salt as other adducts are formed. A small non-annotated
peak adjacent to the parent ion is a sinapinic acid adduct which originates from the MALDI
matrix. The origin of the small shoulder peak centring around 10060 Da was not clear but
is again similar to the BODIPY molecular mass. However, this double-BODIPY ion was
not present in ESI-MS (not shown) which suggests the second peak is a MALDI artifact or
a non-covalent adduct. Whilst the MS does not provide direct evidence that the BODIPY
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is conjugated to CCL2 through a 1,2,3-triazole, the large body of literature in CuAAC con-
jugations showing no significant non-selectivity issues suggests the BODIPY is conjugated
through a triazole. CCL2-dimer peaks were only observed at high concentrations suggesting
Glaser homo-coupling of alkynes did not occur and these peaks are due to supramolecular
dimers.
(a) MALDI MS of CCL2 Ala−1.
(b) MALDI MS of BODIPY labeled CCL2 Ala−1.
(c) MALDI MS of a mixture of unlabeled and BODIPY labeled CCL2 Ala−1.
Figure 4.3: The MALDI-MS highlights close agreement of the unlabeled CCL2 molecular mass with
the theoretical mass of 9048 Da and also exhibits a dimer peak at 18106 Da. A clear mass shift is
present post-conjugation which resembles the BODIPY disulfonate mass of 563 Da (expected mass
9611 Da). The mixture of unlabeled and labeled CCL2 provides evidence the mass shift is real and
both species give strong MS signals.
The initial attempt with CuAAC was successful and subsequent repeats behaved in a simi-
lar manner which highlighted the robust nature of CuAAC. The next step was to perform
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CuAAC conjugations using the other four fluorescent systems described in Chapter 3. The
lipophilic BODIPY azide 8 was selected for the next reaction as again this compound con-
tained an alkyl linker which should not complicate the reaction if any issues arose. Unfortu-
nately, the lipophilic nature of this compound rendered total insolubility in aqueous media.
An attempt at this reaction in water was not successful, even with a potential solubilising
equilibrium which could drive the reaction to completion, only unlabeled CCL2 was recovered
(not shown). Other reaction conditions were therefore investigated and the most promising
system was described by Finn et al. which involved using DMSO in aqueous media as a co-
solvent.207 Clearly DMSO is not ideal in protein conjugations as this is known to denature
proteins resulting in loss of functional activity. However, the detailed analysis provided by
Finn into these reactions gave confidence that the reaction could work and that we could
optimise conditions such that permanent denaturation could be avoided. The reasons CCL2
may be resistant to permanent denaturation are described below:
 CCL2 is a small protein with a highly conserved structure, containing two internal
disulfide bridges which confer rigidity in the structure. Therefore any unfolding due
to interaction with DMSO may be reversible, as the disulfide bonds hold the overall
structure in place.
 The literature reported CCL2 syntheses suggested spontaneous folding of linear pep-
tides which ensured correct disulfide linkages in the protein, this suggests that few other
possible structures are available when the disulfide bridges are intact.245,246
 Any unfolding due to DMSO interaction should only be temporary while DMSO is
present, dialysis ensures a slow transition from high to low concentrations of DMSO.
With these considerations in mind, the conditions for a DMSO/water mixture were devised
following the excellent work of Finn et al. and these conditions are displayed in Scheme 4.3.207
To minimise permanent denaturation of CCL2, only a 30% solution of DMSO:PBS was used
(compared to 90% DMSO described by Finn et al.), this was a good comprimise between
solubility of 8 and high DMSO concentrations. The work up involved a dialysis step to remove
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DMSO before size exclusion chromatography (to prevent sephadex gel dissolution). The
reaction was first attempted on the hydrophilic BODIPY 10 used previously for comparitive
reasons.
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Scheme 4.3: Modified CuAAC conditions for use with DMSO as a co-solvent. The concentration of
CCL2 was 100 µm.
Figure 4.4: MALDI MS of the product of CuAAC between CCL2 Ala−1 and BODIPY azide 10
using conditions described in Scheme 4.3. The reaction appears to have gone to completion and a
supramolecular dimer peak can also be observed at around 19 kDa.
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The conjugation was successful (see Figure 4.4) which demonstrated that the DMSO did not
significantly alter the reaction and so if the lipophilic fluorophores are able to dissolve in 30%
DMSO, the reaction should occur successfully. These conditions were then repeated on both
the lipophilic azide 8, the lipophilic disulfide-linked BODIPY 24 and the FRET pair 45 (this
compound was also reasonably lipophilic). Mass spectra are displayed in Figure 4.5 which
highlights an issue consistently encountered in these conjugation; the reactions do not always
proceed to completion and the compounds may not be stable. The simple lipophilic azide
8 (Figure 4.5a) appeared to have fully conjugated to CCL2, however, the peak was broad
compared to the hydrophilic BODIPY 10 which may overshadow any unconjugated CCL2 due
to the small mass shift of 359 Da. More concerningly, the multiple peaks observed in Figures
4.5b and 4.5c appear to originate from cleavage of the disulfide bond in the fluorophore 24.
In Figure 4.5b, CCL2 has fully conjugated as no starting material is present but a mixture
of intact CCL2 Ala−1-SS-L and CCL2-SR can be observed corresponding to the 9664.5 and
9397.6 Da peaks respectively. The triazoles have been formed in both cases indicating the
reaction is proceeding but a proportion of the disulfide bonds were cleaved at a point during
the reaction or work up. The fluorophore starting materials were both analysed by ESI-MS
to ensure the compounds had not degraded in the stock solutions; both the FRET pair 45
and BODIPY disulfide 24 were intact (not shown). The cleavage was more pronounced in
Figure 4.5c as the desired conjugate was not observed (the mass would be approximately
10310 Da), only unconjugated starting material and the peak at 9872.3 Da; this indicated
loss of a BODIPY thiol species.
A literature search found one example of disulfide cleavage in CuAAC reactions was reported
in the context of small molecule drug discovery.248 The authors reported some negative results
due to ascorbic acid-mediated reduction of disulfide bonds, the resulting thiol then poisons
the copper catalyst preventing the reaction proceeding. Further evidence of the disulfide-
reductive ability of ascorbic acid has also been sparingly reported.249 It is likely the disulfide
reduction observed was due to the action of the excess sodium ascorbate, this is supported
by the incomplete reaction observed with the FRET pair 45, suggesting the resulting thiol
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(a) MALDI MS of CuAAC between CCL2 and lipophilic azide 8 (expected mass 9430
Da).
(b) MALDI MS of CuAAC between CCL2 and lipophilic disulfide 24 (expected mass 9725
Da).
(c) MALDI MS of CuAAC between CCL2 and FRET pair 45 (expected mass 10310 Da).
Figure 4.5: The MALDI-MS of the lipophilic azide 8 demonstrates the conjugation was successful
in DMSO. The disulfide-linked fluorophores, however, have multiple peaks which likely correspond
to disulfide cleavage and in the case of FRET pair 45, incomplete reaction. All conjugations were
performed on CCL2 Ala−1, UV-Vis spectra in Appendix, Figure 8.16.
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poisoned the copper catalyst. Renslo et al. avoided this disulfide reduction through the
use of copper (I) salts and air free techniques, this avoids the need for in situ reduction
of copper (II) with ascorbate, indeed other reports of this strategy have been successful
in CuAAC involving disulfides.248,250,251 Many of the reports were on larger scale reactions
on small molecules where reactions are practically easier to maintain oxygen-free or high
temperatures were used to drive the cycloaddition to completion. The reaction conditions
were modified again to include the use of copper (I) sources in DMSO under nitrogen to
prevent oxidation of Cu (I) (see Scheme 4.4).
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Scheme 4.4: Modified CuAAC conditions for use with Cu (I) sources in prevention of disulfide
reduction. Both Cu(MeCN)4.PF6 and CuBr were used as copper sources and manual attempts
at maintaining oxygen-free atmospheres were unsuccessful (MALDI-MS spectrum displayed in Ap-
pendix, Figure 8.15).
The initial Cu (I) source was the copper complex Cu(MeCN)4.PF6 which is thought to be
less prone to oxidation, although the use of acetonitrile as a solvent is known to comprimise
CuAAC.207 Attempts at manually maintaining oxygen-free conditions were unsuccessful due
to practical reasons as reaction solutions were usually between 100-300 µL. This meant
Schlenk-techniques were not available and nitrogen flushing of centrifuge tubes was not able
to maintain a nitrogen atmosphere leading to oxidation of the copper source. To circumvent
this issue the commercially available AtmosbagTM glove bag was utilised to form a nitrogen
atmosphere which could be used to handle the low volume reactions. The experimental set-up
is described in Chapter 2, DMSO and PBS were purged with nitrogen before use via bubbling
nitrogen gas through the liquid such that all solvents and reagents were oxygen-free. The
previous conjugations had used a significant amount of the expensive CCL2 Ala−1 alkyne and
so trial CuAAC conjugations were performed in the AtmosbagTM using an oligonucleotide-
alkyne to preserve the protein. This ON was selected for a number of reasons including the
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similar molecular mass to CCL2, the rapid availability of relatively large quantities and it’s
intended use as a therapeutic in parallel running projects in the group.
The trial reactions were performed on the robust disulfonate BODIPY 10 and the disulfide-
linked lipophilic BODIPY 24 such that issues with disulfide sensitivity could be detected
through comparison. The copper sources used were CuBr and Cu(MeCN)4.PF6, conditions
are listed in Table 4.2 and Table 4.3, and all reactions were carried out in the AtmosbagTM
under a nitrogen atmosphere. An excess of copper catalyst was used due to any sequestration
of copper by ON base pairs and possible oxidation of Cu(I) via oxygen contamination. The
success of the reaction was determined by ESI-MS where deconvoluted parent ion peaks
would be around 7350 Da and 7450 Da for 10 and 24 respectively. For conjugations on
alkyl-linked BODIPY 10, the CuBr catalyst was most effective and generally performed
better with the addition of sodium ascorbate. This is not surprising as the reducing agent
would reduce any oxidised copper resulting from preparatory exposure to oxygen, however,
this would not be suitable for disulfide-linked fluorophores. The addition of triethylamine
has been suggested to enhance Cu-acetylide formation through alkyne deprotonation; the
most successful reaction included both triethylamine and sodium ascorbate which suggests
this deprotonation may be important. The most surprising result was the relatively poor
performance of Cu(MeCN)4.PF6 which is thought to be less prone to oxidation, this could
Table 4.2: Reaction conditions tested with BODIPY 10 and oligomer-alkyne (molecular mass 6793
Da). All reactions were carried out in the AtmosbagTM under nitrogen with a 30% DMSO in PBS
solvent mixture for 24 h at rt, using (BimH)3 (5 eq.) as the ligand. The ON was at 25 µm and
corresponded to one equivalent. Reactions were assessed using ESI-MS of dialysed samples post-size
exclusion column. SM = starting material, P = product, Asc = sodium ascorbate.
Catalyst Base Red. agent Result Notes
CuBr (10 eq.) - - 40:60 SM:P -
CuBr (10 eq.) - Asc (1 eq.) >90% P -
CuBr (10 eq.) - Asc (10 eq.) >90% P Peak at 8 kDa
CuBr (10 eq.) NEt3 (10 eq.) - >90% P -
CuBr (10 eq.) NEt3 (10 eq.) Asc (1 eq.) 100% P Peak at 8 kDa,
noisy spectrum
Cu(MeCN)4.PF6
(10 eq.)
- - >80% SM
10% P
-
Cu(MeCN)4.PF6
(10 eq.)
NEt3 (10 eq.) - 4:6 SM:P -
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Table 4.3: Reaction conditions tested with BODIPY 24 and the oligonucleotide-alkyne (molecular
mass 6793 Da). All reactions were carried out in the AtmosbagTM under nitrogen with a 30%
DMSO in PBS solvent mixture for 24 h at rt, using (BimH)3 (5 eq.) as the ligand. The ON was
at 25 µm and corresponded to one equivalent. Reactions were assessed using ESI-MS of dialysed
samples post-size exclusion column. SM = starting material, P = product, Asc = sodium ascorbate.
Catalyst Base Red. agent Result Notes
CuBr (10 eq.) - - loss of ON -
CuBr (10 eq.) - Asc (1 eq.) >90% P Some SS cleavage,
noisy spectrum
CuBr (10 eq.) NEt3 (10 eq.) - >90% P Some SS cleavage
CuBr (10 eq.) NEt3 (10 eq.) Asc (1 eq.) 3:7 SM:P Some SS cleavage
Cu(MeCN)4.PF6
(10 eq.)
- - 100% P -
Cu(MeCN)4.PF6
(10 eq.)
NEt3 (10 eq.) - >90% P Some SS cleavage
be a result of strong binding of the acetonitrile ligands which cannot be easily displaced by
(BimH)3, this has been shown in studies involving acetonitrile co-solvents.
207 Another point
of interest is the nature of an unexpected peak at around 8 kDa, however, this minor peak
does not relate to any identifiable molecular mass or adduct.
These results were promising as until this point, the use of copper (I) sources had resulted
in no successful CuAAC conjugations and so the use of an AtmosbagTM allowed the reaction
to work, in principle. Similar conditions were then performed on the disulfide-linked 24
and the ON (Table 4.3). However, the possible candidates for CCL2 conjugations may not
be compatible with the disulfide-linked fluorophores due to disulfide reduction and even
nucleophilic attack from triethylamine. The first entry was a surprising result as no ON was
observed in the mass spectrum suggesting this molecule had been lost during purification,
this was occasionally observed in the project and was likely anomalous. In general, the
reactions were successful, very little starting material remained and the desired product was
the major component. The action of triethylamine led to some disulfide cleavage where a
very minor peak corresponding to triazole formation but loss of a BODIPY-thiolate species
was present, suggesting the disulfide underwent nucleophilic substitution with the amine.
A similar occurrence was found with the use of a low equivalence of sodium ascorbate,
fortunately this reducing agent was not necessary to maintain catalytic copper. The best
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performing reaction was the Cu(MeCN)4.PF6 complex with no base or reducing agent present,
in this case the desired product was the only signal present by MS. It is unclear why this
complex would perform better with the disulfide 24 than the alkyl-linked 10, though the
azides are chemically very different in terms of polarity and the length of the linker between
azide and fluorophore. For example, disulfide 24 contains a PEG chain, the oxygen atoms
within may be able to coordinate metal ions such as the copper and this may influence the
catalytic cycle between CuBr and Cu(MeCN)4.PF6.
Table 4.4: Conditions attempted on CCL2 Ala−1 to conjugate disulfide-linked BODIPYs using the
AtmosbagTM conditions trialled on the ON. Reduced P: triazole formed but disulfide reduced.
Reaction Compound Conditions Result Notes
A 10 Cu(MeCN)4.PF6 (10 eq.), DMSO
(30%)
3:7 SM:P -
B 24 Cu(MeCN)4.PF6 (10 eq.), DMSO
(30%)
No protein -
C 33 Cu(MeCN)4.PF6 (10 eq.), DMSO
(30%)
No protein -
D 32 CuBr (10 eq.), DMSO (30%) Reduced P All product
reduced
E 24 CuBr (10 eq.), DMSO (30%) >80% P Some
cleavage
F 33 CuBr (10 eq.), DMSO (30%) >80% P Many side
products
G 33 CuBr (10 eq.), DMSO (30%) >90% P EDTA in
work-up
In summary, copper bromide combined with triethylamine and a low equivalence of sodium
ascorbate performed best with the ON-alk-H conjugate and the simplest conditions with
Cu(MeCN)4.PF6 was the most successful conditions with disulfide-linked BODIPY 24. A
number of variations on these conditions were also effective and so the next step was to at-
tempt these conditions on CCL2. Attempts are forming a disulfide-linked BODIPY conjugate
are summarised in Table 4.4 and offer varying levels of success. The alkyl-linked BODIPY 10
was used in a CuAAC as a control (Table 4.4, A) with the Cu(MeCN)4.PF6 complex which
was more successful in the disulfide trial reactions. This reaction worked relatively efficiently
and so the same conditions were repeated on disulfide BODIPY 24 (B), unfortunately pro-
tein was not recovered from this reaction, presumably due to work up losses. Precipitates
originating from the lipophilic fluorophore, particularly after dialysis, were observed but how
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(a) MALDI MS of CuAAC between CCL2 Ala−1 and disulfide 32 to form
CCL2 Ala−1-SS-L (Expected mass 9711 Da, Table 4.4, D).
(b) Successful MALDI MS of CuAAC between CCL2 Ala−1 and disulfide 24 to
form CCL2 Ala−1-SS-L (Expected mass 9725 Da, Table 4.4, E).
(c) Successful MALDI MS of CuAAC between CCL2 Ala−1 and disulfide 33 to
form CCL2 Ala−1-SS-H (Expected mass 9892 Da, Table 4.4, G).
Figure 4.6: MALDI MS of reactions described in Table 4.4 highlighting the improvement from initial
fully conjugated but reduced products to fully conjugated with almost no disulfide reduction.
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this would lead to protein losses is not clear. The polar disulfide BODIPY 33 (C) was then
attempted under the same conditions to test this hypothesis, however, this also led to protein
losses. At this stage, it was suspected that the combination of disulfide or the PEG chain
with the Cu(MeCN)4.PF6 was involved in the loss of CCL2 and so the copper source was
substituted for CuBr. Reaction D therefore utilised CuBr and a slight variation of the fluo-
rophore to lipophilic disulfide 32. This reaction did fully conjugate although it was associated
with complete cleavage of the disulfide (see the MALDI-MS in Figure 4.6), there were no
obvious reasons for this cleavage and re-characterisation of the stock fluorophore confirmed
the compound was intact. The alternative lipophilic disulfide BODIPY 24 was used and this
conjugation was successful, with complete conjugation and only minimal disulfide cleavage.
Encouraged by this result, CuAAC on the hydrophilic BODIPY 33 (F) was then attempted
under the same conditions, fortunately this reaction was successful with the desired conjugate
constituting the major product (Figure 4.6b), although a number of unwanted side products
were also present. This reaction was repeated with inclusion of ethylenediaminetetraacetic
acid (EDTA) in the work-up in an effort to sequester any copper ions which may be as-
sociating with the PEG chain and affecting purification (G). This reaction was successful,
producing a clean MALDI MS spectrum and almost no disulfide cleavage.
The next fluorophore to be conjugated to CCL2 Ala−1 was the FRET pair 45; this compound
is also relatively lipophilic but of a distinct structure to the problematic fluorophores. As
previous attempts at CuAAC with this compound had not been successful, possibly due to
solubility of the large molecule, a range of DMSO concentrations in PBS were tested on the
ON and 45 (Table 4.5). Only one concentration generated any conjugated product which
was the relatively high DMSO concentration of 70%. Interestingly, 90% DMSO did not work
possibly due to DNA-mitigated copper sequestration which lowered the effective Cu(I) con-
centration such that very high DMSO concentrations (90%) are sufficient to trap the copper
ion. The successful conditions were then repeated on CCL2 Ala−1 which resulted in conjuga-
tion of the intact FRET pair, accompanied by some disulfide cleavage and residual starting
material (Figure 4.7). Whilst the presence of a mixture of FRET pair, red-fluorescent and
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(a) Full spectrum MALDI MS of FRET-pair-CCL2.
(b) Magnified spectrum MALDI MS of FRET-pair-CCL2.
Figure 4.7: MALDI-MS of successful conjugation of 45 to CCL2 Ala−1, showing a mixture of
unlabeled starting material (9051 Da), cleaved disulfide (9962 Da) and desired product (10317 Da).
UV-Vis Spectra in Appendix, Figure 8.18.
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non-fluorescent CCL2 is not ideal, the lack of remaining CCL2 Ala−1 meant this compromise
was accepted for imaging applications in view of the conjugation difficulties encountered.
Table 4.5: Reaction conditions tested with FRET pair 45 on ON (A-D) and on CCL2 Ala−1 (E).
Reagents were identical in each and included CuBr (10 eq.) and (BimH)3 (5 eq.). SM = starting
material, P = product.
Reaction Substrate DMSO
concentration
Result Notes
A ON 30% SM -
B ON 50% SM -
C ON 70% 60:30 SM:P Some cleavage
D ON 90% SM -
E CCL2 Ala−1 70% 50:40 SM:P Some cleavage
4.2.2 Conjugation of Fluorophores to WT- and P8A-CCL2
With a range of conjugates successfully synthesised on the CCL2 Ala−1 protein, residual
stocks of this peptide were low and so the project moved on to conjugations with WT- and
P8A-CCL2. Beginning with WT-CCL2, BODIPY 10 was first conjugated using the conven-
tional CuSO4 and sodium ascorbate conditions in air. This CCL2 variant was not as versatile
in the CuAAC conjugations as it was often difficult to drive the reaction to completion (see
Figure 4.8). A number of attempts were undertaken using the same conditions as conjuga-
tions on CCL2 Ala−1, however, the same small starting material peak persisted in the mass
spectrum and even a small scale reaction in DMSO did not aid the conjugation. The oxidised
methionine present as an impurity in WT-CCL2 could have been adjacent to the propargyl
glycine residue, this may have been affecting the availability of copper or the catalytic cycle
and so the equivalence of CuSO4 was increased to five equivalents, with matching ratios of
sodium ascorbate and THPTA. The reaction profile as assessed by MS improved (Figure 4.8)
but the starting material peak could not be completely removed, as this represented a mi-
nor impurity, the conjugate was taken forward for functional studies described in chapter
5. Subsequent efforts to form WT-alk-L were not successful, this fluorophore was also more
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(a) MALDI-MS of CuAAC between WT-CCL2 and 10 (Expected mass 9523
Da).
(b) Improved MALDI-MS of CuAAC between WT-CCL2 and 10.
(c) Successful formation of WT-alk-H.
Figure 4.8: MALDI-MS of optimisation of CuAAC between alkyl-linked BODIPY 10 and WT-
CCL2, beginning with equimolar CuSO4 stoichiometry (4.8a). This MALDI-MS profile of the
reaction products was noisy with some starting material present. A further attempt led to an
improved mass spectrum but still had a relatively high percentage of starting material (4.8b).
Finally, excess CuSO4 (5 eq.) was able to minimise the presence of starting material, as assessed
by MALDI-MS (4.8c), this product was therefore taken forward into functional experiments.
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problematic with the previous CCL2 Ala−1, possibly due to self-aggregation.
Due to the difficulties encountered with WT-CCL2 conjugations, which after multiple repeats
were consistently performing poorly with a range of fluorophores, it was decided to move onto
CuAAC conjugations with the final CCL2 variant, P8A-CCL2. Fortunately this protein was
supplied at 90% purity (equivalent to CCL2 Ala−1) and generally conjugated successfully.
P8A-alk-H was formed first using BODIPY 10 and the copper (II) sulfate, sodium ascorbate
conditions used with CCL2 Ala−1 (Table 4.6). This reaction went to completion as indicated
by the lack of starting material present in the MALDI-MS spectrum (Figure 4.9), which
also showed the double BODIPY peak observed in the CCL2 Ala−1 conjugations, again this
was not present by ESI-MS (not shown). The next fluorophore to be conjugated was the
lipophilic alkyl azide 8, this was performed in 30% DMSO with in situ copper reduction
using sodium ascorbate in air. This reaction also proceeded efficiently with the MALDI-MS
presenting mostly conjugated protein, with similar double BODIPY shoulder peaks to the
previous reaction. Starting material was still present in the mass spectrum although this was
a minor peak. Formation of P8A-SS-H using BODIPY 33 was achieved using the previously
Table 4.6: Reaction conditions tested with with fluorophores and the CCL2 variant P8A, the
conjugates taken forward are highlighted. Equivalents of reagents were identical to those previously
used: fluorophore (20 eq.), CuBr (10 eq.), CuSO4 (1 eq.), (BimH)3 (5 eq.), THPTA (5 eq.) and Na
ascorbate (25 eq.). SM = starting material, P = product. Blue highlight: successful reaction.
Reaction Conjugate
& Fluo-
rophore
Conditions Result Notes
F P8A-alk-H
10
PBS, CuSO4, Na
ascorbate and THPTA
>90% P -
G P8A-alk-L
8
30% DMSO, CuSO4,
Na ascorbate and
THPTA
>80% P Residual SM
H P8A-SS-H
33
30% DMSO, CuBr,
(BimH)3
>80% P Some cleavage
I P8A-SS-L
32
30% DMSO, CuBr,
(BimH)3
6:4
SM:cleaved
SS
-
J P8A-SS-L
24
30% DMSO, CuBr,
(BimH)3
3:7 SS
Cleaved:P
Weak UV-VIS
signal
K P8A-SS-L
24
60% DMSO, CuBr,
(BimH)3
3:7 SS
Cleaved:P
-
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(a) Formation of P8A-alk-H (Expected mass 9497 Da, Reaction F).
(b) Formation of P8A-alk-L (Expected mass 9316 Da, Reaction G).
(c) Formation of P8A-SS-H (Expected mass 9778 Da, Reaction H).
Figure 4.9: MALDI-MS of successful conjugations of P8A and BODIPYs 10, 8 and 33. The
reaction using hydrophilic BODIPY 10 gave complete conjugation and also exhibited similar double-
BODIPY peaks found with CCL2 Ala−1. Some residual starting material was observed with the
lipophilic azide 8 with the desired product in the majority. Conjugations with the disulfonate
disulfide 33 resulted in complete conjugation with small amounts of disulfide cleavage. UV-Vis
spectra in Appendix, Figure 8.17
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(a) MALDI-MS of CuAAC between P8A and 32 (Expected mass 9597
Da, Reaction I).
(b) MALDI-MS of CuAAC between P8A and 24 (Expected mass 9611
Da, Reaction J).
(c) Successful formation of P8A-SS-L using BODIPY 24 (Reaction
K).
Figure 4.10: MALDI-MS of optimisation of CuAAC between P8A and a lipophilic disulfide-linked
BODIPYs 24 and 32. At 30% DMSO concentrations, a mixture of starting material and cleaved
disulfide conugate was observed with 32 (4.10a). A greater level of complete conjugation was
observed with the alternative disulfide 24 (4.10b), however, this was not reflected in the UV-Vis
spectrum (Appendix, Figure 8.19). Increasing the DMSO concentration to 60% resulted in a similar
MALDI-MS spectrum (4.10c) but an increased level of labelling as determined by UV.
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successful CuBr conditions in the AtmosbagTM, this resulted in complete conjugation with
only minimal disulfide cleavage. Initial attempts at conjugating the lipophilic disulfide were
not successful using either BODIPY 24 or 32, both using the same CuBr conditions, this re-
sulted in either poor labeling or excessive disulfide cleavage for unclear reasons (Figure 4.10).
It was found that increasing the DMSO concentration to 60% and also increasing the P8A-
CCL2 concentration to 170 µm (from 100 µm) gave fully conjugated protein with only minimal
cleavage of the disulfide. The fluorescence spectra of the CCL2 conjugates generally resem-
bled the unconjugated azide fluorescence spectra, however, some peak broadening relative to
the free fluorophore was observed in the disulfonated BODIPYs (Appendix, Figure 8.20).
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4.3 Conclusion
A number of CCL2 conjugates have been prepared utilising CuAAC and fluorescent properties
have been maintained throughout. The copper (II) sulfate conditions recommended by Bode
et al. operated as expected in the case of hydrophilic alkyl-linked BODIPY 10 which utilised
sodium ascorbate for in situ copper reduction.247 Following this, extensive optimisation was
required to successfully conjugate lipophilic azides such as alkyl-linked BODIPY 8. In this
case, a rare example of DMSO as a co-solvent in protein conjugations is reported, following
the work of Finn et al., which enabled complete conjugation of simple lipophilic azides in
30% DMSO mixtures.207 The DMSO was removed via dialysis and we reasoned that the
small size of CCL2 allows dynamic re-folding to the correct orientation.
Further difficulties were then encountered when CuAAC reactions were performed on disulfide-
linked substrates which raised an infrequently mentioned issue which is that conventional
CuAAC conditions using sodium ascorbate can lead to disulfide reduction and catalyst poi-
soning. Evidently this was problematic in the cleavage of the fluorophores from CCL2 but
also any effect this may have had on the internal disulfides found in CCL2. Three scenarios
are possible from this perspective: the internal disulfides are inaccessible thus remaining oxi-
dised correctly, the internal disulfides are reduced but the tertiary structure of CCL2 ensures
rapid re-oxidation in the correct orientation, or the internal disulfides are reduced and do
not then oxidise correctly. The reduction of disulfides was largely avoided through the use of
copper (I) salts under oxygen-free conditions in an AtmosbagTM. Fortunately, this strategy
was successful and enabled the completion of the array of conjugates which were intended
to be synthesised. To the best of our knowledge, this is the first report of a cleavably-linked
conjugate of CCL2. Furthermore, this is achieved through CuAAC meaning that only a small
modification to the C-terminus of CCL2 is required and only needs incorporation of azide
functionality into the conjugating species. Finally, fluorescent conjugates of three CCL2 vari-
ants are also reported, CCL2 Ala−1 and P8A-CCL2 conjugates represent novel examples of
fluorescent CCL2 mutants.
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5.1 Introduction
A range of CCL2 conjugates were prepared in the previous chapter on three CCL2 sequences
which have been shown to be functionally distinct in the literature.224,225 The focus of this
chapter is to characterise the functional behaviour of the synthesised CCL2 conjugates in
terms of chemotactic activity, specificity of the conjugates for CCR2 and assess any uptake
of the fluorescent chemokines across primary human immune cells. The binding of CCL2
to CCR2 has been characterised extensively using radioligand binding assays, however, this
assay does not provide any functional information. Chemotaxis assays provide functional
information whereby cells migrate towards a concentration gradient of a chemokine. A com-
mon assay utilised in chemotaxis is the Boyden chamber chemotaxis assay; this assay involves
two chambers separated by a porous membrane whereby the chemoattractant is located in
the lower chamber and the cells are placed in the upper chamber.252 If a chemoattractant
is present the cells in the upper chamber will invade the lower chamber using the pores in
the membrane to migrate across. There are many benefits to using this assay which has es-
tablished the Boyden chamber assay as the gold standard in identifying new chemokines, for
example, it is simple to use and the experiment takes a relatively short amount of time (1-6
hours). The short experiment times prevent cell proliferation having any effect on the migra-
tion towards the lower chamber.252 The physical separation of the cells from the chemoat-
tractant allows multiple factors to be included in the upper chamber, such as chemotaxis
inhibitors, to assess selectivity of the chemoattractant.252 This is generally more difficult
or not possible in other assays such as 3D chemotaxis assays where cells are hosted in a
collagen matrix. The results are reliable and the assay tends to be successful whereas in
more complex chemotaxis assays collagen matrix preparation is difficult and often has a high
failure rate. A number of investigations into chemokines have utilised the Boyden chemo-
taxis assay such as the CCL2-mCherry conjugate, CCL2/CCR2 selectivity, CCR2 antagonism
and CCR2 antagonist identification.5,113,253 Following the chemotactic characterisation of the
CCL2 conjugates, the monocyte subset selectivity will be determined using monoclonal an-
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tibody labelling in flow cytometry. Finally, the CCL2 conjugates will be used in fluorescence
microscopy to determine subcellular localisation in cells, including any differences in locali-
sation across the CCL2 conjugates as a result of differences in fluorophore hydrophilicity or
linker chemistry.
The experiments involving monoclonal antibody labelling of PBMCs were performed in col-
laboration by Ryan Brown (RB) and Dr Christopher Weston (CW). Both RB and CW
designed the experiments, RB isolated the primary cells and prepared the labelling experi-
ments, CW operated the flow cytometer, both RB and CW designed the strategy to analyse
the data.
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5.2 Results and Discussion
5.2.1 Assay Development to Characterise CCL2 Conjugates
The first step towards characterising the chemotactic function of the synthesised CCL2 con-
jugates was to perform chemotaxis assays using Boyden 96-well transwell plates. Initial
experiments counted the migrated cells using a hemocytometer, however, this approach was
particularly time-consuming and contained some variation in cell numbers. The plates are
intended for high-throughput experiments and so this strategy was modified to include quan-
tification of the experiment via the use of the Attune Flow Cytometer; this allowed both
cell counts and fluorescence to be rapidly measured in a 96-well auto-sampler. The flow
cytometer measures events per microlitre for gated events in a population and this number
is an indirect measure of the number of cells. This indirect measurement of cell numbers was
therefore validated through seeding a fixed number of cells into a well and comparing this to
the number of events (Figure 5.1). The number of events was consistently slightly lower than
the number of seeded cells and the accuracy was greater around the number of cells which
usually migrate in the transwell experiment and so this showed using this quantification
method was reliable.
These experiments suggested that flow cytometry could be effectively coupled to the Boyden
transwell chemotaxis assay to allow both cell counting and fluorescence measurements. The
experiments were designed as follows: 300 ×103 cells were seeded in the top chamber and
left to incubate for either 24 or 4 hours. The cells were then fixed in the 96-well plate before
sampling in the flow cytometer. Figure 5.2 shows that PBMCs and THP-1 cells exhibited
very different chemotactic responses towards recombinant human CCL2 (purchased from
Peprotech, used as a positive control). The PBMCs do not exhibit an obvious chemotactic
response and also have a number of outliers, for example, at 20 nm. The THP-1 cells on the
other hand offer a more obvious response with a maxima at 10 nm which lies inside the 1-10
nm range reported by Peprotech. One possible reason for this difference is the tendency for
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(a) THP-1 population on Attune flow cytometer
(b) Validation of flow cytometric cell counting
Figure 5.1: Gating strategy using forward and side scatter to isolate the population of cells at R1
(FSC thresholding at 1000). The fluorescence (BL1) was measured using a 488 nm laser for BODIPY
excitation which also allows the fluorescence median per event to be determined. Figure 5.1b displays
the validation of cell counting in a 96-well plate with using THP-1 cells. 500,000 cells seeded in
wells 1-6, 125,000 cells seeded in wells 7-12 and 10,000 cells seeded in wells 13-18. The average cell
counts are 290,933 for wells 1-6, 99,202 for wells 7-12 and 12,204 for wells 13-18.
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(a) Migrated PBMCs and THP-1 cells in Boyden chemotaxis assay.
(b) Recombinant CCL2 and CCL2 Ala−1-alk-H chemotactic response.
Figure 5.2: The bar chart highlights the poor and inconsistent response of PBMCs towards recombi-
nant CCL2 in the transwell chemotaxis assay (5.2a). The THP-1 cells gave a strong response which
correlated with the 1-10 nm chemotactic maxima range reported by Peprotech. The difference in
chemotactic maxima between recombinant CCL2 and the CCL2 Ala−1 conjugate is similar to the
reduced affinity reported in the literature (5.2b). Duplicate wells exhibit a large amount of variation
which was likely due to the fixation step. Cells in 5.2a were incubated in the transwell for 24 h and
in 5.2b for 4 h.
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human monocytes to adhere to the wells and thus a reliable measure of the number of mi-
grated cells is difficult to establish. Another issue with PBMCs is donor variability leading to
inconsistent chemotactic responses. It was therefore decided to use THP-1 cells for migration
experiments as these cells were more consistent and were also practically more preferable for
the large number of experiments to be completed. The length of the transwell incubation
was also reduced to 4 h from 24 h because it was apparent the longer incubation time was
not necessary. Figure 5.2b shows the migratory response of THP-1 cells to the recombinant
CCL2 and the CCL2 Ala−1-alk-H conjugate, this was an encouraging result as the fluorescent
conjugate would appear to be chemotactic and even exhibited a reduced affinity relative to
the wild-type sequence which was reported in the literature. However, considerable variation
was observed between duplicate wells and upon further investigation this was found to be
due to the fixation of the cells in the 96-well plate; subsequent migration experiments were
therefore not fixed and flow cytometry was performed on live cells.
5.2.2 CCL2 Variants on Alkyl Linker System
The optimised transwell assay described in the previous section was then used to quantify
the three CCL2 variants on the hydrophilic-alkyl-BODIPY conjugates. The chemotactic
responses of the variants WT-alk-H, P8A-alk-H and CCL2 Ala−1-alk-H are displayed in Fig-
ure 5.3 which highlights clear differences between the peptides. The percentage of migration
maxima was used as a normalisation technique between experiments due to the variation of
maximal migrational responses of the THP-1 cells between experiments. This accounted for
differences in the THP-1 population over time, cell confluence, time for experimental set up,
cell counting error and pipetting error; this was deemed acceptable as the maximal responses
of the chemokines were not affected and this method is also used in the literature.113 Each
concentration of CCL2 was used in duplicate wells, this was then averaged and each con-
jugate experiment was repeated to N = 3. The conjugates were compared to commercially
available recombinant human CCL2 (Peprotech), this protein exhibited a maximal migra-
tionary response at 3 nm which agreed well with a range of 1-10 nm as quoted by Peprotech,
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this suggested the THP-1 cells were migrating towards a known chemokine and the assay
was functioning correctly. Another experimental consideration was that if less than 20×103
cells migrated at the maximum response of recombinant CCL2, the experiment was deemed
unsuccessful and discarded.
The CCL2 conjugates are clearly chemotactic and have a varied chemotactic response which
correlates well with the reported maxima for unmodified sequences described in the literature.
CCL2 Ala−1-alk-H exhibited a maxima at 200 nm which corresponds with the literature
reported reduction in affinity of 1-200 fold relative to WT CCL2.224 P8A-alk-H, on the other
hand, exhibited a greater affinity for the receptor with maximal induction of chemotaxis at
Figure 5.3: The chemotactic migrational repsonses of THP-1 cells to alkyl-linked fluorescent
chemokines WT-alk-H, P8A-alk-H and CCL2 Ala−1-alk-H. The number of migrated cells has been
normalised to the percentage of the maximal migration and the x-axis is on a log scale. The Boyden
transwell chemotaxis assay was devised as described in the previous section and each concentration
was carried out in duplicate and averaged. The three conjugates were chemotactic and each exhib-
ited different chemotactic maxima which correlated strongly with literature reports suggesting both
the amino acid additions at the C-terminus and the conjugates were not affecting chemotaxis.224,225
Error bars correspond to standard error where N = 3. Negative controls relevant to each CCL2
conjugate: WT-alk-H = 11.4% ± 3.68%, P8A-alk-H = 30.3% ± 1.87% and CCL2 Ala−1-alk-H =
10.2% ± 2.68%.
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3 nM which also agrees with literature reports of the unmodified P8A sequence.225 Finally,
the wild-type sequence WT-alk-H exhibited a slightly reduced maxima at 10 nm, however,
this falls within the 1-10 nm range for recombinant CCL2. One reason for this reduction
in migrational maxima is the lower purity of the WT sequence relative to P8A-CCL2 which
was also an issue in the CuAAC conjugations. For each conjugate, the migratory response
gradually reduces above and below the maximal concentration, this behaviour provides more
evidence the conjugates are recruiting the cells via chemotactic signaling. Clearly, at concen-
trations less than the maxima, fewer cells will migrate towards the chemokine, however, at
higher concentrations fewer cells are recruited as the concentration of chemokine surrounding
the cell is so high that the direction of concentration gradient cannot be detected easily. This
behaviour is indicative of the action of chemokines and can be rationalised through a switch
in mechanism from chemotaxis to chemokinesis, whereby the cells are moving in a random
motion, not a chemotactic motion.11
The graph displayed in Figure 5.4 highlights the difference between unlabelled and labelled
CCL2 variants for WT and P8A sequences. In the case of WT-CCL2 and WT-alk-H, the
migratory maxima is the same at 10 nm suggesting the presence of the fluorophore at the
C-terminus has little effect on chemotactic signalling. It could be argued that the curve is
slightly shifted to higher concentration in WT-alk-H relative to WT-CCL2, however, this
shift is minor and would have little effect on subsequent experiments. Interestingly, P8A-
alk-H and P8A-CCL2 had the same maximal chemotactic concentrations but there was more
peak broadening in P8A-alk-H. The reasons for this broadening were unclear as only one
species was present in the MALDI-MS spectrum (Figure 4.9a) and so this effect was not due
to a mixture of P8A-alk-H and P8A-CCL2. The chemotactic response of recombinant CCL2
was used as a positive control (5.4b) which shows the assay is operating correctly. Finally,
the lower affinity CCL2 Ala−1 chemokine displayed a migratory peak shifted to higher con-
centrations relative to recombinant CCL2 (Figure 5.5). The unlabelled CCL2 Ala−1 protein
exhibited a chemotactic maxima of around 300 nm whereas the CCL2 Ala−1-alk-H exhibited
a maxima at 200 nm. However, close inspection of the unlabelled peak suggests this maxima
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(a) Migration data for labelled and unlabelled WT-CCL2
(b) Migration data for recombinant CCL2 and labelled and unlabelled P8A-
CCL2
Figure 5.4: Transwell chemotaxis assay showing the migratory responses for both unlabelled and labelled
CCL2 variants. Generally, the presence of the fluorophore had little effect on the chemotactic potency of the
chemokines, however, some peak broadening was observed in P8A-alk-H. Recombinant CCL2 (Peprotech)
exhibited a maxima at 3 nm with a slightly broader peak than P8A-CCL2. Negative control for WT-CCL2
= 11.4% ± 3.68 and for P8A-CCL2 = 30.3% ±1.87. Error bars refer to standard error for N = 3.
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may not be accurate due to the error at 400 and 200 nm, this suggests the maxima may
lie between 200 and 300 nm. For the purposes of this project, this was deemed acceptable
as calculating the chemotactic maxima to high accuracy would involve radioligand labelling
which is beyond the scope of this project.
Figure 5.5: Boyden transwell chemotaxis assay displaying migration data for unlabelled CCL2 Ala−1
and CCL2 Ala−1-alk-H. The chemokines have less affinity for CCR2 and therefore exhibit maxima
at 300 and 200 nm, respectively. However, the error around the maxima for unlabelled CCL2 Ala−1
suggests the true maxima may be between 200 and 300 nm. Negative control = 10.2% ± 2.68%.
Error bars refer to standard error and N = 3.
The median fluorescence across the THP-1 cells was also utilised in these experiments to
determine internalisation dynamics of the fluorescent chemokines. Figure 5.6 highlights the
fluorescence of the cells with respect to the chemokine concentration and this data is co-
plotted alongside the migration data for comparison with chemotaxis. The fluorescence of
P8A-alk-H and WT-alk-H rapidly increase with higher concentration until a pseudo-steady
state is reached at around 30 nm. An important point to note is that the cells migrate in
the receiver well and are then in a high CCL2 concentration medium for the remainder of
the experiment and so should continue to internalise the ligand. In terms of P8A-alk-H, a
steady state was observed at approximately ten-fold higher concentration than the chemotac-
tic maxima and for WT-alk-H the steady state began around 3-5 fold above the chemotactic
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(a) Comparison of fluorescence and chemotaxis for WT-alk-H.
(b) Comparison of fluorescence and chemotaxis for P8A-alk-H.
Figure 5.6: Graphs showing the migration of THP-1 cells in a transwell Boyden chemotaxis assay as a bar
graph and the median fluorescence of migrated cells as a scatter graph. Steady states of fluorescence are
observed for both WT-alk-H and P8A-alk-H above the chemotactic maxima suggesting depletion of surface
CCR2 limits internalisation of the chemokine. The steady state could also be caused by equilibria between
internalisation and lysosomal degradation of the fluorophore under acidic conditions. Error bars refer to
standard error at N = 3.
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maxima. A steady state in fluorescence above the chemotactic maxima was not observed for
CCL2 Ala−1-alk-H, however, in comparison to P8A-alk-H and WT-alk-H, the concentrations
measured were perhaps not high enough to attain a steady state (Figure 5.7). Attempts
were therefore made to find a steady state between internalisation and degradation of the
fluorophore in CCL2 Ala−1 by measuring the migration and fluorescence at 200, 600, 800 and
1000 nm in a Boyden transwell chemotaxis assay. Figure 5.8 displays two attempts at evalu-
ating these higher concentrations, however, some inconsistent results were encountered which
made drawing any conclusions difficult. In Figure 5.8a, the migration above the chemotactic
maxima appeared to give a second peak in comparison to the data presented in Figure 5.7,
however, the fluorescence increased from around 2500 A.U. to 5000 A.U. from 200 nm to 600
nm and then modestly increased to around 6000 A.U. at 800 nm which was then maintained
to 1000 nm. This suggested some steady state in fluorescence but the ambiguous chemotactic
data meant that this was not conclusive. At this stage, no further experiments wer performed
due to the inconsistency of the results requiring more repeats which were very costly in terms
of the amount of CCL2 Ala−1-alk-H required to produce the high concentrations. The incon-
sistent results could have been due to occasional formation of high order oligomers (known
to occur in chemokines254) which may then internalise through a non-endocytic mechanism
such as macro-pinocytosis or phagocytosis. The steady states observed in WT-alk-H and
P8A-alk-H are interesting because if the chemokines are being continuously internalised, this
fluorescence should steadily increase with higher concentrations. The steady states suggest
that the levels of surface receptor CCR2 are being depleted at high concentrations which lim-
its the entry of the fluorescent chemokines. Another explanation is that the ligand-receptor
complex is being processed by the endocytic machinery and the fluorophore is being localised
in lysosomes, this could then lead to degradation of the fluorophore and loss of fluorescence
(the acid-sensitivity of the boron centre of BODIPY would suggest this is possible). An
equilibrium would then be achieved between uptake of the chemokine and degradation of the
fluorophore, leading to the steady state.
In terms of the absolute fluorescence of the chemokines, CCL2 Ala−1-alk-H exhibited the
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(a) Comparison of fluorescence and chemotaxis for CCL2 Ala−1-alk-H.
(b) Median fluorescence of the three CCL2-alk-H conjugates.
Figure 5.7: The CCL2 Ala−1-alk-H conjugate did not exhibit a steady state suggesting the equilibrium found
with P8A and WT-CCL2 was not reproduced (5.7a). A graph showing concentration of chemokine conjugate
against median fluorescence, highlighting the difference in progression of chemokine internalisation and the
absolute fluorescence achieved (5.7b). The steady state achieved by WT-alk-H is at a higher level than
P8A-alk-H, however, these are both surpassed by CCL2 Ala−1-alk-H which does not reach a steady state at
the concentrations examined. Error bars refer to standard error at N=3.
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(a) First attempt at comparison of fluorescence and chemotaxis for high con-
centrations of CCL2 Ala−1-alk-H.
(b) Second attempt at comparison of fluorescence and chemotaxis for high con-
centrations of CCL2 Ala−1-alk-H.
Figure 5.8: Boyden transwell chemotaxis assay comparing the fluorescence and migration of THP-1 cells
towards high concentrations of CCL2 Ala−1-alk-H, in order to discover a steady state between internalisation
and fluorophore degradation. Some indications of a steady state were observed but the ambiguity of the
migratory response of the cells rendered these results unclear.
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highest fluorescence median at 400 nm, this could therefore be an attractive prospect for
future therapeutic applications as the lack of a steady state does not limit the internalisa-
tion of the conjugate (Figure 5.7). However, if the CCL2 Ala−1-alk-H conjugate is forming
oligomers at high concentrations leading to non-specific internalisation pathways this limits
therapeutic applications. The differences in internalisation of the chemokine variants appear
to correlate with the relative chemotactic affinities of the CCL2 variants and so there is lim-
ited evidence of separation of internalisation and chemotaxis in these models. Compared to
the results reported by Handel et al., the behaviour of P8A-alk-H appears to replicate the in
vitro behaviour of P8A-CCL2 leading to induction of chemotaxis and internalisation.225
5.2.2.1 CCL2/CCR2 Inhibition Studies
The transwell Boyden chemotaxis assay allowed the confirmation that the CCL2 conjugates
were behaving as chemokines and that the sequence alterations were having a pronounced
effect on both the chemotactic signalling and internalisation of the THP-1 cells. The next aim
was to then demonstrate that this chemotaxis and internalisation was the result of CCR2-
mediated endocytosis and not some other unknown mechanism. This was pursued through
the use of a small molecule CCR2 antagonist developed by Incyte, this compound should
prevent chemotaxis and internalisation of the CCL2 conjugates if they are CCR2 specific.172
This compound has an IC50 = 4.7 nm for chemotaxis inhibition and 3.7 nm for internalisation
of CCL2, it was therefore decided to work from 4.7 nm to prevent both chemotaxis and
internalisation. Inhibition studies were performed in the transwell chemotaxis assay with
an additional incubation step with INCB 3284. The concentrations of INCB 3284 used for
inhibition were 4.7, 47 and 470 nm which represents a theoretical inhibitory dose of 50, 90 and
95%, respectively. This experiment was initially performed on recombinant CCL2 showing
that the INCB 3284 does inhibit the action of CCL2 (Appendix, Figure 8.21). A dose
dependent inhibitory response was observed against WT-alk-H and WT-CCL2 (Figure 5.9).
At 4.7 nm of INCB 3284, migration was inhibited to around 60% of the maximum response,
this was accompanied by a reduction in fluorescence of around 20%. This suggests that the
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(a) Comparison of fluorescence and chemotaxis for WT-alk-H (10 nm) after
CCR2 inhibition.
(b) Chemotactic response of unlabelled WT-CCL2 (10 nm) after CCR2 inhibi-
tion.
Figure 5.9: Boyden chemotaxis transwell assay with CCR2 inhibition using INCB 3284 at 4.7, 47 and 470
nm representing 50, 90 and 95% inhibition, respectively. The chemokines were used at their respective
chemotactic maxima (WT-alk-H = 10 nm, WT-CCL2 unlabelled = 10 nm). Control I: no chemokine or
antagonist, control II: no chemokine, 470 nm INCB 3284. A clear trend can be observed whereby both
migration and fluorescence decrease with increasing doses of the CCR2 antagonist. Error bars refer to
standard error at N=2.
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chemotaxis is CCR2-dependent and similarly, the internalisation of the fluorescent chemokine
is also CCR2-dependent. This inhibition then continues in a dose-dependent manner in
terms of the antagonist; chemotaxis is inhibited by 470 nm INCB 3284 to around 30% of the
untreated cells. This amount of migration is slightly greater than both controls, firstly this
indicates that CCR2 blockade almost completely inhibits chemotaxis, and secondly, this slight
increase over the controls likely indicates the 5% of the population which are not inhibited and
thus respond to the chemokine ligand. The fluorescence of cells inhibited with 470 nm INCB
3284 was greatly reduced relative to the maximum response and followed the dose-dependent
trend observed with chemotaxis inhibition. The level of fluorescence observed with 470 nm
INCB 3284 is around double that of both controls (which represent autofluorescence levels),
this provides further evidence for the hypothesis that an equilibrium is reached between
uptake of chemokine and degradation of the fluorophore. At this concentration of antagonist,
95% of CCR2 is inhibited and the remaining receptors can bind the ligand, if an equilibrium
was not achieved the remaining 5% of receptors would gradually internalise the fluorescent
chemokine over the duration of the experiment to a level resembling non-inhibition. This
is not observed, suggesting an equilibrium of reduced magnitude is reached in the 5% of
receptors not blocked by the antagonist. The chemotactic function of the unlabelled WT-
CCL2 was also inhibited by INCB 3284 in a dose dependent manner, with 4.7 nm INCB 3284
reaching approximately 60% maximum migration, followed by 30% and 20% for 47 and 470
nm INCB 3284 respectively. This level of inhibition closely matches the inhibition observed
in WT-alk-H providing further evidence that the conjugation does not affect function.
Antagonism of CCR2 in the same experimental system also resulted in inhibition of both P8A-
alk-H and unlabelled P8A-CCL2 (Figure 5.10). A dose dependent reduction in migration was
observed for P8A-alk-H (Figure 5.10a), however, this trend was increasingly step-wise from
4.7 - 470 nm INCB 3284 relative to WT-alk-H which rapidly reduced from 4.7 - 47 nm INCB
3284. The migration at 4.7 nm reduced to 70% of the maximum migration, which represents
a lower amount of inhibition compared to WT-alk-H. This is likely a result of the 35%
migrational response of the negative controls meaning the dose response may be contracted.
5.2. Results and Discussion 177
(a) Comparison of fluorescence and chemotaxis for P8A-alk-H (3 nm) after
CCR2 inhibition.
(b) Comparison of fluorescence and chemotaxis for unlabelled P8A-CCL2 (3
nm) after CCR2 inhibition.
Figure 5.10: Chemotaxis assay with CCR2 inhibition using INCB 3284 at 4.7, 47 and 470 nm. The chemokines
were used at their respective chemotactic maxima (P8A-alk-H = 3 nm, P8A-CCL2 unlabelled = 3 nm).
Control I: no chemokine or antagonist, control II: no chemokine, 470 nm INCB 3284. P8A-alk-H elicited a
similar effect to WT-alk-H whereby both migration and fluorescence decrease with increasing doses of INCB
3284, however, higher concentrations of antagonist are needed to completely inhibit P8A-alk-H relative to
WT-alk-H. Error bars refer to standard error at N=2.
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This 70% migration for 4.7 nm INCB 3284 represents a midway point between the control
and the maximum migration, which for 4.7 nm INCB 3284 would represent half-maximal
inhibition. At 47 nm, the approximately 50% of maximum migration does not represent the
expected 90% inhibition but is still a dose-dependent decrease in migration. The near total
inhibition at 470 nm towards control I and II, in terms of migration, suggests the action
of this conjugate is similarly due to CCR2 and not another mechanism. The fluorescence
also decreases in a dose-dependent manner suggesting that P8A-alk-H internalisation is also
inhibited. Again, this response is initially incremental but after 470 nm the fluorescence
median has significantly decreased to similar levels found with WT-alk-H. The 470 nm INCB
3284 is then at a concentration high enough to effectively inhibit P8A-alk-H to approach
control levels of migration. This conjugate also exhibits the residual fluorescence at 470 nm
INCB 3284 suggesting the presence of an equilibrium between internalisation and fluorophore
degradation, this suggests both peptides are operating through a similar mechanism which is
likely to be via CCR2. The unlabelled P8A-CCL2 (Figure 5.10b) is similar to the conjugated
peptide at 4.7 nm but exhibits the expected 90 - 95% inhibition level, relative to control, at
47 and 470 nm INCB 3284.
The final CCL2 variant, CCL2 Ala−1-alk-H, was also inhibited in a dose-dependent manner,
however, this effect was different to the previous two CCL2 variants (Figure 5.11). A slight
decrease in migration at 4.7 nm INCB 3284 occurred, followed by a large decrease at 47 nm to
around 30% of maximum migration, and again the 470 nm INCB 3284 was sufficient to render
migration to background levels. The inhibition of fluorescence did not follow the same trend
which gave a gradual decrease in fluorescence with increasing inhibitor concentration. At 470
nm INCB 3284 the fluorescence median was still significantly higher than autofluorescence
(at around 40% of the fluorescence median when not inhibited). Whilst CCL2 Ala−1-alk-H
did possess a higher level of fluorescence at the migrational maxima than the other CCL2
variants, effective inhibition of CCL2 Ala−1-alk-H with 470 nm INCB 3284 should result in a
fluorescence median closer to autofluorescence levels. This suggests that either CCL2 Ala−1-
alk-H does not reach an equilibrium between internalisation and fluorophore degradation
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(which is possible and was suggested by the lack of a steady state in the chemotaxis assays,
Figure 5.7) resulting in the fluorescence gradually increasing inside the cell as chemokine
is internalised through the reduced number of available CCR2 receptors. An alternative
explanation is that there is a disconnect between signalling and internalisation in CCL2 Ala−1
resulting in a larger difference between IC50 for chemotaxis and CCR2 binding, suggesting
CCL2 Ala−1 mediated chemotaxis is more readily inhibited than internalisation.
Figure 5.11: Boyden chemotaxis transwell assay with CCR2 inhibition using the CCR2 antagonist INCB
3284. The chemokine was used at the chemotactic maxima (CCL2 Ala−1-alk-H = 200 nm). Control I: no
chemokine or antagonist, control II: no chemokine, 470 nm INCB 3284. The difference between migration and
internalisation inhibition suggests these pathways may be more independent with respect to CCL2 Ala−1-
alk-H. Error bars refer to standard error at N=2.
Further evidence for CCR2-mediated chemotaxis was attained following inspiration from
Graham et al., in this study it was found that pre-incubation of murine monocytes with 250
nm recombinant CCL2 resulted in surface CCR2 depletion to levels resembling CCR2−/−
knockout mice.184 We therefore treated THP-1 cells with 250 nm CCL2 prior to the chemo-
taxis assay as a second method to determine CCR2 selectivity of the chemokine conjugates.
Figure 5.12 displays both the migration and fluorescence data resulting from this experiment,
the method described by Graham et al. was slightly modified to include a pre-incubation
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(a) Response of cell migration to pre-incubation of 250 nm CCL2 using WT-
CCL2 and WT-alk-H.
(b) Effect of pre-incubation with 250 nm CCL2 on fluorescent CCL2 uptake.
Figure 5.12: Boyden chemotaxis transwell assay with initial 250 nm CCL2 pre-incubation to reduce surface
levels of CCR2, evaulating WT-CCL2 and WT-alk-H.184 The migration of THP-1 cells towards the unlabelled
and fluorescent WT-CCL2 is reduced when pre-incubated with either recombinant CCL2 or unlabelled WT-
CCL2 (5.12a). The fluorescence is not greatly affected by pre-incubation which is most likely due to the
pre-incubation creating a heterogeneous population of CCR2 levels giving a positive selection process in the
transwell assay (5.12b). Error bars correspond to N = 2. Untreated - no pre-incubation. 250 nm recombinant
CCL2 - pre-incubation with this dose.
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using either recombinant human CCL2 or the unlabelled synthetic CCL2 variant of interest.
For example, in the case of Figure 5.12, this included recombinant human CCL2 and a sepa-
rate incubation of unlabelled WT-CCL2, these cells were then exposed to either 10 or 30 nm
WT-alk-H or WT-CCL2, measuring both migration and, where appropriate, fluorescence.
The concentrations of 10 nm and 30 nm were selected such that the chemotactic maxima was
used which would give the strongest chemotactic response, and a second concentration was
selected to show any results were consistent in terms of migration and fluorescence. Figure
5.12a highlights that inhibition of chemotaxis is achieved using this method, suggesting the
chemokines are signalling through CCR2. With WT-CCL2 10 nM, the recombinant CCL2
reduced migration to around 40% of the maximum response suggesting that the action of the
recombinant CCL2 reduces surface levels of CCR2 such that the synthetic WT-CCL2 was not
able to recruit the cells. A similar effect was observed with pre-incubation using WT-CCL2,
this evidence is two-fold in that it shows incubation with 250 nm WT-CCL2 reduces levels
of surface CCR2 (through binding and internalisation of the ligand-receptor complex) such
that a dose of 10 nm WT-CCL2 is not able to recruit cells chemotactically. Similar results
were observed with 30 nm WT-CCL2. This effect is also seen on the fluorescent WT-alk-H
for both 10 and 30 nm, particularly for WT-alk-H at 10 nm with reduction in migration to
around 20%. Again, a similar result was found with WT-alk-H at 30 nm, indicating that
for both fluorescent and non-fluorescent WT-CCL2, the ability to recruit cells is reduced by
recombinant and synthetic WT-CCL2 incubations.
The fluorescence medians for this experiment are displayed in Figure 5.12b and present an
interesting effect. For both 10 and 30 nm WT-alk-H, the fluorescence medians only slightly
decrease when pre-treated with recombinant CCL2 and unlabelled WT-CCL2. This effect is
very different to the studies using the CCR2 antagonist INCB 3284 where a dose-dependent
reduction in fluorescence was observed with increasing concentrations of inhibitor. This
effect could be due to the cells which are able to migrate into the receiver well having only
slightly reduced levels of surface CCR2 and so continue to internalise fluorescent chemokine
when in the receiver well. This is because the pre-incubation of CCL2 likely produces a
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heterogeneous population of THP-1 cells with respect to surface CCR2 expression and so the
cells measured in the receiver well have undergone a positive selection process by the nature
of the experiment. In the INCB 3284 experiments, all cells possess INCB 3284 bound to 50,
90 or 95% of the CCR2 receptors, leading to the steady state between internalisation and
degradation maintaining a reduced fluorescence level.
The CCL2-mediated CCR2 depletion studies were then performed on P8A-alk-H and P8A-
CCL2 at 3 nm and 10 nm which represents the chmotactic maxima and a second concentration
for comparison. Both the unlabelled P8A-CCL2 and P8A-alk-H exhibited a reduced ability
to recruit THP-1 cells after pre-incubation with both recombinant and P8A-CCL2 (Figure
5.13a). This suggests the fluorescent and non-fluorescent proteins are operating through
the same mechanisms. This CCL2 variant was more consistent than WT-alk-H in terms of
the level of migration across the treatments and concentrations being reduced to a similar
level, which was coincident with the three control conditions. The fluorescence medians with
P8A-alk-H were again only slightly lower in the CCL2 pre-incubated cells than the untreated
cells (Figure 5.13b). The study into P8A antagonism concluded the mode of action was an
inability to dimerise on GAGs and so CCL2-P8A heterodimers would not then bind GAGs
leading to chemotaxis inhibition in vivo. The results displayed in Figure 5.13b therefore
provide indirect evidence that P8A-CCL2 does not directly antagonise CCR2.
Finally, the CCL2 Ala−1 variant was tested in a similar manner (Figure 5.14), however, un-
labelled CCL2 Ala−1 was not used in pre-incubation as very high concentrations would be
required. For example, recombinant CCL2 (potency 1-10 nM) requires a dose of 250 nm;
this represents a 25-250 fold increase over the chemotactic maxima which for CCL2 Ala−1,
which has a maxima around 200 nm, would be over 5 µm which would represent a significant
proportion of material. Furthermore, the inconsistent results obtained with high concentra-
tions of CCL2 Ala−1-alk-H in the previous migration experiments suggest this pre-incubation
may not work due to possible oligomerisation of the chemokine at high concentrations. Pre-
incubation using 250 nm recombinant CCL2 resulted in a reduction from 70% to around 20%
of the maximum for 100 nm CCL2 Ala−1-alk-H. Pre-incubation for 200 nm CCL2 Ala−1-alk-
5.2. Results and Discussion 183
(a) Response of cell migration to pre-incubation of 250 nm CCL2, using P8A-
CCL2 and P8A-alk-H.
(b) Effect of pre-incubation with 250 nm CCL2 on fluorescent CCL2 uptake.
Figure 5.13: Boyden chemotaxis transwell assay with initial 250 nm CCL2 pre-incubation to reduce surface
levels of CCR2, evaluating P8A-CCL2 and P8A-alk-H. Pre-treatment with recombinant CCL2 or unlabelled
P8A-CCL2 results in reduced migration towards both unlabelled P8A-CCL2 and P8A-alk-H indicating these
initiate chemotaxis through the CCR2 receptor. This also shows P8A-CCL2 is able to reduce surface CCR2
similarly to recombinant CCL2. The fluorescence does not greatly decrease with CCL2 pre-incubation due
to formation of a CCR2 heterogeneous population. Error bars correspond to N = 2. Untreated - no pre-
incubation. 250 nm recombinant CCL2 - pre-incubation with this dose.
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(a) Response of cell migration to pre-incubation of 250 nm recombinant CCL2,
using CCL2 Ala−1-alk-H.
(b) Effect of pre-incubation with 250 nm CCL2 on fluorescent CCL2 Ala−1
uptake.
Figure 5.14: Boyden chemotaxis transwell assay with initial 250 nm CCL2 pre-incubation to reduce surface
levels of CCR2, evaluating CCL2 Ala−1-alk-H. Pre-treatment with recombinant CCL2 results in reduced
migration towards CCL2 Ala−1-alk-H, indicating this initiates chemotaxis through the CCR2 receptor. A
similar effect was observed with the possible formation of a heterogeneous population leading to minimal
differences in fluorescence for CCL2 Ala−1-alk-H. Error bars correspond to standard error N = 2. Untreated
- no pre-incubation. 250 nm recombinant CCL2 - pre-incubation with this dose.
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H led to a reduction from 100% to around 35%, this reduction in the amount of migrated
cells is of a level close to the control cells. This result is similar to both P8A-CCL2 and
WT-CCL2 suggesting that CCL2 Ala−1 is inducing chemotaxis via CCR2 and the reduction
in chemotactic potency is due to a reduced affinity for CCR2 due to the N-terminal alanine
addition. The fluorescence median behaved in much the same manner as found with the
previous two CCL2 variants whereby a slight reduction in fluorescence median was observed,
suggesting a heterogeneous population of CCR2-bearing cells is being produced. This repre-
sents consistent fluorescence data for three separate fluorescent CCL2 variants when cells are
treated with recombinant or synthetic CCL2, suggesting these conjugates are operating as
chemokines and the effect of pre-incubation of the cells with recombinant or synthetic CCL2
is to produce a heterogeneous population of CCR2-bearing cells. Finally, similar chemotactic
inhibition was found when the experiments were performed on recombinant CCL2 demon-
strating these experiments consistently work on known systems (see Appendix, Figure 8.22).
5.2.2.2 CCL2 Conjugate Timecourse Experiments
The CCL2 variants have been extensively characterised in the transwell Boyden chemotaxis
assay and strong evidence for CCR2-mediated chemotaxis and internalisation has been pre-
sented. The steady-state between internalisation and fluorophore degradation seen in the
transwell experiments suggests this internalisation is a receptor-mediated endocytosis event
whereby the cell processes the incoming material through lysosomes which prevents further
increase of fluorescence. The next series of experiments involve incubation of the THP-1 cells
in the fluorescent chemokines over a timecourse in order to determine if a similar steady-state
is observed over time, without the involvement of a migration step. Figure 5.15a shows the
fluorescence medians resulting from incubation of THP-1 cells in media containing WT-alk-H
over 4 hours which reflects the time period of the transwell experiments. At 0 h, the fluo-
rescence median begins at around 150 A.U. due to autofluorescence, this gradually increases
to around 650 A.U. after 2 h with 10 nm WT-alk-H, demonstrating that internalisation is
occurring at a higher rate than any degradation. However, after 2 h the fluorescence only
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(a) Fluorescence timecourse of WT-alk-H.
(b) Fluorescence timecourse of P8A-alk-H.
Figure 5.15: Timecourse experiment monitoring the fluorescence median of THP-1 cells incubated in WT-
alk-H (5.15a) or P8A-alk-H (5.15b). For each CCL2 variant, the fluorescence increases from 0 - 2 h, a steady
state is then reached whereby fluorescence only modestly increases from 2 - 4 h. Concentrations of 10 and 30
nm only affect the magnitude of the curve, not the shape, suggesting an equilibrium between internalisation
of the ligand and lysosomal degradation of the fluorophore. 100 x 103 cells seeded and error bars represent
standard error at N = 2.
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increases to around 800 A.U. suggesting a steady state has been reached between these times.
The higher concentration of 30 nm WT-alk-H exhibited a similar response but at an increased
overall magnitude. This higher magnitude steady state demonstrates that this behaviour is
not just due to depletion of surface CCR2 receptors which prevent further internalisation of
fluorescent chemokine at the same rate. If this was the case, the 10 and 30 nm chemokines
would reach the same fluorescence median but the 30 nm WT-alk-H would approach this
maxima faster than the 10 nm, as the magnitude of the steady state is dictated by the cell-
surface receptor not the ligand. This is clearly not the case as both concentrations approach
the steady state after 2 h and the magnitudes of these states are different. Instead, this
provides further evidence of a steady state between internalisation and lysosomal degrada-
tion of the fluorophore which is independent of the amount of CCR2 available on the surface
of the cells. This is further supported by the inclusion of 470 nm INCB 3284, firstly this
largely diminished fluorescence profile demonstrates that the fluorescence is due to selective
CCR2-mediated uptake. Secondly, a contracted increase in fluorescence can be observed from
0 - 2 h which then equalises to form a steady state, it could be argued that after 4 h the
fluorescence then decreases but this is a very small reduction in fluorescence and is likely
within biological variation.
The P8A-alk-H variant also displayed similar behaviour (Figure 5.15b) to WT-alk-H, begin-
ning at around 150 A.U. at 0 h, this then increased to around 400 A.U. after 0.5 h for 10 nm
P8A-alk-H. This continues to increase to around 750 A.U. at 2 h and only reaches around
950 A.U. by the end of the experiment. The shape of the curve is almost identical with 30 nm
P8A-alk-H, just at a higher magnitude mirroring the behaviour of WT-alk-H. This identifies
another steady state which presents around 2 h after first stimulation with the fluorescent
chemokine suggesting that P8A-CCL2 is operating through the same underlying molecular
mechanisms as WT-CCL2. This behaviour was also observed with CCL2 Ala−1-alk-H (Fig-
ure 5.16a), after 0.5 h the fluorescence rapidly increased to around 500 A.U. which then
increased to 750 A.U. at 1 h. The increase began to slow whereby at 2 h the median reached
around 1050 A.U., this represented the beginning of a steady state. By 4 h the fluorescence
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(a) Fluorescence timecourse of CCL2 Ala−1-alk-H.
(b) Comparison of the fluorescence timecourse for WT-alk-H, P8A-alk-H and
CCL2 Ala−1-alk-H.
Figure 5.16: Timecourse experiment monitoring the fluorescence median of THP-1 cells incubated in 200 nm
CCL2 Ala−1-alk-H (5.16a). The fluorescence increases from 0 - 2 h before a steady state is reached. 100
x103 cells seeded and error bars refer to standard error for N = 2. Timecourse data overlaid for WT-alk-H,
P8A-alk-H and CCL2 Ala−1-alk-H which shows that the curves are very similar in shape and differ slightly
in magnitude (5.16b). This suggests each conjugate is internalising through the same mechanism and the
fluorophores are being degraded by the cell.
5.2. Results and Discussion 189
was only modestly increased to around 1250 A.U., suggesting that CCL2 Ala−1 also exhibits
a steady state between internalisation and lysosomal degradation. This is interesting as this
was not conclusively observed in the transwell data at the concentrations tested. The three
CCL2 variants are overlaid in Figure 5.16b for direct comparison in the timecourse exper-
iments. The similarity in the shape of the curves is evident, the only difference being the
magnitude of the curves, suggesting all chemokines are behaving similarly and each reaches
a steady state between internalisation and lysosomal degradation. The magnitude of the
CCL2 Ala−1 is perhaps unexpectedly high relative to the other sequences as 200 nm is still
at the chemotactic maxima of the compound and so should be closer to the other chemokines
in terms of fluorescence.
The next set of experiments involved further testing of the selectivity of the chemokine
conjugates towards monocytes. The previous experiments have all been performed on the
monocytic cell line THP-1 and while there is very strong evidence for CCR2-selective uptake
and migration, this could be due to some irregularity of the cell line rather than a true
result. We therefore decided to test the response of the jurkat cell line which is a lymphoycte
cell line that does not express CCR2 but will respond to other chemokines. As can be
seen from Figure 5.17, the jurkat cells do not migrate towards WT-alk-H at either 30 or 10
nm and the background level of migrated cells do not internalise the fluorescent chemokine.
The jurkat cells migrated towards CXCL12 in a dose-dependent manner which demonstrates
that the cells are able to respond chemotactically given the correct stimulus. This gives
further evidence that chemotaxis resulting from the CCL2 conjugates in the THP-1 cells
is CCR2 specific. An incubation experiment was also performed with the jurkat cells in
case the transwell experiment resulted in some unfavourable selection process through the
membrane which rendered migrated jurkat unable to internalise the fluorescent chemokine
by another CCR2 independent process. WT-alk-H, P8A-alk-H and CCL2 Ala−1-alk-H all
behaved similarly and produced fluorescence medians which coincided with the negative
control cells demonstrating that jurkat cells were unable to internalise any chemokines.
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(a) Migration of jurkat cells towards CXCL12 and WT-alk-H.
(b) Incubation of jurkat cells in the fluorescent CCL2 conjugates.
Figure 5.17: Boyden transwell chemotaxis assay using the lymphocyte cell line, jurkat, showing positive
chemotactic migration towards CXCL12 in a dose dependent manner (5.17a). Migration is then not ob-
served with the CCL2 conjugate WT-alk-H, demonstrating the selectivity of the CCL2 conjugates for CCR2-
expressing cells. Incubation of the CCL2 conjugates also does not result in internalisation of the fluorescent
chemokines, presumably due to the lack of CCR2 (5.17b). Error bars refer to standard error for N = 2.
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5.2.3 Comparison of the Properties of CCL2 Conjugates
The previous section characterised the three CCL2 constructs which resulted in determination
of chemotactic maxima both pre- and post-labelling, and also demonstrated the chemotaxis
and fluorophore internalisation was CCR2-dependent. The next stage of the project was to
determine whether the nature of the fluorophore core and the accompanying linker had any
effect on the properties described in the previous section. High concentrations of DMSO
were needed in the preparation of the remaining CCL2 conjugates and so it was important
to determine if this had a deleterious effect on the function of the chemokine. The CCL2
conjugates used are listed in Table 5.1, this summarises the reaction conditions used to form
the conjugates, this will become important in interpreting results obtained in the subsequent
experiments. Unfortunately, the difficulties encountered in these CuAAC reactions meant
that only small amounts of the CCL2 conjugates were prepared, thus a only a reduced dose
response could be measured in the Boyden chemotaxis assays.
The Boyden transwell chemotaxis assay was first used on the CCL2 Ala−1 conjugates, these
were normalised against P8A-alk-H at 3 nm which was used as a reference point and as a
positive control (Figure 5.18a). The -alk-L and -SS-L conjugates were measured at 50, 100
and 200 nm in order to generate a maximal response and to limit the amount of material
used in a larger dose response. The CCL2 Ala−1-alk-L conjugate resulted in around 40% of
maximal migration for 50 and 100 nm, the expected chemotactic maximal concentration of
200 nm actually resulted in a decrease to around 20% of the maximum migration. When these
data points are compared to the negative control (at 38% of the maximum) and accounting
for error, this suggests the CCL2 Ala−1-alk-L conjugate was not initiating much chemotaxis
of THP-1 cells in this assay. The CCL2 Ala−1-SS-L was slightly more encouraging, 50 nm
resulted in 41% of maximal migration which again could be attributed to background levels
of migrations, however slight increases for 100 and 200 nm to 52 and 56% respectively, were
observed which, even accounting for error, resembles limited chemotactic activity. The best
performing conjugate was CCL2 Ala−1-SS-H which resulted in 51% migration at 100 nm and
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Table 5.1: Summary of conditions used to form the CCL2 conjugates taken forward into biological
characterisation experiments.
Conjugate Conditions
Reaction
Completion
CCL2 Ala−1-alk-L CuSO4, Na ascorbate, DMSO Yes
CCL2 Ala−1-SS-L CuSO4, Na ascorbate, DMSO
Product and
reduced disulfide
CCL2 Ala−1-SS-H CuBr, DMSO (under N2) Yes
P8A-alk-L CuSO4,Na ascorbate, DMSO >80% product
P8A-SS-L CuBr, DMSO (under N2)
Product and
reduced disulfide
P8A-SS-H CuBr, DMSO (under N2) Yes
a strong increase to 86% of the maximal migration at the expected maxima of 200 nm. This
behaviour indicates the THP-1 cells are migrating to a concentration gradient of CCL2 Ala−1-
SS-H. The median fluorescence intensity for the CCL2 Ala−1 conjugates is displayed in
Figure 5.18b, these results were unexpected and help elucidate the behaviour observed in
Figure 5.18a. The most striking result was the greatly increased intensities observed for
CCL2 Ala−1-alk-L which reach around 68000 A.U. at 200 nm, the corresponding concentra-
tion for CCL2 Ala−1-alk-H was less than 2000 A.U. in the transwell assay. Whilst these
are different fluorophores with different properties (see Table 3.4), the higher quantum yield
of 0.63 for -alk-L and similar extinction coefficient could not explain this large increase in
fluorescence between the two conjugates. Furthermore, the concentrations of 50, 100 and
200 nm are doubling and a similar trend is observed in the respective fluorescence intensities
of CCL2 Ala−1-alk-L from 19000 to 35000 to 68000 A.U. which was not observed for the
-alk-H conjugate. This could be attributed to endosomal escape, however, the alkyl linker
and triazole ring would tether the compound to the C-terminus of CCL2 which would reduce
endosomal escape even if the peptide chain was hydrolysed by lysosomes. Therefore, the
lack of chemotactic migration of CCL2 Ala−1-alk-L and the doubling effect of the median
fluorescence intensity suggest that the chemokine is not being internalised through CCR2
and the protein is entering the cell via another process, such as pinocytosis.
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(a) Migratory responses for CCL2 Ala−1 fluorescent conjugates.
(b) Fluorescence medians of the CCL2 Ala−1 conjugates.
Figure 5.18: Migration and fluorescence responses for THP-1 cells towards CCL2 Ala−1 conjugates in the
Boyden transwell chemotaxis assay. Migration responses were normalised against P8A-alk-H (3 nm, 100%),
CCL2 Ala−1-alk-L did not appear to be chemotactic, whereas CCL2 Ala−1-SS-L appeared to have a slight
response with a stunted maxima at 200 nm. A strong response was observed with CCL2 Ala−1-SS-H with a
maxima at 200 nm. The fluorescence medians (5.18b) were highly varied with high ranges for -alk-L and -SS-L
suggesting non-specific uptake, the -SS-H conjugate exhibited medians around 2000 A.U. which correlated
with CCL2 Ala−1-alk-H. Error bars refer to standard error of N = 2.
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CCL2 Ala−1-SS-L did not exhibit median fluorescence intensities as high as CCL2 Ala−1-alk-
L, with 3000, 7500 and 10000 A.U. for 50, 100 and 200 nm, respectively. The fluorescence
intensities are not always doubling in proportion to the doubling of concentration of the
chemokine suggesting the cell has some control over the fluorescence intensity, unlike the
observations found with CCL2 Ala−1-alk-L. It is possible that the -SS-L fluorophore is able
to avoid lysosomal degradation via endosomal escape due to reduction of the disulfide linker
which liberates the lipophilic fluorophore from the protein leading to increased fluorescence.
The final conjugate, CCL2 Ala−1-SS-H exhibited median fluorescence intensities which re-
sembled CCL2 Ala−1-alk-H in terms of magnitude and also the trend from 100 to 200 nm.
The similarity in fluorescence intensity and the chemotactic migration suggest this conjugate
is functioning as a chemokine and is highly similar to CCL2 Ala−1-alk-H. Interestingly, de-
spite the disulfide bond in CCL2 Ala−1-SS-H, the median fluorescence intensity at 100 and
200 nm still closely matches CCL2 Ala−1-alk-H, this suggests that the fluorophore cannot
escape the endosome after the disulfide bond is reduced due to the hydrophilicity of the
fluorophore. This means that the BODIPY undergoes lysosomal degradation, preventing the
fluorescence intensity from increasing in proportion to concentration of the chemokine in the
same manner as CCL2 Ala−1-alk-H.
Chemotactic responses for P8A-CCL2 conjugates are displayed in Figure 5.19a, generally
these conjugates performed better than the CCL2 Ala−1 conjugates. The P8A-alk-L conju-
gate exhibited a maximal response at 3 nm at 69% which decreased to 51% at 10 nm. This
did not reach the same amount of migrated cells as P8A-alk-H but was dose-dependent indi-
cating a level of chemotaxis that may be weaker than P8A-alk-H. The P8A-SS-H conjugate
exhibited a clear chemotactic dose-dependent response; the maxima of 98% at 3 nm matches
the P8A-alk-H maxima and this gradually decreases to 65% at 10 nm and 38% at 30 nm.
The P8A-SS-L conjugate attained 111% of maximal migration at 3 nm which then rapidly
decreased to 52% and 45% at 10 and 30 nm respectively, demonstrating the dose-dependent
chemotactic response.
The median fluorescence intensity is displayed in Figure 5.19b, P8A-alk-L fluorescence is at
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(a) Migratory responses for P8A-CCL2 fluorescent conjugates.
(b) Fluorescence medians of the P8A-CCL2 conjugates.
Figure 5.19: Migration and fluorescence responses for THP-1 cells towards P8A-CCL2 conjugates in the
Boyden transwell chemotaxis assay. Migration responses were normalised against P8A-alk-H (3 nm), All con-
jugates appeared to be chemotactic, however P8A-alk-L only reached around 70% of the maximum response.
The fluorescence medians (5.19b) were generally of similar ranges to P8A-alk-H apart from P8A-SS-L which
continued to increase. Error bars refer to N = 2.
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328 and 397 A.U. for 3 and 10 nm respectively, this is minimally greater than autofluorescence
(232 A.U.). This suggests P8A-alk-L is weakly chemotactic and internalisation is also only
minimal. The P8A-SS-H conjugate exhibited fluorescence of a similar magnitude to P8A-alk-
H, this in combination with the migration data, suggests this conjugate is functioning as a
chemokine in a similar manner to P8A-alk-H. Interestingly, the intensity at 3 nm is lower than
P8A-alk-H and this only modestly increases from 10 to 30 nm to a level commensurate with
P8A-alk-H at 3 nm. The fluorescence is reaching a steady state suggesting the fluorophore
is degraded and is not able to escape endosomes which was also observed with CCL2 Ala−1-
SS-H. The free fluorophore is then degraded more rapidly by lysosomes than the P8A-alk-
H fluorophore which is still bonded to CCL2 and is potentially sterically protected from
degradation. The clear outlier in median fluorescence intensity is P8A-SS-L, at 3 nm the
fluorescence is 715 A.U., this then rapidly increases to 2275 A.U. and 5126 A.U. at 10 and
30 nm, respectively. This trend suggests the disulfide is being reduced enabling endosomal
escape of the lipophilic fluorophore and so lysosomal degradation is avoided resulting in
the concentration of fluorescent BODIPY increasing over time as further chemokines are
internalised.
These results suggested that the following conjugates were functioning correctly: CCL2 Ala−1-
SS-H, P8A-SS-H and P8A-SS-L. The CCL2 Ala−1-alk-L and P8A-alk-L are probably not
functioning correctly and CCL2 Ala−1-SS-L was weakly chemotactic but not to the extent
of the clearly successful conjugates. Correlating these results with the data presented in Ta-
ble 5.1 presents a common theme between these less-effective conjugates, all were prepared
using DMSO in combination with sodium ascorbate. Chapter 4 indicated that sodium ascor-
bate is capable of reducing disulfide bonds, this was particularly observed with the disulfide
bonds in the fluorophores but it is possible that the sodium ascorbate could also reduce
the internal disulfide bonds of CCL2. All the CCL2-alk-H variants contained sodium ascor-
bate in the reaction, however, these conjugates functioned correctly in terms of chemotaxis
and CCR2-dependence. It is therefore possible that the combination of DMSO and sodium
ascorbate results in permanent denaturation of CCL2 to an inactive form. In the absence of
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DMSO, the sodium ascorbate either is unable to reduce the disulfide bonds of CCL2 due to
the folding of the protein or does reduce the bonds momentarily but the conserved tertiary
structure of CCL2 holds the cysteines in place such that they oxidise correctly and the cor-
rect folding of the protein is maintained. In the presence of DMSO, CCL2 unfolds and if the
disulfides are intact, CCL2 can refold correctly after dialysis (which is likely the case with
the successful conjugates). The combination of DMSO and sodium ascorbate on the other
hand leads to unfolding of the protein and reduction of the disulfides, the linear peptide may
then re-oxidise with the disulfides in the incorrect orientation leading to misfolding to an
inactive CCL2 species. This scenario would explain the results observed in the chemotaxis
assay. One explanation for CCL2 Ala−1-SS-L being partially chemotactic is that the large
excess of BODIPY-disulfide relative to CCL2 protects the internal disulfides of CCL2 from
reduction as the majority of sodium ascorbate reduces the fluorophore and Cu(II), leaving a
percentage of CCL2 folded correctly and another folded incorrectly.
At this stage the activity of the CCL2 Ala−1-FRET conjugate was also measured, unfortu-
nately this conjugate yielded many inconsistent results. The fluorescence spectra was promis-
ing in that the conjugate appeared to be acting as a FRET pair (see Appendix Figure 8.23),
however, when this conjugate was used in a confocal microscopy system designed to detect
FRET signals no FRET signal was observed (data not shown) and some false-positive signals
were also detected. Furthermore, the transwell migration data for this compound was poor.
It was clear that this research path required extensive optimisation and based on the positive
findings from the other CCL2 conjugates it was decided not to pursue this route further.
The single fluorophore conjugates were then further characterised using the CCR2 antago-
nist INCB 3284, this would determine whether the chemotaxis was CCR2 dependent and
could aid in explaining some of the ambiguous results encountered in the chemotaxis assays.
Furthermore, with the disulfide-linked conjugates, it is possible that the median fluorescence
intensity may not decrease in the presence of inhibitor to the same magnitude encountered
with the alkyl-linked conjugates. Figure 5.20 shows migration and fluorescence data for the
CCL2 Ala−1 conjugates, normalisation to the non-inhibited cells was not used in these ex-
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(a) Migratory responses for CCL2 Ala−1 fluorescent conjugates post-INCB 3284
treatment.
(b) Fluorescence medians of the CCL2 Ala−1 conjugates post-INCB 3284 treat-
ment.
Figure 5.20: Migration and fluorescence responses for THP-1 cells towards CCL2 Ala−1 conjugates in the
Boyden transwell chemotaxis assay when inhibited with INCB 3284. Migration responses were inhibited in
the presence of the INCB 3284, except with -alk-L, suggesting the migration observed previously was due
to CCR2. The fluorescence medians (5.20b) were similarly inhibited except for CCL2 Ala−1-SS-L which did
not alter in the presence of INCB 3284 and also CCL2 Ala−1-alk-L. Negative control uninhibited: migration
= 8944 ±2533, fluorescence = 154 ±3. Inhibited: migration = 9722 ±2108, fluorescence = 151 ±2. Error
bars refer to N = 2.
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periments due to the weak migratory responses for some conjugates which were not clear
post-normalisation. The positive control, CCL2 Ala−1-alk-H, functioned correctly resulting
in 57000 migrated cells which was then inhibited by 470 nm INCB 3284 to 18000. The level
of migration observed with the CCL2 Ala−1-alk-L conjugate had little difference between in-
hibition and no inhibition. Only 21000 cells were recruited when no INCB 3284 was present
and when accounting for error, INCB 3284 appeared to have little effect. Furthermore, the
migration to this conjugate was not particularly higher than the negative controls, these
results suggest that CCL2 Ala−1-alk-L is not functioning as a chemokine and the CCR2
antagonist has little effect on the conjugate’s function. The CCL2 Ala−1-SS-H conjugate
was more promising, 33000 cells migrated when uninhibited before decreasing to 15000 cells
upon treatment with 470 nm INCB 3284 suggesting CCL2 Ala−1-SS-H initiates chemotaxis
in a CCR2-dependent manner. In the previous chemotaxis assay, CCL2 Ala−1-SS-L was
weakly chemotactic and it was not clear whether this due to this conjugate operating in a
conventional chemotactic manner. Treatment with 470 nm INCB 3284 led to a reduction
in the number of migrated cells from 30000 to 10000 cells, indicating that chemotaxis was
affected by INCB 3284. The median fluorescence intensities highlighted clear differences in
how the conjugates responded to inhibition, for example, CCL2 Ala−1-alk-H was inhibited
to the same extent determined previously. CCL2 Ala−1-SS-H was almost identical in that
CCR2 antagonism resulted in a decrease in intensity of over 50%. This provided more evi-
dence to suggest that disulfide linkers aid endosomal escape but this can be limited by the
hydrophilicity of the compound. The CCL2 Ala−1-alk-L conjugate exhibited extremely high
median fluorescence intensities, as found in the previous experiments, and the small reduction
in intensity is likely within error. When compared with the poor migration data, the logical
conclusion follows that this CuAAC reaction has been unsuccessful in producing functional
CCL2. The CCL2 Ala−1-SS-L conjugate is interesting because there is minimal difference
in fluorescence intensity whether CCR2 is inhibited or not. The migration of THP-1 cells
towards this conjugate was inhibited with INCB 3284, the lack of effect on fluorescence is
therefore due to disulfide linker reduction and cytoplasmic distribution of the fluorophore.
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Whilst the rate of internalisation has been reduced as fewer CCR2 receptors are available,
any fluorophore that is internalised can avoid lysosomal degradation through endosomal es-
cape. This causes the concentration of intact BODIPY to gradually increase over time and
reach levels of fluorescence approaching the uninhibited cells.
The responses of the P8A-CCL2 conjugates to INCB 3284 were then measured and these re-
sults were generally more consistent and more clearly indicated CCR2-dependency than the
CCL2 Ala−1 conjugates. Figure 5.21 shows the strong chemotactic response of P8A-alk-H
when not inhibited, this is greatly reduced when treated with increasing concentrations of
INCB 3284. As expected from the previous chemotaxis assays on these conjugates, P8A-alk-L
elicited a weak chemotactic response when not inhibited. CCR2 inhibition actually increased
the level of migration with this conjugate, although the large amount of error found with P8A-
alk-L suggests this is within error and CCR2 inhibition has little effect on THP-1 migration
towards P8A-alk-L. Similarly, the low median fluorescence intensities for this conjugate only
slightly reduced in response to CCR2 antagonism, suggesting P8A-alk-L is not fully func-
tional as a chemokine and the CuAAC reaction was unsuccessful. P8A-SS-H was strongly
chemotactic when not inhibited and this was greatly reduced in a dose-dependent manner
in response to INCB 3284, indicating the chemotaxis was CCR2-dependent. The median
fluorescence intensity for this conjugate was relatively low (possibly due to the aforemen-
tioned instability of the free fluorophore), however, relatively large reductions in fluorescence
intensity can be seen with increasing CCR2 inhibition. This migration and fluorescence data
provides evidence that this conjugation was successful and P8A-SS-H is initiating chemotaxis
and internalisation via CCR2. Migration in response to P8A-SS-L was inhibited by INCB
3284 in a dose dependent manner in proportion to P8A-SS-H. The fluorescence intensities
were similar to the behaviour observed with CCL2 Ala−1-SS-L, whereby CCR2 antagonism
did not greatly reduce fluorescence intensity. This provides another example where disulfide-
linked lipophilic fluorophores do not lead to decreased fluorescence in response to CCR2
antagonism. As before, this is likely due to the remaining CCR2 receptors internalising
the conjugate, the fluorophore can then localise outside of endosomes and the fluorescence
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(a) Migratory responses for P8A-CCL2 fluorescent conjugates post-INCB 3284
treatment.
(b) Fluorescence medians of the P8A-CCL2 conjugates post-INCB 3284 treat-
ment.
Figure 5.21: Migration and fluorescence responses for THP-1 cells towards P8A-CCL2 conjugates in the
transwell chemotaxis assay with INCB 3284 treatment. Migration responses were all inhibited in the presence
of the INCB 3284 except for P8A-alk-L. The fluorescence medians (5.20b) were similarly inhibited except for
CCL2 Ala−1-SS-L which did not alter in the presence of INCB 3284. Negative control uninhibited: migration
= 17976 ±1054, fluorescence = 149 ±3. 470 nm INCB: migration = 18523 ±1120, fluorescence = 145 ±2.
Error bars refer to N = 2.
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gradually increases to approach non-inhibited levels.
5.2.4 Uptake of CCL2 Conjugates in White Blood Cells
The previous experiments highlighted P8A-SS-H and P8A-SS-L as successful CCL2 conju-
gates which can effectively accompany the other alkyl-linked conjugates discussed in 5.2.2 in
further experiments. These conjugates were therefore taken forward with CCL2 Ala−1-alk-H,
WT-alk-H and P8A-alk-H into flow cytometric experiments with primary human white blood
cells. The purpose of using flow cytometry was to determine the selectivity of the CCL2 con-
jugates towards monocytes and whether any labelling is correlated with CCR2 expression.
Furthermore, the use of human primary cells allows more reliable conclusions to be drawn as
the ex vivo cells are more representative of the in vivo environment than the immortalised
secondary cell lines. Firstly, blood from healthy donors was taken, PBMCs were isolated as
well as neutrophils, these populations were mixed and treated with 30 nm WT-alk-H for 1
h. The cells were then labelled with monoclonal antibodies including anti-CD3, anti-CD14
and anti-CD15 to identify lymphocyte, monocyte and neutrophil populations respectively.
Figure 5.22 shows the gating strategy to identify uptake of WT-alk-H in neutrophils; firstly
neutrophils were gated based on physical characteristics and the BODIPY fluorescence is
then plotted against fluorescence of the aforementioned antibodies to identify which popula-
tions are internalising the chemokine. The fluorescence minus one (FMO) plots show that the
population cloud consists of CD15-positive neutrophils which should not respond to CCL2
and thus not internalise WT-alk-H. This effect can be seen in the WT-alk-H plot whereby
no increase in green fluorescence was observed in any gated population. The FSC/SSC gate
was then moved to the lymphocyte/monocyte cloud and the same gating strategy was used
to assess uptake of WT-alk-H across these cells (Figure 5.23). As expected, CD14-positive
monocytes clearly internalised the WT-alk-H conjugate resulting in the shift of the CD14-
positive population to the BODIPY/CD14 double positive quadrant. Interestingly, uptake
of WT-alk-H was observed in CD3-positive lymphocyte population, it was not clear which
lymphocyte subset was causing this behaviour and so further experiments were devised to
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explore this phenomenon.
Figure 5.22: Neutrophils are first gated based on physical characteristics such as increased granularity (A),
singlet events are selected (B) and dead cells are excluded (C). Matched isotype controls for CD3, CD14 and
CD15 directed placement of quadrants for cells untreated with WT-alk-H (IMC). FMO techniques highlight
the population consists of CD15-positive neutrophils (FMO). Cells treated with the chemokine show no
increase in green fluorescence in any of the gated populations (WT-alk-H).
To further characterise the uptake of CCL2 conjugates across monocyte and lymphocyte
populations, experiments were designed to gate populations of classical, intermediate and
non-classical monocytes, as well as lymphocyte populations of T cells, NK cells and NKT
cells. The gating strategy to assess CCL2 conjugate labelling of monocyte subsets was de-
vised according to the work of Abeles et al., using CD14, CD16 and HLA-DR expression to
positively include the monocyte subsets.255 This gating strategy is displayed in Figure 5.24,
firstly the monocyte cloud is gated on physical characteristics using FSC against SSC (A).
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Figure 5.23: The monocyte/lymphocyte population was gated based on physical characteristics (A), singlet
events were selected (B) and dead cells are excluded (C). The same antibody labelling strategy as Figure 5.22
was used to identify monocytes, lymphocytes and neutrophils. The majority of the monocyte population were
positive for WT-alk-H and a small subset of lymphocytes were also positive.
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Figure 5.24: Flow cytometry gating strategy for monocyte subsets using CD14, CD16 and HLA-DR. Mono-
cytes were selected based on physical characteristics (A). ‘True’ monocytes are positively gated using HLA-DR
against CD14 (B) using matched isotype controls to direct placement of gates. Monocytes were positively
selected with fluorescence minus one (FMO) techniques utilised to minimise bleedthrough issues with CCL2-
BODIPY (C). Surface markers CD14 and CD16 labelling allowed classical, intermediate and non-classical
monocytes to be gated (D). These individual populations were then assessed in terms of CCR2 expression
and CCL2-BODIPY labelling as follows: non-classical (E), intermediate (F) and classical (G).
Monoclonal antibody labelling of the surface markers CD14 and HLA-DR were then used to
gate for ‘true’ monocytes, this was performed with reference to a matched isotype control
(B). The gated population then positively selected the monocytes (C) using FMO techniques,
this refers to inclusion of all monoclonal antibodies but not fluorescent CCL2 meaning any
fluorescence from CCL2 conjugates is due to the BODIPY fluorophore, not a bleedthrough
artifact. Finally, CD14 and CD16 were used to identify monocyte subsets (D), showing the
three subsets: CD14+CD16− (Classical), CD14+CD16+ (Intermediate) and CD14−CD16+
(Non-classical). The three subsets were individually interrogated in terms of CCR2 expres-
sion and CCL2-BODIPY labelling (E, F and G), here the CCR2 expression is shown to be
distinct between subsets, for example, classical and intermediate monocytes express high
levels of CCR2 and non-classical are generally low in CCR2. The different densities of the
plots can be attributed to the relative numbers of the populations, for example, classical
monocytes are the most-prevalent monocytes in peripheral blood and this is illustrated in
the high density of cells in these plots.
5.2. Results and Discussion 206
Figure 5.25 shows the extent of CCL2 conjugate labelling of the three monocyte subsets, the
double positive gates were selected on the basis of FMO. In this experiment, CCL2 Ala−1-
alk-H was used at 200 nm and all other conjugates were used at 30 nm, this was based on
the lower affinity of CCL2 Ala−1 for CCR2. Using 30 nm for the other conjugates was due
to this lower concentration being near the chemotactic maxima for these sequences, however,
the maxima at 3 and 10 nm for WT-alk-H and P8A-alk-H were difficult to detect in these
experiments and so the higher concentration of 30 nm was selected. CCL2 Ala−1-alk-H did
not greatly affect surface CCR2 levels on the classical monocytes, however a clear increase
in green fluorescence can be seen for CCR2 positive cells. This was also observed in the
intermediate monocytes although to a lesser extent. Heterogeneity was observed in this pop-
ulation where cells with lower CCR2 expression exhibited diminished CCL2 labelling. The
non-classical monocytes were also heterogeneous whereby cells with higher CCR2 expression
exhibited higher CCL2 labelling and cells negative in CCR2 giving no CCL2 Ala−1-alk-H la-
belling. This data suggests that this conjugate is uptaken only by CCR2-positive monocytes,
with a preference for classical and intermediate monocytes. The WT-alk-H conjugate had a
stronger effect on surface CCR2 levels relative to FMO, suggesting the chemokine was bind-
ing CCR2 and reducing surface levels of the receptor. Similar population heterogeneities were
observed in intermediate monocytes with WT-alk-H whereby a proportion of the population
exhibited lower CCR2 expression and concurrently no WT-alk-H labelling. Interestingly, the
population of non-classical monocytes high in CCR2 were labelled with WT-alk-H and the
level of surface CCR2 was reduced relative to cells treated with CCL2 Ala−1-alk-H, suggest-
ing WT-alk-H had a greater effect on CCR2 than CCL2 Ala−1-alk-H. The effect on CCR2
with P8A-alk-H treated cells appeared to be greater still, for example, the classical mono-
cytes were clearly labelled with P8A-alk-H to a greater extent than WT-alk-H and similarly
the CCR2 surface levels were also diminished. This trend of increasing fluorescence from
CCL2 Ala−1 to WT-CCL2 to P8A-CCL2 is consistent with the THP-1 chemotaxis assays as
this trend reflects the relative affinities of the chemokines.
A noteworthy observation is that CCL2 Ala−1-alk-H, despite the concentration being almost
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Figure 5.25: Density plots of cells treated with CCL2 conjugates in positively gated classical, intermediate
and non-classical monocytes based the strategy presented in Figure 5.24. P8A-alk-H exhibited the strongest
BODIPY labelling of the three alkyl-linked conjugates and the largest effect on CCR2-surface expression,
followed by WT-alk-H and CCL2 Ala−1-alk-H. A clear preference for classical monocytes was observed,
followed closely by intermediate, with non-classical monocytes having the lowest amount of CCL2-labelling.
The disulfide linked conjugates behaved similarly with the exception of P8A-SS-L labelling CCR2-negative
cells, likely as a result of leaching.
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ten-fold higher than the other variants, still exhibited a reduction in fluorescence. This
difference in CCR2 binding affinity is also indicated by the effects on surface CCR2 across
the three chemokines in all three subsets, this provides more evidence that the chemokine
conjugates operate through CCR2-binding and the extent of labelling of these cells is due to
relative affinities for the CCR2 receptor. The relative behaviour of the P8A-CCL2 conjugates
was similar in terms of selectivity towards classical and intermediate monocytes over non-
classical monocytes, and also the relationship between BODIPY labelling and surface levels
of CCR2 pre- and post-CCL2 labelling. Some contrasting behaviour was apparent in the
disfulfide-linked conjugates, however, P8A-SS-H exhibited a lower level of BODIPY labelling
relative to P8A-alk-H despite a similar level of CCR2-levels on the surface of the classical
and intermediate monocytes. This suggests the chemokine is being uptaken by CCR2 to a
similar extent but the properties of the conjugate are altering the level of fluorescence inside
the cell. This is consistent with data presented in Figure 5.19, where P8A-SS-H did not
exhibit as high median fluorescence intensity as P8A-alk-H and that fluorescence intensity did
not increase with concentration relative to P8A-alk-H, possibly due to fluorophore stability
post-disulfide reduction. The P8A-SS-L conjugate on the other hand was very different, this
compound exhibited a greater level of fluorescence in the classical monocytes and an even
greater effect on CCR2 surface levels. The high level of BODIPY labelling in P8A-SS-L
was likely due to endosomal escape due to the lipophilicity of the fluorophore, evidence for
this behaviour was observed in Figure 5.19 whereby median fluorescence intensity greatly
increased with concentration and did not reach a steady state as was found in the other
conjugates. The intermediate monocytes exhibited further differences and a large amount of
heterogeneity both in terms of BODIPY labelling and CCR2 levels. The major population
behaved identically to classical monocytes with a population of cells with decreasing CCR2
and BODIPY labelling which was also observed in the other conjugates. However, a handful
of events can be observed in the CCR2-negative/BODIPY-positive quadrant suggesting a
small amount of uptake by CCR2-negative intermediate monocytes. This could be due to
complete depletion of surface CCR2 to IMC levels or leaching of the lipophilic fluorophore
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out of the initial cell and into nearby cells, resulting in labelling of CCR2-negative cells. The
classical monocytes do not appear to be affected as this population are homogeneous in terms
of CCR2 and so any free fluorophore which leaches into these cells is not easily detected. The
intermediate monocytes and non-classical monocytes, however, are heterogeneous in CCR2
and so CCR2-negative cells which absorb leached fluorophore are more clearly observed.
Figure 5.26 quantitatively describes the preferential uptake of the CCL2 conjugates towards
classical monocytes, with intermediate monocytes closely behind. All conjugates except
CCL2 Ala−1-alk-H effectively labelled all classical monocytes, with CCL2 Ala−1-alk-H reach-
ing 77% of the population likely as a result of the reduced affinity of this peptide for CCR2.
Intermediate monocytes were labelled to around 70% of the population with P8A-alk-H being
the highest at 77% followed by WT-alk-H, P8A-SS-H and P8A-SS-L; again, CCL2 Ala−1-
alk-H labelled around 50% of the intermediate population. The reason for the intermediate
monocytes being labelled to a lesser extent is clear from the heterogeneity of CCR2 expres-
sion (Figure 5.25), this suggests CCL2 uptake is mitigated by CCR2. Finally, non-classical
monocytes were poorly labelled by all conjugates indicating a selectivity of the CCL2 conju-
gates for classical and intermediate monocytes. Figure 5.26b highlights a negative correlation
between CCR2 surface levels and BODIPY fluorescence. As CCR2 is high, the level of CCL2-
BODIPY uptake is low and as the CCL2-BODIPY uptake increases (to P8A-SS-L intensities)
the CCR2 MFI decreases suggesting the CCR2 receptor is being depleted by the chemokine
conjugates. The fitted line has a reasonable R2 which is only adversely affected by the
reduced MFI of P8A-SS-H. The intermediate population exhibited a similar negative correla-
tion between CCR2 MFI and BODIPY MFI (Figure 5.27a) with a similar R2 fitted line. The
gradient of this line was slightly reduced relative to the classical population suggesting the
BODIPY fluorescence does not increase as rapidly as the CCR2 receptor is depleted. The
non-classical monocyte population was quite different to the preceding populations; the neg-
ative correlation was still present but the gradient was reduced (Figure 5.27b). Furthermore
the line of best fit was relatively poor as a result of the P8A-SS-H outlier which has been ob-
served throughout these data. The plot indicates that surface CCR2 is being depleted more
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(a) Dual CCR2/BODIPY percentage for CCL2 conjugates across monocyte sub-
sets
(b) MFI of CCR2 against BODIPY in classical monocytes
Figure 5.26: Comparison of classical, intermediate and non-classical monocytes in the BODIPY/CCR2 dual
positive quadrant, showing clear preferential uptake in classical and intermediate monocytes (5.26a). FMO
CCR2 expression level: 99.98, 70.90 and 19.67% for classical, intermediate and non-classical monocytes
respectively. 5.26b shows MFI for CCR2 against BODIPY for classical monocytes, indicating a negative
correlation between CCR2 and BODIPY, as a result of ligand depletion of the CCR2 receptor. Data is
representative of N=1.
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(a) MFI of CCR2 against BODIPY in intermediate monocytes
(b) MFI of CCR2 against BODIPY in non-classical monocytes
Figure 5.27: 5.27a shows MFI for CCR2 against BODIPY for intermediate monocytes, indicating a negative
correlation between CCR2 and BODIPY (which was also found in classical monocyte populations) suggesting
increased uptake of CCL2 conjugates depletes CCR2. 5.27b exhibited a weaker negative correlation with poor
R2, mostly due to the P8A-SS-H outlier. Data is representative of N=1.
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strongly by the P8A conjugates but only a modest increase in BODIPY MFI is occurring as
a result.
Figure 5.28: Gating strategy to define T cells, NK cells and NKT cells. Lymphocyte populations defined
physically (A) and singlet events were positively gated (B). Matched isotype controls directed gate placement
for CD3 and CD56 expression (C). FMO techniques presented positive lymphocyte sub-populations which
were further gated (D). The defined populations were then characterised in terms of CCR2 expression relative
to BODIPY (Bottom, FMO).
Initial flow cytometry experiments using PBMCs revealed labelling of the CCL2-BODIPY
conjugates in some CD3+ lymphocyte populations, further experiments were therefore de-
signed to probe the nature of this sub-population. Interestingly, a number of CCR2-positive
lymphocyte sub-populations have been identified in the literature including effector memory
CD4+ T cells, NK subsets and NKT cell sub-populations.256–258 In consideration of these
studies, it was decided to segregate the lymphocyte population into T cell, NK cell and NKT
cell using CD3+CD56−, CD3−CD56+ and CD3+CD56+ antibody labelling respectively. Fig-
ure 5.28 highlights the gating strategy used to define these populations, firstly, the lympho-
cyte cloud was selected based on physical characteristics (A) and the pulse width ensured
events were singlets (B). Lymphocyte subsets were then defined through differential CD3
and CD56 expression, gates were aligned using matched isotype controls (C) and positive
populations were selected using FMO techniques (D). The FMO density plots then display
the surface CCR2 level for each population, this highlighted that each population contained
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CCR2+ subsets to varying extents, with the NKT cells containing the highest proportion of
CCR2+ cells.
Figure 5.29 shows the extent of labelling of the T cell, NK cell and NKT cell populations
and the effect on surface CCR2 post-labelling. CCL2 Ala−1-alk-H caused a slight increase in
BODIPY fluorescence intensity in only the CCR2-positive cells showing that uptake of this
chemokine in lymphocytes was CCR2-dependent and all three subsets displayed a modest
increase in BODIPY intensity. The WT-alk-H conjugate gave a greater increase in BODIPY
fluorescence intensity in the same CCR2+ populations which highlighted the difference in
affinity for CCR2 between these peptides which provided further evidence this CCL2 uptake
was due to CCR2. Similarly, P8A-alk-H also increased the BODIPY intensity and this was
accompanied by a notable reduction in surface CCR2 in NKT cells, NK and T cells. The P8A
conjugates were again interesting in that the P8A-SS-H conjugate greatly reduced surface
CCR2 but was accompanied by only a modest increase in BODIPY intensity which varied
across the lymphocyte populations. For example, the NKT cells and the T cells yielded a
similar level of BODIPY intensity and surface CCR2, however, the NK cells exhibited a much
greater level of both BODIPY intensity and surface CCR2. Further evidence for leaching of
the P8A-SS-L fluorophore out of the initial cell and into neighbouring cells was observed in
lymphocytes. In the NKT cell population, the CCR2-negative BODIPY-positive population
could just be a result of very effective depletion of surface CCR2 to CCR2-negative intensities,
and a similar phenomena could be observed in the other subsets. However, in the NK cells,
for example, the large CCR2-negative population (pre-chemokine treatment) is clearly shifted
to increased BODIPY intensity. Similar arguments can be made for the T cell and NKT cell
CCR2− subset, this suggests that the P8A-SS-L fluorophore is indeed being liberated from
endosomes and subsequently leaching into CCR2− cells.
The percentage of CCR2/BODIPY dual positive events (Figure 5.30) is more difficult to
interpret correctly with the lymphocytes than the monocyte populations described previously
due to the CCR2-expression heterogeneity. For example, a clear preference can be seen for
NKT cells where high proportions of the NKT subset were labelled by BODIPY in the
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Figure 5.29: Density plots of lymphocyte populations gated into T cell, NK cell and NKT cells with surface
CCR2 labelling against CCL2-BODIPY labelling for CCL2 conjugates. All lymphocyte subsets displayed
heterogeneity in terms of CCR2 expression and this CCR2-positive population was labelled by all CCL2
conjugates. Some CCR2 negative populations were BODIPY-positive, however, this was likely due to ligand-
mediated depletion of the receptor and in the case of P8A-SS-L the labelling of CCR2− cells was likely due
to fluorophore leaching.
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(a) Dual CCR2/BODIPY percentage for CCL2 conjugates across lymphocyte
subsets.
(b) Percentage of BODIPY-positive cells in each gated sub-population.
Figure 5.30: Comparison of T cell, NK cells and NKT cells in the BODIPY/CCR2 dual positive quadrant,
showing clear preferential uptake in NKT cells (Figure 5.31). FMO CCR2 expression level: 10.11 , 1.42 and
83.47% for T cells, NK cells and NKT cells respectively. 5.30b displays the global percentage of BODIPY
across the T cell, NK cell and NKT cell populations which exhibit a clear preference for NKT cells in all CCL2
conjugates. P8A-SS-L exhibits uptake in the NK cells and T cells as a result of fluorophore lipophilicity and
leaching. Data is representative of N=1.
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majority of CCL2 conjugates, however, this is as a result of the CCR2-positive NKT subset
being the largest subset of the NKT cells. On the other hand, the NK population is mostly
CCR2-negative and so the CCR2/BODIPY dual positive population is relatively small but
the BODIPY MFI is in fact higher than the NKT subset. The correct interpretation of
these results would be that the CCL2 conjugates are generally selective for NKT cells due
to the large proportion of CCR2+ cells in this subset and the overwhelming majority of
T cells and NK cells do not possess surface CCR2 and are therefore not labelled by the
CCL2 conjugates. The small proportion of T cells and NK cells which are CCR2+ are
labelled by the CCL2 conjugates to a similar extent as the CCR2+ NKT cells. The exception
to this trend is P8A-SS-L which was only 3.6% CCR2/BODIPY dual positive, this can be
explained by the comparison with Figure 5.29 where the NKT cells are clearly being depleted
of surface CCR2 by a large amount relative to FMO, moving these cells to a BODIPY
positive/CCR2− population. Another factor is P8A-SS-L labelling of formally CCR2− cells
most likely as a result of leaching into these cells due to the physicochemical properties of the
linker-fluorophore system. This behaviour is effectively illustrated in Figure 5.30b whereby
preference for NKT cells is clear in all conjugates but P8A-SS-L was more promiscuous across
cell types, again, most likely due to extracellular leaching.
Analysis of the relationship between surface CCR2 and BODIPY fluorescence intensity is
displayed in Figure 5.31, a negative correlation was present between surface CCR2 and uptake
of CCL2 conjugates in lymphocyte populations. The MFI of BODIPY was generally higher in
the NK cells than T or NKT cells suggesting the conjugates were more effectively internalised
in NK cells. Interestingly, the surface CCR2 rapidly decreases across the conjugates in both
T and NKT cells, however, the BODIPY fluorescence does not increase at the same rate.
This suggests CCR2 is being depleted but the fluorescent chemokines are either not being
internalised or any internalised fluorophores are rapidly degraded.
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(a) Dual MFI CCR2/BODIPY of the T cell sub-population.
(b) Dual MFI CCR2/BODIPY of the NK cells.
(c) Dual MFI CCR2/BODIPY of the NKT cells.
Figure 5.31: Relationship between CCR2 and CCL2-BODIPY uptake in T cell, NK cell and NKT cell
populations. Dual MFI of CCR2 against BODIPY reveals a negative correlation between surface CCR2 and
CCL2-BODIPY fluorescence intensity, akin to the behaviour in monocytes but the correlation is weaker. NK
cells had the strongest correlation and best R2 for the fitted line, clearly demonstrating the CCL2 conjugates
deplete the surface receptor. Data is representative of N=1.
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5.2.5 Fluorescence Microscopy with CCL2 conjugates
The fluorescent CCL2 conjugates have been extensively characterised in both primary human
PBMCs and the secondary THP-1 cell line, both in terms of chemotaxis and the CCR2-
selective internalisation pathway. The behaviour of these fluorescent systems inside cells
was then determined using fluorescence microscopy to investigate whether the nature of
fluorophore or linker system had any effect on sub-cellular localisation in both THP-1 cells
and PBMCs. Initially, THP-1 cells were incubated in media containing either of the five
CCL2 conjugates for 2 h before the cells were mounted onto glass coverslips via cytospin
and fixed in para-formaldehyde (pFA). The 2 h incubation time was selected on the basis
of timecourse experiments which showed fluorescence generally did not greatly increase after
this time. The nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI) to ascertain
that BODIPY fluorescence is excluded from the nucleus. Images were captured on a Zeiss
Axio Observer, this microscope simulates confocal microscopy through utilising diffraction
grating to distort a grid over topological abberations, these deformations allow for optical
sectioning of the cells, any fluorescence was therefore originating from inside the cell. The
images were captured as follows: five slices were captured through the cell and maximum
intensity projections averaged the distribution of fluorescence intensity throughout the slices
into a single 2d image.
Figure 5.32 shows fluorescence microscopy images from THP-1 cells treated with the alkyl-
linked CCL2 conjugates CCL2 Ala−1-alk-H, WT-alk-H and P8A-alk-H. The low level of aut-
ofluorescence originating from the negative control suggests that increases in fluorescence
originating from cells treated with CCL2-conjugates is resulting from the conjugated fluo-
rophore not any endogenous fluorescent species. In CCL2 Ala−1-alk-H, the green channel
exhibited mainly circular regions of fluorescence that resemble vesicle structures and the
previous chemotaxis assays suggested a steady state between internalisation and lysosomal
degradation of the BODIPY fluorophore meaning the vesicles are likely to be endosomes or
lysosomes. The majority of the fluorescence is outside the nucleus in all conjugates, however,
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(a) THP-1 cells treated with CCL2 Ala−1-alk-H.
(b) THP-1 cells treated with WT-alk-H.
(c) THP-1 cells treated with P8A-alk-H.
(d) Unlabelled THP-1 cells.
Figure 5.32: Fluorescence images of fixed THP-1 cells treated with alkyl-linked CCL2 conjugates for 2 h. The
cells treated with fluorescent conjugates exhibited localised fluorescence in vesicle-like structures which are
most likely endosomes or lysosomes, suggesting the chemokine is located intracellularly and the hydrophilic
fluorophores cannot escape vesicular environments. A small amount of autofluorescence was observed in the
untreated cells which was used as a control. DAPI: blue, CCL2-BODIPY: green. Green channel exposure
time: 1000 ms, blue channel exposure time: 120 ms. CCL2 conjugates used at 200 nm.
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some indications can be observed inside the nucleus, this is likely due to the maximum inten-
sity projection calculation resulting in green fluorescence above or below the nucleus which is
then projected through the cell. In some cases, CCL2 Ala−1-alk-H appeared to be polarised
towards one side of the cell, this effect has been observed previously in the literature where
fluorescently labelled CCR2 was internalised and the receptor was transported to the rear of
the cell.5 Relative to the maximal migration concentration, both P8A-alk-H and WT-alk-H
were used at a higher concentration of 200 nm, this was due to initial experiments with
lower concentrations giving weak fluorescence intensities and so the higher concentration was
selected. Again, the fluorescence is mostly outside the nucleus of the edge of the cell and
appears to be localised in vesicles. Interestingly, the morphology of the vesicles observed
with both WT-alk-H and P8A-alk-H are quite different from that of CCL2 Ala−1-alk-H. The
vesicles from P8A-alk-H and WT-alk-H are more numerous and are also much smaller in size
than the vesicles observed in CCL2 Ala−1-alk-H. This suggests that the THP-1 cells may be
processing the chemokine ligands differently, however, the nature of any differential mecha-
nism was unclear. In both WT-alk-H and P8A-alk-H, there appeared to be some polarisation
of fluorescence towards one side of the cell, however, it was not as distinct as the polarisation
found in CCL2 Ala−1-alk-H.
The fluorescence microscopy images from disulfide-linked CCL2 conjugates are displayed in
Figure 5.33. The P8A-SS-H conjugate was consistently of lower fluorescence intensity than
the other conjugates in both the Boyden chemotaxis transwell assays and the PBMC flow
cytometry experiments potentially due to instability of the fluorophore post-disulfide reduc-
tion. This conjugate was localised in vesicles in these images which suggests the compound
cannot escape endosomes, however there is little direct evidence to prove the disulfide is being
reduced. Combining these observations with the behaviour of P8A-SS-L in previous experi-
ments provides a reasonable argument that the disulfide is being reduced and the hydrophilic
fluorophore is more prone to degradation than conjugated fluorophore. The P8A-SS-L image
was very different to all previous images for example, very few vesicle-like objects could be
identified and a diffuse morphological profile of fluorescence was observed. This is likely due
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(a) THP-1 cells treated with P8A-SS-H.
(b) THP-1 cells treated with P8A-SS-L.
Figure 5.33: Fluorescence images of fixed THP-1 cells treated with disulfide-linked CCL2 conjugates for 2 h.
Differences in subcellular localisation between P8A-SS-H and P8A-SS-L suggest that the lipophilic fluorophore
is able to escape endosomes leading to a diffuse morphological profile. DAPI: blue, CCL2-BODIPY: green.
Green channel exposure time: 1000 ms, blue channel exposure time: 120 ms. CCL2 conjugates used at 200
nm.
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to disulfide reduction liberating the lipophilic fluorophore which can then escape endosomes
and localise in lipophilic environments throughout the cell. This effect corroborates with
the results observed with chemotaxis assays and PBMC flow cytometry. Furthermore, the
diffuse nature of the fluorescence has not resulted in reduced fluorescence intensity but rather
the whole diffuse fluorescence profile is of high intensity. This suggests that the THP-1 cells
are capable of continuously internalising the ligand and the fluorophore avoids degradation
in lysosomes and the intensity of fluorescence is retained throughout the cell. Interestingly,
the fluorescence is still polarised to one side of the cell, this could just be a result of the
THP-1 cell being dominated by a large nucleus and so there is little cytoplasm around the
opposite sides of the cell. Another explanation is that the early endosomes are transported
to the polarised side and the BODIPY then escapes from the polarised endosomes and just
resides in nearby lipophilic compartments of the cell. Many cells have a ring of fluorescence
outside of the main polarised side of the cell, this is likely the lipophilic BODIPY residing in
the cell membrane, these molecules may have originated from the polarised side and diffused
along the membrane to encapsulate the cell. In any case, these images are clear evidence of a
distinct labelling profile to the other conjugates which correlates with previous experiments.
The imaging experiments were repeated on PBMCs, however, it is important to note that
many of the cells are CCR2-negative lymphocytes or granulocytes and therefore some of
the cells in the images may not be labelled by the fluorescent chemokines. Figure 5.34
displays fluorescence images of PBMCs treated with the alykl-linked conjugates CCL2 Ala−1-
alk-H, WT-alk-H and P8A-alk-H. A large proportion of the cells in the CCL2 Ala−1-alk-H
treated PBMCs exhibited fluorescence, interestingly, these fluorophores were localised in
small vesicles. This is different to the localisation of this chemokine in the THP-1 cells which
were in much larger vesicles, suggesting the behaviour in THP-1 cells could just be a result of
the secondary cell line rather than a cross cell-type effect. The large number of vesicles in the
PBMCs labelled with CCL2 Ala−1-alk-H suggests the BODIPY was localised in endosomes
which correlates with the previous results found in migration experiments and flow cytometry.
In WT-alk-H treated PBMCs, a handful of vesicles are present in this image, again, showing
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(a) PBMCs treated with CCL2 Ala−1-alk-H.
(b) PBMCs treated with WT-alk-H.
(c) PBMCs treated with P8A-alk-H.
(d) Unlabelled PBMCs.
Figure 5.34: Fluorescence images of fixed PBMCs treated with alkyl-linked CCL2 conjugates for 2 h. The
majority of PBMCs internalised the conjugates and the alkyl-linked conjugates appeared to localise within
vesicles, similar to the behaviour observed in THP-1 cells. DAPI: blue, CCL2-BODIPY: green. Green channel
exposure time: 1000 ms, blue channel exposure time: 120 ms. CCL2 conjugates used at 200 nm.
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the conjugate is internalised by the cell and the fluorophore remains in the endosome or
lysosome. P8A-alk-H exhibited a wider extent of labelling compared to WT-alk-H, with
many vesicles containing the fluorophore present in the cytoplasm.
The disulfide-linked CCL2 conjugates exhibited the greatest extent of labelling (Figure 5.35)
of the PBMCs. Interestingly, P8A-SS-H was not particularly effective at labelling THP-1
cells as determined by fluorescence microscopy but this conjugate was more easily visualised
in PBMCs. Once again, the hydrophilic fluorophore labelled vesicles indicating the reduced
conjugate could not escape endosomes and in some cases a degree of polarisation can be
observed in the cells (Larger images for P8A-SS-H and P8A-SS-L are shown in Figure 5.36).
The action of P8A-SS-L on the PBMCs was similar to that of the THP-1 cells: a diffuse
distribution of fluorescence can be observed indicating the reduced lipophilic fluorophore
can escape endosomes. Some of the PBMCs are more polarised than others suggesting a
bias exists for how the lipophilic fluorophore distributes across the cell and the fluorescence
intensity is still qualitatively high despite the diluting effect of diffusion of the fluorophore.
This diluting effect suggests that the fluorophore concentration is being maintained in the
cytoplasm by further internalisation of P8A-SS-L and subsequent endosomal escape.
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(a) PBMCs treated with P8A-SS-H.
(b) PBMCs treated with P8A-SS-L.
Figure 5.35: Fluorescence images of fixed PBMCs treated with disulfide-linked CCL2 conjugates for 2 h.
The lipophilic fluorophore is thoroughly diffused across the cell, again suggesting endosomal escape into
the cytoplasm. This behaviour supports evidence for extracellular leaching into CCR2− cells in the flow
cytometry experiments. DAPI: blue, CCL2-BODIPY: green. Green channel exposure time: 1000 ms, blue
channel exposure time: 120 ms. CCL2 conjugates used at 200 nm.
5.2. Results and Discussion 226
(a) BODIPY channel of PBMCs treated with P8A-SS-H.
(b) BODIPY channel of PBMCs treated with P8A-SS-L.
Figure 5.36: Comparison of fluorescence images of fixed PBMCs treated with disulfide-linked CCL2 conjugates
for 2 h. The P8A-SS-L fluorophore appears to have a more diffuse distribution across the cells than the P8A-
SS-H fluorophore. Exposure time: 1000 ms. CCL2 conjugates used at 200 nm.
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5.3 Conclusion
This chapter successfully characterised the CCL2 conjugates across a range of experiments
and through the use of both THP-1 cell lines and PBMCs. Initial assay development of the
Boyden transwell chemotaxis assay allowed experiments to be performed in a high-throughput
manner which was essential to gain the results obtained. The use of fixed volume flow cytom-
etry on the BD Biosystems Attune resulted in attainment of a broader range of data from a
single chemotaxis assay which decreased experiment time and also increased the consistency
of the number of migrated cells. The migration data could be determined simultaneously
to the fluorescence intensity of cells which allowed chemotactic function and chemokine in-
ternalisation to be coincidentally measured. The three CCL2 variants, CCL2 Ala−1-alk-H,
WT-alk-H and P8A-alk-H, exhibited chemotactic maxima which correlated with literature
precedent. P8A-alk-H was slightly more potent than WT-alk-H, however, this could have
been due to purity of the starting protein rather than as a result of the amino acid substi-
tution. Interestingly, measurement of the fluorescence intensity of migrated cells revealed
a state of equilibria at concentrations above the chemotactic maxima in both P8A-alk-H
and WT-alk-H. This equilibria demonstrated that the fluorescence did not increase with
concentration above the chemotactic maxima, suggesting that the fluorophore was being de-
graded by lysosomes at the same rate as internalisation of new chemokine. The lower affinity
CCL2 Ala−1-alk-H conjugate did not exhibit this same fluorescence steady state, however,
some evidence for this was inconsistently observed at higher concentrations. The chemotaxis
and internalisation of all the CCL2 conjugates was shown to be CCR2-dependent via two
distinct inhibitory mechanisms. The small molecule CCR2 antagonist INCB 3284 exhibited
a clear dose-dependent inhibitory effect on all CCL2 conjugates, both in terms of chemotaxis
and fluorescence internalisation. Similarly, a high dose incubation of recombinant human
CCL2 also resulted in inhibition of chemotaxis towards the CCL2 conjugates as a result of
surface CCR2 depletion. Interestingly, the fluorescence intensities of cells were not affected
by the high dose CCL2 pre-incubation most likely due to the heterogeneous population of
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cells created followed by a positive selection of cells still high in surface CCR2 during the
chemotaxis assay. This CCR2 dependency was also exemplified in chemotaxis assays with
the lymphocytic cell line, jurkats, whereby cessation of chemotaxis was observed. Further
evidence for the fluorescence steady state was produced in timecourse incubation experiments
highlighting a steady state after 2 hours. The fluorescence properties in the transwell assay
and in response to inhibitors could be modulated with differing physicochemical properties of
the conjugate. For example, P8A-SS-L did not exhibit a steady state in fluorescence and was
also not affected by INCB 3284 inhibition, most likely as a result of the disulfide reduction
followed by endosomal escape of the very lipophilic fluorophore.
The selectivity for CCR2 by the CCL2 conjugates was also demonstrated in primary human
PBMCs, both in monocyte and lymphocyte sub-populations. The only outlier was again
P8A-SS-L which exhibited uptake in CCR2-negative cells, however, as directed by earlier
chemotaxis experiments this was probably due to leaching of the reduced fluorophore into
neighbouring cells by passive diffusion. The other CCL2 conjugates were selective for CCR2-
positive cells resulting in labelling of disease-associated monocyte subsets such as classical
and intermediate but very little uptake in non-classical monocytes. In the lymphocytes, the
majority of lymphocytes were not labelled (due to no CCR2 expression) and so labelled cells
included: NKT cells and subsets of NK cells and T cells (presumably memory effector T cells)
which correlated with CCR2 expression. Finally, fluorescence microscopy in both THP-1 cells
and PBMCs revealed the fluorescent chemokines localised inside the cell, outside the nucleus
and generally within vesicles. Again, the P8A-SS-L conjugate was distinct from the other
conjugates, the fluorescence was much more diffuse across the cell suggesting the fluorophore
was localising in lipophilic microenvironments in the cytoplasm or membrane structures.
Chapter 6
Conclusion
This project aimed to investigate the potential for using CCL2 as a method for targeting
monocytes and whether any monocyte subset preference could be achieved. The strategy to
answer this question was to utilise fluorescent conjugates of CCL2 in an effort to characterise
the system, with a longer term goal to translate these finding towards novel therapeutics.
Chapter 3 detailed the synthesis of novel BODIPY azide conjugates whereby the lipophilicity
of the fluorescent core was modified to give distinct preferences for microenvironments within
the cell. This was combined with varying the linker in the form of a cleavable disulfide bond
or a non-cleavable alkyl linker between the fluorophore and the azide group. The project
then progressed onto synthesis of a novel FRET pair separated by a disulfide bond which
after optimisation was synthesised with the lipophilic BODIPY included as the liberating
fluorophore. Synthetic constraints prevented a hydrophilic BODIPY from being installed
on the FRET pair due to difficulty in forming the disulfonate in combination with a thiol.
The successfully synthesised FRET pair gave a clear FRET signal from the BODIPY donor
to the rhodamine acceptor, treatment with TCEP led to cessation of the energy transfer
confirming the on/off behaviour of the system in response to reducing agents. At this stage,
a potential issue was observed in the photophysical behaviour of the FRET pair involving
fluorescence quenching in aqueous media. Further experiments confirmed this behaviour was
due to aggregation of the FRET pair leading to auto-quenching and loss of fluorescence.
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Chapter 4 then aimed to conjugate the five compounds synthesised in the previous chapter
to three CCL2 variants: WT-CCL2, P8A-CCL2 and CCL2 Ala−1. The ‘alk-H’ fluorophore
was the most successful in terms of ability to conjugate, resulting in facile CuAAC conju-
gations with all three CCL2 variants. The reaction conditions were modified for the ‘alk-L’
fluorophore to include DMSO as a co-solvent which was necessary to facilitate solubility.
Unfortunately, issues with WT-CCL2 were present resulting in only the WT-alk-H conju-
gate being successfully formed and failure to form any of the other fluorophore conjugates.
This could have been due to the lower purity of WT-CCL2 preventing reaction completion
in the more complex reactions involving DMSO and the disulfide-linked fluorophores. With
both P8A-CCL2 and CCL2 Ala−1, the reaction conditions were modified to include DMSO
as a co-solvent which successfully allowed the other fluorophores to be conjugated to these
variants. This is a good example of a reaction involving very lipophilic compounds and a
protein without losing biological function which highlights the versatility of CCL2. However,
it was later revealed that inclusion of sodium ascorbate in reactions containing DMSO led to
loss of CCL2 function, likely due to native disulfide reduction followed by denaturation. The
internal disulfides of CCL2 appear to anchor the tertiary structure such that it can re-fold
correctly after DMSO denaturation, it is therefore very important to maintain these bonds.
Sodium ascorbate mitigated disulfide reduction was therefore avoided through the use of
copper (I) salts and the exclusion of oxygen via an Atmosbag, this was performed on P8A-
CCL2 resulting in successful formation of P8A-SS-L and P8A-SS-H and also the FRET pair
formation on CCL2 Ala−1. This issue of sodium ascorbate reducing disulfides is a neglected
area in the literature and highlights an issue with using these conditions in protein CuAAC
conjugations. For example, it is possible this phenomenon is occurring in other conjugates
in the literature but investigators may be unaware, leading to reaction failure due to the
conditions rather than some intrinsic reaction difficulty.
In relation to the literature, CCL2-mCherry and CCL2-SA1 were successful bis-functional
proteins however the protein fusion limits the scope of these systems to proteins. The inclu-
sion of an extra conjugation step in this project broadens the scope of potential conjugates
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which could be explored and the nature of CuAAC conjugations means that only minimal al-
terations to molecules are needed. For example, in the case of the PPTase system, it is unclear
whether larger conjugates (such as oligonucleotides, nanoparticles or sugars) could interfere
with the enzymatic reaction or whether the inclusion of coenzyme A is feasible.7 The use of
CuAAC requires only an azide to be installed on the conjugate and the azide can be alkyl
or aryl in nature which broadens the scope of the reaction to oligonucleotides, nanoparticles,
sugars, lipids or virtually any conceivable molecule. Clearly, as this project demonstrates,
the reaction is not perfect and care must be taken when designing these systems but the
problems encountered in this project could be optimised.
The CCL2 conjugates were thoroughly characterised in Chapter 5 which identified P8A-
CCL2 as the most active chemokine, followed by WT-CCL2 and finally CCL2 Ala−1. This
behaviour validated reports of these systems in the literature and also gave evidence that
the chemokines were functioning correctly. The combination of the chemotaxis experiment
with flow cytometry enabled both migration and fluorescence internalisation to be assessed
in the same experiment which was not done in the CCL2-mCherry or the chemokine PPTase
projects.5,7 This allowed the chemotactic responses of the cells to be correlated with fluores-
cence internalisation which resulted in the detection of a fluorescence steady state at con-
centrations higher than the chemotactic maxima. The CCR2-dependency of this behaviour
was also determined across all three CCL2 variants using two distinct inhibitory mechanisms
which presented some interesting results. When CCR2 was antagonised using INCB 3284,
both the migration and fluorescence internalisation were inhibited in all variants, however,
when surface CCR2 was depleted using both recombinant human CCL2 and the unlabelled
synthetic variants, only migration was inhibited. This was most likely due to production
of a heterogeneous CCR2-presenting population of THP-1 cells and a positive selection of
cells high in surface CCR2 through the transwell membrane. The CCR2 antagonist, on the
other hand, likely resulted in a homogeneous population of CCR2-inhibitor complexes and so
any migrated cells were still inhibited by bound INCB 3284 thus the fluorescence remained
low. Jurkat cells lacking in CCR2 were also refractory to WT-alk-H recruitment but were
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chemotactic towards CXCL12, suggesting that CCR2 was necessary for migration in these
assays.
Similar experiments with the other P8A-CCL2 and CCL2 Ala−1 conjugates highlighted the
issue with using sodium ascorbate in combination with DMSO in the CuAAC conjugations
as these compounds all performed poorly in these experiments. This meant that only the
P8A-SS-L and P8A-SS-H had conjugated successfully to produce functional CCL2, however,
this was only due to reaction conditions and not an intrinsic property of CCL2 Ala−1 or
the lipophilic BODIPY azide 8. It was at this point that the effects of the disulfide linker
in combination with a lipophilic leaving group were apparent as the P8A-SS-L conjugate
exhibited a greatly increasing MFI at increasing concentrations relative to other conjugates
which all attained a maximum. This suggestion of endosomal escape was further evidenced
by the MFI of P8A-SS-L being of a similar magnitude whether inhibited by INCB 3284 or
not. More evidence of P8A-SS-L endosomal escape was provided in fluorescence microscopy
experiments in both THP-1 cells and PBMCs.
The final aims of the project were then achieved via monoclonal antibody labelling in flow
cytometry. PBMCs were obtained from human donors and four of these conjugates demon-
strated selectivity for CCR2-positive cells, with the exception of P8A-SS-L, however, con-
sidering the suggestion for endosomal escape from the cell line experiments this was likely
due to secondary-leaching. Monocyte subsets were separated and a preference for classi-
cal monocytes was observed, followed by intermediate monocytes and only some uptake by
the non-classical monocytes. This also correlated closely with CCR2 expression and a re-
lationship between increased MFI and decreased surface CCR2 was also observed in these
experiments suggesting the conjugates were depleting the receptor from the surface of the
cells. Similar behaviour in lymphocytes was observed whereby conjugates were CCR2 se-
lective and labelled subsets of T cells, NK cells and NKT cells. In terms of percentage of
each population, the NKT cells were preferentially selected by the CCL2 conjugates due to
high CCR2 expression. However, uptake was observed in all three populations due to CCR2
expressing subsets of both NK cells and T cells, though this was in a very small minority
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of these populations. In terms of the suitability of CCL2 variants as a monocyte-specific
delivery vehicle, the consensus of data suggests a strong preference for the classical and in-
termediate monocytes which are the intentional targets of this project. Whilst some uptake
occurs in cells outside this target (for example, lymphocyte subsets), this is a minority of cells
and it is also an expected effect of using the CCL2-CCR2 pathway which can be predicted.
This means that uptake of the CCL2 conjugates will likely occur in all cells which express
functional CCR2 (and potentially related chemokine scavengers such as D6/DARC).
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6.1 Future Work
This project was able to achieve the majority of the goals which were established in the
aims section and promising results were obtained for this initial proof of concept to identify
the potential for CCL2 conjugates to be a monocyte-subset specific delivery vehicle. This
section will now detail potential routes to progress the project further towards the longer
term goals of monocyte specific therapeutics. Some evidence for endosomal escape of P8A-
SS-L was observed, to confirm this behaviour, endosomal or lysosomal markers (such as
EEA-1 or LAMP-1) could be used in fluorescence microscopy to colocalise these signals
with the hydrophilic fluorophores and a lower colocalisation should be apparent with P8A-
SS-L. Another option would be to inhibit the action of dynamin through the use of the
well known endocytosis inhibitor dynasore. Re-development of the CCL2 FRET system
would be complementary to these experiments as loss of FRET due to disulfide reduction
provides more evidence that the fluorophores are separated from the parent protein conjugate.
These imaging experiments could be further progressed through incorporating this into a live
imaging system to remove any effects of fixation and also monitor uptake of the chemokines
in real time. An interesting imaging experiment would utilise the 3D chemotaxis assays
available from IBIDI, these involve formation of a collagen matrix which hosts the cells and
a chemotactic gradient can be applied across the gel. This then allows imaging of the cells
which would internalise the fluorescent chemokine and also allow observation of chemotactic
migration through a medium which better simulates the in vivo environment.
To ascertain whether the uptake of P8A-SS-L was in CCR2-negative cells due to leaching,
the INCB 3284 antagonist could be used to prevent primary uptake and therefore reduce
leaching effects. Further characterisation of cell-type uptake would also be beneficial, for
example, identification of the CCR2-positive populations in the lymphocyte subsets. Gating
of the PBMC population to MDSCs would offer further clinical relevance to this project,
broadening the scope of the CCL2 conjugates to cancer.
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Finally, the characterisation of the chemokines would translate into the development of mono-
cyte targeted therapeutics in an effort to address the issues with treatment of diseases in this
area. The variable phenotypes of monocytes mean that systemic inhibition or killing of these
cells has not generally been effective. Using the CCL2 conjugates to select the monocyte
subsets closely related to a disease would be the optimal route, therefore conjugating small
molecule therapeutics to CCL2 is a clear pathway for development. This would be guided
by the findings generated in this project in terms of the need for both a disulfide linker and
that the therapeutic would need to be sufficiently lipophillic in order to reach the cytoplasm
where the majority of therapeutics operate. The lipophilicity would need to be carefully
modulated depending on the disease due to the leaching effect observed with P8A-SS-L, this
would be problematic in treatment of delocalised monocytes in fibrosis for example, however,
this effect could be useful when targeting monocytes or macrophages in the treatment of solid
tumours. Evidently, the scope for future work is varied and the research would benefit from
performing the experiments outlined at the beginning of this section first before moving onto
the applications of the CCL2 conjugates towards therapeutic delivery.
Chapter 7
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(a) 1H NMR spectrum of BODIPY 8.
(b) 13C NMR spectrum of BODIPY 8.
Figure 8.1: 1D NMR spectra of lipophilic BODIPY 8.
251
(a) COSY NMR spectrum of BODIPY 8.
(b) HSQC NMR spectrum of BODIPY 8.
Figure 8.2: 2D NMR spectra of hydrophilic BODIPY 8.
252
(a) HMBC NMR spectrum of BODIPY 8.
(b) 1H NMR spectrum of BODIPY 10.
Figure 8.3: HMBC NMR spectra of BODIPY 8 and 1H NMR spectrum of hydrophilic BODIPY
10.
253
(a) 13C NMR spectrum of BODIPY 10.
(b) HSQC NMR spectrum of BODIPY 10.
Figure 8.4: 13C NMR spectrum and HSQC NMR spectra of BODIPY 10.
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(a) HMBC NMR spectrum of BODIPY 10.
(b) 1H NMR spectrum of BODIPY 24.
Figure 8.5: HMBC NMR spectrum of BODIPY 10 and 1H NMR spectra of BODIPY 24.
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(a) 13C NMR spectrum of BODIPY 24.
(b) COSY NMR spectrum of BODIPY 24.
Figure 8.6: 13C NMR and COSY NMR spectra of BODIPY 24.
256
(a) HSQC NMR spectrum of BODIPY 24.
(b) HMBC NMR spectrum of BODIPY 24.
Figure 8.7: 13C NMR and COSY NMR spectra of BODIPY 24.
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(a) 1H NMR spectrum of BODIPY 32.
(b) 13C NMR spectrum of BODIPY 32.
Figure 8.8: 1H and 13C NMR spectra of BODIPY 32.
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(a) COSY NMR spectrum of BODIPY 32.
(b) HSQC NMR spectrum of BODIPY 32.
Figure 8.9: COSY and HSQC NMR spectra of BODIPY 32.
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(a) HMBC NMR spectrum of BODIPY 32.
(b) 1H NMR spectrum of BODIPY 33.
Figure 8.10: HMBC NMR spectra of BODIPY 32 and 1H NMR specra of BODIPY 33.
260
(a) 13C NMR spectrum of BODIPY 33.
(b) HSQC NMR spectrum of BODIPY 33.
Figure 8.11: 13C and HSQC NMR spectra of BODIPY 33.
261
Figure 8.12: HMBC NMR spectrum of BODIPY 33.
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(a) 1H NMR spectrum of FRET pair 45.
(b) 13C NMR spectrum of FRET pair 45.
Figure 8.13: 13C and HSQC NMR spectra of BODIPY 33.
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(a) BODIPY 8 (b) BODIPY 10
(c) BODIPY 24 (d) BODIPY 33.
Figure 8.14: Non-normalised fluorescence spectra of fluorophores synthesised in Chapter 3.
264
Figure 8.15: MALDI-MS of an unsuccessful attempt to form CCL2 Ala−1-SS-L (corresponding to
Scheme 4.4).
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(a) CCL2 Ala−1-alk-H (b) CCL2 Ala−1-alk-L
(c) CCL2 Ala−1-SS-L (d) CCL2 Ala−1-SS-H
Figure 8.16: UV-Vis Spectra of CCL2 Ala−1 conjugates.
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(a) WT-alk-H (b) P8A-alk-H
(c) P8A-alk-L (d) P8A-SS-H
Figure 8.17: UV-Vis Spectra of P8A-CCL2 conjugates.
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Figure 8.18: UV-Vis Spectra of CCL2 Ala−1-FRET Conjugate.
268
(a) UV-Vis spectra of CuAAC between P8A and 32 (Reaction J).
(b) UV-Vis spectra of CuAAC between P8A and 24 (Reaction K).
Figure 8.19: UV-Vis spectra of CuAAC between P8A and lipophilic disulfide-linked BODIPYs 24
and 32. Whilst the MALDI-MS signal indicated formation of P8A-SS-L from the reaction between
P8A-CCL2 and BODIPY compoundRB324, the UV-Vis BODIPY absorption was weak (8.19a)
which corresponds to the MALDI-MS displayed in Figure 4.10b. The UV-Vis spectra indicated a
greater level of conjugation between P8A-CCL2 and BODIPY 24 (8.19b) which corresponds to the
MALDI-MS displayed in Figure 4.10c
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(a) P8A-alk-H (b) P8A-alk-L
(c) P8A-SS-L (d) P8A-SS-H
Figure 8.20: Normalised fluorescence spectra of conjugates synthesised on P8A-CCL2, all samples
were run in PBS at rt. All CCL2 conjugates were excited at 488 nm as this corresponds to green
laser lines which will be used in flow cytometry and microscopy.
270
Figure 8.21: Boyden chemotaxis assay of THP-1 cells response to recombinant CCL2 in combi-
nation with INCB 3284 inhibition. The CCR2 inhibition is effective at preventing chemotaxis of
recombinant CCL2. N = 2.
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Figure 8.22: Effects of pre-treatment with 250 nm CCL2 on the chemotaxis of recombinant CCL2
in Boyden transwell chemotaxis assays. The high concentration of CCL2 reduces the amount of
surface CCR2 on THP-1 cells leading to a reduction in chemotaxis towards CCL2. Error bars refer
to standard error at N = 2.
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Figure 8.23: Fluorescence spectra of CCL2 Ala−1-FRET before an after TCEP treatment. Some
scattering was observed below 500 nm (not shown). The FRET signal was promising but could not
be reproduced in a cellular system.
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